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General Introduction  




Diabetes mellitus is a condition characterized by hyperglycemia and caused 
by an absolute or relative insulin deficit. The global prevalence of diabetes 
mellitus is rapidly increasing. This increase is fueled by a growing prevalence 
of obesity due to increased caloric intake and lack of physical activity.(1-3) 
Diabetes is classified into two main types: type 1 and type 2 diabetes. 
 Type 1 diabetes mellitus (T1DM) is an autoimmune process leading to 
the destruction of insulin secreting beta cells in the pancreas and a rapid 
development of absolute insulin deficiency. This results in the dependence 
on exogenous insulin administration. 
 Type 2 diabetes mellitus (T2DM) is characterized by the combination of 
insulin resistance and a relative insulin deficit and is strongly associated 
with obesity. It is often treated with a diet and/or oral glucose lowering 
medication. However, due to progressive beta cell loss and / or the inability 
of the own beta cells to produce sufficient insulin to maintain euglycemia, 
T2DM can also result in the need to initiate exogenous insulin administration. 
 Diabetes can lead to serious long term micro- and macrovascular 
complications such as nephropathy, which potentially leads to end stage 
renal disease and need for renal replacement therapy, neuropathy, which 
– amongst others – contributes to the development of chronic foot ulcers 
and foot amputation, and retinopathy, which can cause blindness. 
Furthermore, diabetes is associated with an increased risk for cardio- 
vascular morbidity and mortality. Whereas T1DM is characterized by isolated 
chronic hyperglycemia due to absolute insulin deficiency, T2DM -in the 
majority of cases- is associated with abdominal obesity, dyslipidemia and 
hypertension in the context of the metabolic syndrome. Furthermore, 
exercise capacity is often reduced in T2DM (4). Whether this reduced 
exercise capacity has a causal relationship with the manifestation of T2DM, 
or whether both the manifestation of T2DM and reduced exercise capacity 
are a consequence of lack of physical activity, remains open for discussion.
Both in people with and people without diabetes, regular physical activity 
elicits many favorable effects on the body such as improvements in exercise 
capacity, circulating lipids, blood pressure, insulin sensitivity, body weight, 
the regulation of food intake and psychological well being. (5)
 Exercise may, however, be of even greater importance to subjects with 




risk, dyslipidemia, hypertension, excess body weight and lower psychological 
well being. As stated by the American Diabetes Association (ADA) and 
American College of Sports Medicine (ACSM) subjects with T2DM “should 
undertake at least 150 minutes/week of moderate to vigorous aerobic exercise 
and practice resistance training at least twice a week”. These societies have 
also released a joined statement for T2DM including recommendations 
regarding pre-exercise evaluation, the amount and type of exercise, and 
exercise in the presence of diabetic complications.(6)
 For T1DM, no specific recommendations regarding the type or the 
amount of exercise exist, and according to the ADA, “all levels of physical 
activity can be performed by people with T1DM who do not have complications 
and are in good blood glucose control”. (7) Given the emphasis on a healthy 
and active lifestyle and an increasing popularity of leisure activities in the 
mountains, a growing number of subjects with diabetes participating in 
activities at altitude -such as trekking, hiking and skiing- is expected. 
Stays at altitudes up to 2500m are well tolerated by most people including 
the majority of subjects with diabetes. (8) However, altitude (i.e. hypobaric 
hypoxia: a lower partial oxygen pressure in inhaled ambient air causing a 
lower arterial oxygen pressure) can affect many organs and regulatory 
systems in the body, potentially leading to medical problems, especially at 
higher elevations and in case of rapid ascents. Hypoxemia, acute mountain 
sickness, altitude related anorexia, equipment failure or inaccuracy due to 
freezing and hypoxia are all factors that can complicate activities at altitude. 
(9-12) Specific diabetes related problems at altitude include: the loss of 
glycemic control due to hypoxia induced increments in gluco-counter 
regulatory hormones, the inaccuracy of blood glucose meters due to cold 
and/or the use of oxygen for its chemical reaction, the potential freezing of 
insulin resulting in the loss of its therapeutic potency, the theoretical risk of 
diabetic keto-acidosis due to the prophylactic use of acetazolamide for 
acute mountain sickness, the hypoxia induced loss of appetite and reduced 
food intake, potentially causing hypoglycemia, and the remoteness and 
scarcity of medical care. 
 While medical literature contains some information regarding the effects of 
altitude on diabetes, the information is often contradictory, limited, exclusively 
related to T1DM, or the material used is outdated. (10,13,14) Furthermore, 
very little of this information is known to diabetes care providers or individuals 
with diabetes who consider activities at (high) altitude. Many questions 
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regarding physical activities at high altitude and its consequences for the 
subject with diabetes remain unanswered. The research described in this 
thesis aims to answer a number of these questions and to increase the 
knowledge in this particular field. 
To promote physical activity in patients with diabetes and to demonstrate 
the ability of these patients to meet sports challenges and achieve their 
goals, the Bas van de Goor Foundation organized a high altitude trekking 
expedition in October 2008. Eight subjects with T1DM participated in a 
12-day trekking expedition to mount Meru (alt 4562m) and mount Kilimanjaro 
(alt. 5895m) in Tanzania. (15) All participants were selected by this foundation 
on the basis of personal motivation, physical fitness and adequate diabetes 
self management. A medical team examined, tested and accompanied the 
participants before, during and after the expedition. Throughout the whole 
period, a number of experiments and measurements were performed. 
Due to the enormous success of this expedition, a subsequent expedition 
was organized, this time with subjects with type 2 diabetes. 
 Again, its primary goal was to promote physical activity, to challenge 
oneself and to try to achieve set goals. Similarly, this expedition was also 
combined with medical research. This time, an extensive preparatory 
training phase was included as well, which enabled us to study changes 
associated with exercise training and subsequently study the effects of 
altitude in subjects with T2DM. In September 2010, after completion of a six 
month preparatory training period, twelve subjects with uncomplicated 
T2DM set out on a 12-day expedition to the summit of mount Toubkal 
(4167m) in Morocco. (16)
The data obtained prior to, during and after these two mountain expeditions 
form the basis of the present thesis. An outline of the studies is provided 
below. The aim of these studies was to add new facts to the existing 
knowledge regarding the metabolic effects, safety and technical aspects of 




Outline of the thesis
Chapter 2 describes in detail the physiological effects of physical activity at 
altitude and the particular challenges for subjects with diabetes mellitus. 
These include; adaptation and acclimatization to hypobaric hypoxia, 
metabolic effects of hypobaric hypoxia – including glucose control – the 
occurrence of acute mountain illness and its treatment, technical and safety 
considerations and pre-travel recommendations for both subjects with 
T1DM and T2DM.  
For subjects with diabetes mellitus at altitude, frequent blood glucose 
measurement under constantly changing conditions becomes of even 
greater importance, especially for subjects using medication potentially 
leading to hypoglycemia, such as insulin or sulfonylurea derivates. 
Hypoglycemic symptoms can be mistaken for acute mountain sickness, 
and hypoglycemia can lead to extremely dangerous situations when the 
individual is securing fellow climbers by rope or is close to a ledge.(10) 
Reliable measurement of glucose is thus mandatory under these conditions. 
Because certain capillary blood glucose meters need oxygen in the 
enzymatic reaction to measure glucose, one may anticipate errors in blood 
glucose measurements at altitude. We therefore investigated the effect of 
hypobaric hypoxia on capillary blood glucose determination by modern 
handheld blood glucose meters. In detail, we tested nine modern handheld 
blood glucose meters that measure capillary glucose, based on either 
glucose oxidase or glucose dehydrogenase enzymatic technology. These 
tests were performed in a hypobaric chamber simulating different altitudes. 
Subsequently, we compared the accuracy and precision of four modern 
blood glucose meters under field conditions at true high altitude on mount 
Kilimanjaro (altitude: 5895m), Tanzania. The results of these studies are 
described in chapter 3. 
When going to altitude, gluco-regulation and glycemic control change as a 
consequence of hypobaric hypoxia and related hormonal responses, even 
in non-diabetic subjects. (16,17) Adequate glucose control in patients with 
T1DM at altitude is thus a major challenge and summit success rates in 
subjects with T1DM have been variable. (9) Another challenge is the 
occurrence of acute mountain sickness (AMS), which seems to affect 
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subjects with T1DM and non-diabetic subjects similarly. (9)  The symptoms 
associated with AMS may be confused with hyper- or hypoglycemic 
symptoms and may affect oral intake. (10) In addition, prophylactic 
medication for AMS is relatively contra-indicated in T1DM. (18) In chapter 4 
we describe insulin requirements and continuously monitored glucose 
profiles in subjects with T1DM during the ascents of mount Meru (alt. 
4568m) and mount Kilimanjaro (alt. 5895m) in Tanzania.  We also measured 
symptom scores of acute mountain sickness (AMS) and estimated daily 
energy expenditure in subjects with T1DM in comparison to non-diabetic 
subjects during this expedition.  
The number of people going to high altitude for work or recreational 
purposes, is growing.(19) In literature, there still is a paucity of data regarding 
the metabolic effects of high altitude travel in subjects with T2DM. (20,21) 
Some studies, performed in non-diabetic subjects and in subjects with 
T1DM, have reported impaired glycemic control. (11,16) In subjects with 
T2DM, experimental studies have reported increased peripheral glucose 
uptake during exercise under normobaric hypoxic conditions (22). In 
chapter 5 the metabolic effects of a high altitude trekking expedition in 
subjects with uncomplicated T2DM are described. During a 12 day 
expedition to the summit of mount Toubkal (alt. 4167m), Morocco, we 
investigated glucose profiles by continuous glucose monitoring, lipids, 
energy expenditure, caloric intake and AMS symptom scores in subjects 
with uncomplicated T2DM. In addition, we investigated the effect of a 
6-months preparatory exercise training period on body weight, HbA1C, 
estimated insulin sensitivity (HOMA-IR), fasting blood glucose, lipids, food 
intake and energy expenditure prior to this high altitude expedition. 
In the majority of cases, T2DM is associated with obesity and the 
accumulation of excess fat in non-adipose tissue: ectopic fat deposition. 
Ectopic fat deposition is tightly correlated to insulin resistance and T2DM.
(23) Weight loss, achieved by dietary or, a combined dietary and exercise 
intervention, decreases ectopic fat deposition, both in subjects with and 
without T2DM.(24-26) As opposed to a dietary intervention, exercise alone 
could be a more sustainable way of decreasing ectopic fat depositions with 
the preservation of muscle mass as an advantage. We aimed to determine 
whether a 6-month period of exercise, including the 2-week trekking 




intervention or expected weight change, could change ectopic fat depots in 
subjects with T2DM. Therefore, we compared ectopic fat deposition, 
measured by proton magnetic resonance spectroscopy, in the heart, the 
liver and in skeletal muscle prior to the preparatory training program and 
after the expedition. In addition, we assessed changes in subcutaneous-, 
visceral-, paracardial- and epicardial fat depots and changes in cardiac 
function by magnetic resonance imaging. The results of these measurements 
are described in chapter 6.
 Finally, chapter 7 provides a summary of the results of all studies and 
put these in perspective. 
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Challenges for people with diabetes.
A review.
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A growing number of subjects with diabetes take part in physical activities 
at altitude such as skiing, climbing and trekking. Exercise under conditions 
of hypobaric hypoxia poses some unique challenges on subjects with 
diabetes and the presence of diabetes can complicate safe and successful 
participation in mountain activities. Amongst others, altitude can alter gluco- 
regulation. Furthermore, cold temperatures and altitude can complicate 
accurate reading of glucose monitoring equipment and storage of insulin. 
These factors potentially lead to dangerous hyper- or hypoglycemia. Over 
the last years more information has become available on this subject.
Purpose: 
To provide an up-to-date overview of the (patho-) physiological changes 
during physical activity at altitude and the potential problems related to 
diabetes, including the use of (continuous) blood glucose monitors and 
insulin pumps. To propose practical recommendations for preparations and 
travel to altitude for subjects with diabetes.
Data sources and synthesis: 
We researched PubMed, medical textbooks and related internet sites and 
extracted human studies and data based on relevance for diabetes, exercise 
and altitude. 
Limitations: 
Given the paucity of controlled trials regarding diabetes and altitude, we 
composed a narrative review and filled in areas lacking diabetes specific 
studies with data obtained from non-diabetic subjects. 
Conclusions: 
Subjects with diabetes can take part in activities at high, and even extreme, 
altitude. However, careful assessment of diabetes-related complications, 
optimal preparation, adequate knowledge of glycemic regulation at altitude 
and altitude-related complications is needed. 
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Introduction
An increasing number of subjects with diabetes reside at high altitude for 
short periods of time, partly for work, but mainly for recreational purposes 
such as skiing, trekking and climbing. Exercise under conditions of hypobaric 
hypoxia poses some unique challenges for subjects with diabetes and 
could potentially lead to dangerous situations such as unexpected hypo- 
and hyperglycemia, inaccurate reading of blood glucose monitors and 
freezing of insulin. New study results have become available over the recent 
years. Here, we review and update the information regarding subjects with 
either type 1 or type 2 diabetes who intend to take part in activities such as 
high altitude trekking: walking and hiking for several hours a day above 
1500 m altitude. The goal of the present review is to describe the physio- 
logical changes occurring at altitude and to identify potential problems 
when unacclimatized subjects with either type 1 or type 2 diabetes, travel 
to or spent time at altitude for physical activities. Furthermore, we compose 
practical recommendations in preparation for and when being at altitude 
with diabetes. 
Altitude
The following definitions are used to define different altitudes (1) (Fig 1):
– High altitude: 1500-3500m (5000-11500 ft.)
– Very high altitude: 3500-5500m (11500-18000 ft.)
– Extreme altitude: above 5500m (18000 ft.) 
With increasing altitude, the inspired oxygen partial pressure (PiO2) 
decreases due to a progressive decline in barometric pressure (hypobaric 
condition). Barometric pressure at sea level is ~760 mmHg (containing 20.9 
% of oxygen) corresponding to a PiO2 of 160 mmHg. (2) At 8848m, the 
summit of Mount Everest, the barometric pressure is ~ 253 mmHg and the 
PiO2 is ~ 42mmHg which results in almost immediate unconsciousness in 




Physiological changes occurring at altitude and 
specific issues in subjects with diabetes
a. Ventilatory effects
When going to altitude, respiratory rate increases due to hypoxia, which will 
also result in a decrease in arterial carbon dioxide (PaCO2). Temporarily, 
this hypocapnia lowers the ventilatory drive but this effect disappears 
with acclimatization. The decline in PaCO2  results in respiratory alkalosis, 
followed by renal compensatory loss of bicarbonate during the first days to 
weeks at altitude, partly restoring blood pH to sea level values. (4) Alkalemia 
Figure 1   Summary of findings in studies involving subjects with at high 
altitudes
Left: arrows indicating different altitude zones and technical and physiological findings with 
implications for the subject with diabetes. Right: outcomes and summit success rates (number 
of climbers successfully summiting (total climbers)) of reported diabetes studies in medical 
literature. (DKA: Diabetic keto-acidosis, HARH: high altitude retinal hemorrhage, AMS: acute 
mountain sickness, HOMA-IR: homeostasis model assessment of insulin resistance, CGMS: 
continuous glucose monitoring system, BGMs: blood glucose meters) *= not studied
Everest  
8848m 









Some BGMs tested  
reliable  up to 5000m (74)  
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AMS possible  
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mild AMS reported (28)   
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increases the affinity of hemoglobin for oxygen which is beneficial regarding 
the lower ambient oxygen pressure at altitude.
 Diabetes, in particular type 2 diabetes, seems to be associated with 
a modest decrease in lung transfer capacity for carbon monoxide (CO), 
lower ventilatory responses to hypoxia and a mild restrictive lung function 
impairment, but the clinical implications are unclear. (5,6) One might 
suspect that these subtle impairments result in lower arterial oxygen content 
and limitations in exercise capacity at altitude but this is unknown. We found 
similar arterial O2 saturation, as determined by pulse oxymetry, in 12 non- 
smoking subjects with uncomplicated type 2 diabetes compared to 
non-diabetic controls at 876m, 3200m and 4167m (97.4±1.8 vs. 97.6±0.8; 
92.9±2.4 vs. 94.0±2.7; 91.5±2.4 vs. 90.3±3.2 % SpO2 respectively; 
unpublished data).
 Altogether, we think that subjects with complication-free diabetes in 
good glycemic control, do not differ from non-diabetic subjects at high 
altitude with respect to ventilation and ventilatory adaptations. Whether 
clinically relevant respiratory impairments become apparent at very high or 
extreme altitude remains to be investigated.
b. Renal effects
Luks et al. advices subjects with chronic kidney disease to continue sea 
level medication as usual at high altitude and to adjust diuretic therapy 
according to weight changes to anticipate fluid retention or dehydration. 
Given the fact that proteinuria may increase at altitude, it seems advisable 
to continue angiotensin-converting enzyme (ACE) inhibitors or angiotensin 
receptor blockers also in subjects with diabetes. (7) Acetazolamide for the 
prophylaxis of AMS and HACE (see below) can be used in case of chronic 
kidney disease, provided that the patient does not have a pre-existing 
metabolic acidosis and has an estimated glomerular filtration rate (eGFR) 
>50ml/min.. Further advices regarding the use of medication at altitude are 
reviewed in detail elsewhere. (7-9)
 Subjects with type 2 diabetes living at 1727m altitude, have higher 
24-hour urinary protein excretion and serum creatinine, and decreased 
eGFR, compared to matched subjects at sea level. (10) Whether diabetic 
nephropathy complicates altitude acclimatization is unknown. Neither is 
known whether diabetic nephropathy worsens during travel to, or prolonged 





c. Cardiovascular effects and exercise capacity
Acute altitude exposure increases heart rate (and thereby cardiac output), 
as a consequence of cardiac beta adrenergic receptor stimulation by the 
sympathetic nervous system and by epinephrine release in response to 
hypoxia. (11) During the process of acclimatization, the initial increase in 
heart rate decreases probably due to decreased cardiac responsiveness to 
beta adrenergic stimulation (12) and increased vagal tone. (13,14). As stroke 
volume is decreased after prolonged altitude exposure due to a decrease 
in plasma volume, heart rate remains increased to maintain cardiac output 
at altitude. (15,16). Even after acclimatization, maximum heart rate, maximum 
cardiac output and maximum exercise capacity remain suppressed. (17,18) 
 Maximum oxygen consumption (VO2max) is reduced by 1% with every 
100m elevation above 2500m. (19) At altitude, VO2max is lower and is reached 
at lower workloads; exercise feels more strenuous. (20) However, the 
corresponding energy expenditure for a given workload is equal. (21)
 Mean arterial blood pressure at altitude often increases over the first 
days to weeks due to increased sympathetic tone. (22) Acclimatization 
results in a reduction in plasma volume, cardiac output and epinephrine 
levels, resulting in normalization of, or even a decrease in blood pressure. 
(23) Pulmonary vasoconstriction in response to hypobaric hypoxia leads to 
an elevated pulmonary artery pressure. Pulmonary hypertension is common 
during exposure to altitude and is most pronounced during exercise. (23)
 In subjects with diabetes, ischemic heart disease and diabetic cardiac 
autonomic neuropathy may limit adaptive responses to altitude. (24) One 
retrospective study reported that in the Austrian Alps, male hikers with 
diabetes had a 7.4 times higher risk for sudden cardiac death compared to 
non-diabetic subjects. (25)  Data suggest that subjects with coronary artery 
disease without diabetes can go to altitudes up to, and possibly over, 
3500m, provided that they have stable disease, preserved left ventricular 
function and normal exercise capacity.(26,27) It is advised to continue 
medication for coronary artery disease (-including beta blockers-) as 
prescribed at sea level and monitor blood pressure regularly. (9) If cardiac 
autonomic neuropathy includes symptoms such as resting tachycardia and 
exercise intolerance, (24) we discourage these subjects to go to very high 
or extreme altitudes where maximal heart rate and exercise capacity are 
further reduced. (19)
 There have been no specific studies regarding the effect of altitude 
exposure on exercise capacity in diabetes. Relying on derivative measures, 
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Pavan found no difference in heart rate and blood pressure responses to 0, 
3700 and 5800 m altitude between subjects with complication-free, well- 
controlled type 1 diabetes and non-diabetic subjects. (28) In agreement, we 
found no differences in blood pressure and echocardiographic parameters 
at sea level and at 4000m altitude between similar groups with and without 
diabetes type 1.(29) 
 Data on cardiovascular responses at altitude in subjects with type 2 
diabetes are scarce and partly contradictory. We found no differences in 
systolic (+3.7 ±11.3 mmHg) and diastolic (+1.5 ± 7.0 mmHg) blood 
pressure at 3200m vs. sea level, in 13 trained subjects with uncomplicated 
type 2 diabetes who successfully hiked to 4167m (30). Others have reported 
a slight decrease in blood pressure in 22 subjects with a metabolic syndrome 
sojourning to 1700m altitude.(31) At high altitude, regular monitoring of 
blood pressure is strongly recommended for subjects with hypertension. 
Anti-hypertensive medication should be continued at altitude and adjustments 
should only be made in those individuals that have persistent and marked 
elevations or drops in blood pressure. (9) 
The American Diabetes Association and the American College of Sports 
Medicine advice previously sedentary subjects with diabetes type 2 to 
undergo exercise stress testing when the intended exercise intensity 
exceeds that of brisk walking (32), which is obviously the case during hiking 
at altitude. Taken together, the available data suggest that subjects with well 
controlled diabetes, both type 1 and type 2, can successfully take part in 
high (and possibly even very high to extreme) altitude trekking, provided 
that they are physically fit and free from micro- and macro-vascular 
complications.
d. Cerebrovascular effects. 
The effect of altitude on the coagulation system is subject to debate (33,34) 
Although plausible, there is no direct evidence that anti-platelet aggregation 
and/or anti-coagulant therapy are risk factors for high altitude retinal 
hemorrhages (HARH) or hemorrhagic stroke. At sea level, the incidence of 
cardiovascular disease, including stroke, in diabetes (especially type 2) is 
increased compared to subjects without diabetes.(35) At altitude, the 
incidence of stroke  seems to be increased. This increase is associated with 
prolonged stay at very high and extreme altitude. Polycythemia, in the 
context of increased red blood cell mass due to stimulated erythropoietin 




increased risk of dehydration and vascular disorders in diabetes super - 
imposed on the effects of altitude (hypoxia, increased viscosity, and 
hypocapnia causing cerebral vasoconstriction), may render patients with 
type 2 diabetes particularly at risk for stroke at very high and extreme 
altitude. Still, this needs to be confirmed by future study. 
e. Sympatho-adrenergic effects
Altitude exposure elicits an increase in sympatho-adrenergic activity, which 
is highly relevant for glucose regulation in subjects with diabetes (see 
below). (38) In rest, acute exposure to altitude causes a rise in epinephrine 
with higher concentrations of epinephrine at higher altitudes. This initial 
increase in epinephrine partially restores to near sea level concentrations 
after 1-2 weeks and rises again with further elevation. (39) Norepinephrine 
concentrations are elevated at altitude, reflecting a persistent increase in 
sympathetic nervous system activity, even during and after prolonged 
altitude exposure.(40) 
 Under conditions of acute hypoxia, the epinephrine response to exercise 
is more profound than under normoxic (sea level) conditions. Again, this 
epinephrine response returns to sea level concentrations after acclimatization, 
while norepinephrine concentrations remain increased during exercise at 
altitude.(38) However, if the workload is adjusted to the corresponding relative 
workload at altitude (i.e. a similar percentage of VO2max), norepinephrine 
concentrations at altitude are similar to sea level values. (11) 
f. Gluco-regulatory effects
Glucose regulation is clearly affected by altitude exposure in subjects with 
and without diabetes. (41) A number of studies have been conducted to 
unravel the complex mechanisms in gluco-regulation under conditions of 
acute and prolonged hypoxia in rest and during exercise and are discussed 
below. 
 I. Acute hypoxia
In acute hypoxia, a state of relative hyperglycemia as reflected by plasma 
glucose and insulin concentrations (3500, 5080m) (39), and a decrease in 
insulin stimulated glucose uptake is induced as demonstrated by findings 
from hyperinsulinemic euglycemic clamping (4559m). (41)
 Labeled glucose tracer studies show an increase in glucose rate of 
appearance and disappearance, and leg glucose uptake at 4300m on acute 
altitude exposure (42,43). Both beta-blockage and sub-maximal exercise 
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augment these effects. The increased turnover of glucose under beta–
blockade suggests that epinephrine is not solely responsible for the 
increments in glucose appearance but epinephrine may be involved in the 
initially decreased insulin stimulated glucose uptake in skeletal muscle and 
increased muscle glycogenolysis. (Fig. 2) (42) Central sympathetic inhibition 
by clonidine attenuates the initial insulin resistance induced by acute 
altitude exposure as shown in a clamp study. (44) This suggests an 
important role for the sympathetic nervous system in hypoxia-induced 
insulin resistance.
 II. Acclimatization
After prolonged altitude exposure (acclimatization), fasting glucose 
concentrations seem decreased while the concentration of insulin is 
unchanged and the glucose rate of appearance remains increased (43) 
This suggests a transition from an initial decrease, to a subsequent increase 
in glucose disposal during prolonged (weeks) stay at altitude. Glucose 
concentrations increase again when one ascends to higher elevations. 
Hereafter, again normalization of glucose concentrations occurs and these 
changes in glucose are paralleled by similar changes in epinephrine. (42) 
Cortisol seems to follow this same pattern while growth hormone seems to 
be increased only after prolonged stay at very high or extreme altitudes 
(39,45)
 III. Exercise 
Acute altitude exposure exaggerates the increases in epinephrine, glucose 
rate of appearance and the glucose disappearance, in response to 
sub-maximal exercise. The plasma glucose concentrations in response to 
exercise are similar at sea level and during acute altitude exposure.(42,43)
With acclimatization, appearance and disappearance rates of glucose 
increase further. Glucose concentrations in rest and during exercise drop 
as compared to sea level (43) suggesting increased glucose disappearance 
or decreased glucose production. Increased glucose disappearance may 
be explained by the fact that both exercise and hypoxia facilitate insulin 
independent glucose uptake into skeletal muscle. (46) Possibly this 
contributes to the creation of a new equilibrium with lower fasting glucose 
concentrations seen after acclimatization as compared to sea level. 
In summary, in non-diabetic subjects, altitude exposure seems to induce a 
state of temporary insulin resistance paralleled by sympatho-adrenergic 




state of increased dependency on glucose (increased glucose production 
and disposal) appears, resulting in lower fasting blood glucose concentrations. 
(Fig. 2)
Glucoregulatory effects in subjects with diabetes
Type 1 diabetes 
Relative to sea level, most previous studies in subjects with type 1 diabetes 
have reported reductions in insulin doses at lower altitudes and increments 
in doses at higher altitudes (>3700-5000m).(Fig 1) (47-49) Very high or 
extreme altitude seems to be associated with increased insulin requirements 
and worsening of HbA1C, despite the exercise.(28)  In most studies, carbohydrate 
intake was not monitored. A case report observed hyperglycemia despite 
increased exercise with unchanged food intake and insulin dosing at 
4000m. (49) One study that reported reduced insulin requirements by 49% 
during the ascent of mount Kilimanjaro, also noted that four out of fifteen 
subjects with diabetes developed ketonuria of which two keto-acidosis. (50) 
This suggests relative under dosage of insulin; the insulin dosage was 
reduced but the requirements may have been equal or even increased 
relative to sea level. 
Hypoxia and AMS stimulate sympatho-adrenergic activity (51), which may 
partly explain the loss of glycemic control. (Fig. 2) We have reported a 
positive correlation between increased insulin requirements and AMS 
symptom scores. (47) More studies are needed to document the changes 
in sympathetic nervous system activity and gluco-counter regulatory 
hormones in response to altitude exposure in subjects with diabetes. 
 Cold may also play a role in increased insulin requirements as it may 
decrease the potency of insulin and the absorption of insulin from 
subcutaneous injection sites. As relative exercise intensity, and thereby 
catecholamine responses, increase with (acute) altitude exposure, glucose 
concentrations may be higher at higher altitudes.
 A number of changes associated with altitude may increase the risk of 
hypoglycemia: the facilitated glucose uptake in skeletal muscle as a result 
of hypoxia and exercise; increased glucose disposal with acclimatization; 
appetite suppression common at altitude, and difficulties in distinguishing 
symptoms of hypoglycemia from AMS (50). Most exercising subjects with 
diabetes preferentially adjust insulin requirements to avoid hypoglycemia, 
thus rather seeing hyperglycemia as a result. 
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 In summary,  in type 1 diabetes it appears that due to the lower exercise 
intensity relative to hypoxia, and the lower concentrations of gluco-counter 
regulatory hormones, while AMS is infrequent, blood glucose decreases at 
lower altitudes in response to exercise. However it is unknown whether the 
glucose lowering effect at lower altitudes is greater than the glucose 
lowering effect of exercise at sea level. The opposite occurs at very high to 
extreme altitudes resulting in hyperglycemia despite exercise and possible 
anorexia. (Fig. 2) These mechanisms explain the observed differences in 
insulin need at different altitudes. (44)
C
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Figure 2   Concept of glucoregulation at altitude
Acute hypoxia stimulates (as indicated by arrows) the sympathetic nervous system (SNS) and 
the production of epinephrine, norepinephrine and cortisol. This inhibits (indicated by T-shaped 
lines) insulin-stimulated skeletal muscle glucose uptake, stimulates muscle (and liver) glyco- 
genolysis and increases lactate production resulting in an increased glucose production by the 
liver. Exercise and hypoxia may partly compensate this relative hyperglycemia by stimulating 
insulin independent skeletal muscle glucose uptake and insulin dependent glucose uptake 
(insulin sensitizing effect of exercise indicated by dashed line). After acclimatization, the counter- 
regulatory actions of epinephrine (and cortisol) decrease while glucose uptake is still enhanced 
by hypoxia and exercise. Possibly, this overcomes the remaining increment in norepinephrine 
levels that may play a partial role in (hepatic) glucose production and inhibition of insulin action. 
The presence of AMS (Acute Mountain Sickness) causes increased activity of the sympathetic 
nervous system contributing to glucose counter-regulation. (see text for details)
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Type 2 diabetes 
A number of studies have investigated glucose and insulin sensitivity in 
response to exercise under hypoxic conditions in type 2 diabetes. Mackenzie 
et al. showed that one hour of exercise while breathing 14.8% O2 
(corresponding to ± 2800m) increased glucose disposal and decreased 
blood glucose levels and HOMA-IR to a greater extent than normoxic 
exercise in subjects with uncomplicated type 2 diabetes. (52) After acclima-
tization, we found lower fasting insulin concentrations while fasting glucose 
and food intake did not differ from sea level values in 12 subjects with 
uncomplicated type 2 diabetes hiking up to 4167m. Also, we did not observe 
changes in the number of (mild) hypoglycemic episodes whereas the number 
of hyperglycemic episodes initially increased at high altitude compared to 
sea level. There were no differences in glycemia between subjects using 
insulin, metformin, sulphonylurea derivatives, dipeptidyl peptidase-4 inhibitors 
or thiazolidinedione although the numbers of subjects using these drugs were 
small. (30) Schobersberger et al. found reductions in glucose concentrations 
and HOMA-IR after oral glucose loading, following 3 weeks of exercise at 
1700m in subjects with metabolic syndrome, four of whom had type 2 
diabetes.(31) These findings indicate increased insulin sensitivity at high to 
very high altitude and a possible additive effect of hypoxia and exercise in 
type 2 diabetes.
 In summary, in subjects with type 2 diabetes, altitude does not seem to 
cause major glycemic changes and possibly even contributes to improved 
insulin sensitivity. However, data is very limited, and only comprises studies 
at relatively low (sometimes simulated and acute) elevations (1700-4000m). 
We advice to continue antihyperglycemic medication at altitude. One should 
anticipate possible hyperglycemia during the first days at higher altitudes 
especially following a rapid ascent. Short acting insulin to correct hyper- 
glycemia should be carried. After acclimatization, reductions in insulin and 
sulphonylurea derivatives may be necessary especially during prolonged sub- 
maximal exercise. 
g. Effect on body mass and fluid balances
A commonly reported finding at altitude is appetite loss, perhaps associated 
with changes in hormones affecting satiety and resulting in decreased food 
intake. (53,54) Together with increased energy needs, this often results in a 
caloric imbalance and weight loss.  Furthermore, renal excretion of body 
water and insensible fluid losses, due to the increase in ventilatory rate and 
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perspiration during exercise, can contribute to the weight loss at altitude. 
(55)
 Theoretically, especially in subjects with type 1 diabetes, fluid loss and 
a tendency towards hyperglycemia at altitude, may increase the risk of 
dehydration and the development of diabetic ketoacidosis. One case of an 
experienced diabetic climber with severe dehydration in the absence of 
ketoacidosis managed by saline infusion (28) , and two cases of diabetic 
ketoacidosis on descent from Mt Kilimanjaro have been reported. (50) The 
latter were probably induced by a reduction in insulin doses and continued 
exercise whilst present ketonuria, but dehydration may have played a role. 
 Adequate fluid intake to balance fluid losses at altitude is paramount for 
successful altitude travel as dehydration at altitude is a common finding. 
Fluid intake and hydration status can be based on urine quantity (equal to, 
or initially even more than at sea level) and color (light yellow urine indicating 
proper fluid status; dark urine indicating dehydration). (56) However, in case 
of glucosuria, urine quantity and color cannot be used to judge fluid status. 
Because early fluid retention due to decreased renal excretion of body 
water is associated with the development of AMS, over-hydration should be 
avoided.(57)
Acute mountain illnesses
Acute mountain illnesses comprise a spectrum of conditions ranging from 
a mild, self-limiting disease; acute mountain sickness (AMS), to potentially 
lethal conditions such as high altitude pulmonary edema (HAPE) and high 
altitude cerebral edema (HACE). See Table 1.
 AMS is uncommon at altitudes below 2500m. The exact pathophysiology 
of AMS is unknown. (58) Its symptoms can present within hours of (often 
acute) altitude exposure. Physical fitness does not protect against AMS and 
both sexes and all ages are affected. HACE refers to a condition in which 
the patient with AMS deteriorates due to cerebral edema and increased 
intra-cranial pressure. In HAPE subjects can deteriorate quickly as signs of 
pulmonary edema develop. The pathogenesis of HAPE comprises hypoxic 
pulmonary vasoconstriction, increased pulmonary capillary pressure, and 
increased capillary endothelial permeability resulting in edema.(59) 
 High altitude retinal hemorrhage (HARH) is frequently found in subjects 





Acute mountain illnesses in subjects with diabetes
Preventive measures, treatment and diabetes specific points of attention 
are listed in Table 1. The incidence of AMS in subjects with type 1 diabetes 
does not differ from non-diabetic subjects and the use of acetazolamide 
was similar in both groups (47,50,61). Acetazolamide should be used with 
caution as it may lead to increased diuresis and acidosis. (62) Theoretically 
this may precipitate the development of diabetic ketoacidosis although this 
has not been shown in humans. In fact, the International Mountaineering 
and Climbing Federation advices against the use of acetazolamide in subjects 
with type 1 diabetes. (63) The alternative prophylactic drug for AMS, dexa-
methasone, is unattractive as it causes hyperglycemia. (64) We have found 
a total of eight reported or cited cases of diabetic keto-acidosis at altitude, 
three of which were lethal (65), and one occurred in a subject with 
undiagnosed type 2 diabetes and HAPE.(66) One fatal case of HACE in a 
subject with type 1 diabetes was reported (67), and one case of AMS in a 
subject with metabolic syndrome (68). Type 2 diabetes is associated with 
obesity and a lower ventilatory response to hypoxia (6), both risk factors for 
the development of AMS. (69,70)  Subjects with type 2 diabetes may 
therefore be at higher risk for AMS. We found, however, no differences in 
AMS symptoms compared to non-diabetic subjects up to 4167m altitude. 
(30) HACE has not been reported in subjects with type 2 diabetes. 
Acetazolamide can be used in subjects with type 2 diabetes taken into 
account the earlier mentioned restrictions. The risk of developing keto- 
acidosis is probably low in subjects with type 2 diabetes on oral antihyper-
glycemic drugs, but in insulin deficient diabetes type 2, the risk of development 
of ketoacidosis is probably approaching the risk in diabetes type 1.  
Specific conditions
High altitude retinal hemorrhage. (HARH)
Previous studies have found no retinal hemorrhages in 6 subjects with 
uncomplicated diabetes type 1 with good glycemic control at altitudes 
ranging from 5800 up to 8201m (28), and 2 cases of asymptomatic HARH 
in a group of 15 subjects with type 1 diabetes, after summiting Mt Kilimanjaro. 
(50) One of these two cases had pre-existing background retinopathy; 
hemorrhages resolved within three months. Leal et al. investigated 7 
subjects with well controlled type 1 diabetes by non-midriatic retinography 
prior to and two weeks after an average stay of ± 30 days above 5000m 























































































































































































































































































































































































































































































































































































































































































































Thus, it is advised that any patient with diabetes undergoes an ophthalmo-
logical exam by a skilled specialist prior to, and after very high and extreme 
altitude visits.
Neuropathy
Cold perception may be impaired in subjects with diabetes, even if signs of 
peripheral sensory neuropathy are absent (72). This can lead to serious 
cold injuries under extreme conditions at altitude. Daily inspection of 
extremities exposed to cold, maintenance of adequate nutrition, hydration, 
foot- (good fit, non-sweating socks with good insulation) and hand-wear 
(mittens instead of gloves, consider chemical hand warmers) and layered 
clothing comprise basic precautions to prevent cold injuries.
Blood Glucose Monitoring
The performance of hand held blood glucose meters (BGM) can be affected 
by environmental conditions at altitude. Most studies have reported 
overestimation of true blood glucose concentrations and possibly better 
performance of glucose dehydrogenase based, as opposed to glucose 
oxidase based, blood glucose meters at altitude.(73,74) Of all interfering 
factors, cold may be more problematic than hypoxia in accurate blood 
glucose determination at altitude (73,75) as modern BGMs do not show 
large deviations from true blood glucose when kept above freezing point. 
(74,76) Keeping test strips, batteries and BGMs above freezing point is of 
major importance. This can be done by wearing them in pouches close to 
bare skin and inside all layers of clothing. Regular assessment of BGM 
accuracy with glucose control solutions is recommended. (Fig 3)
 Continuous glucose monitoring (CGM) may limit the necessity for 
frequent capillary blood glucose measurements and built-in alarms for 
changing glucose levels are a practical advantage. An early study on the 
accuracy and reliability of a CGM system at altitude is promising, but further 
studies are warranted. (77)  Some CGMs are susceptible for interference 
caused by local tissue hypoxia, temperature and chemicals such as, 
amongst others, acetaminophen. (78,79)
Insulin storage and insulin delivery
At altitude both freezing and prolonged exposure to sunlight or high temperature 
(> 30º C) can lead to loss of insulin’s potency or freezing of insulin. (80) 
(Fig.3) Freezing can be prevented by keeping insulin close to skin. (47,67)
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 Modern insulin pumps have built-in pressure equilibration mechanisms, 
but some pumps have been reported to deliver excess insulin due to (sub-)
acute pressure changes during air flight. (81) However, excess insulin 
delivery was limited and predictable. It is unknown whether this phenomenon 
could have clinical implications during gradual ascents such as hiking at 
altitude. Part of the contradictory results on this aspect might be due to the 
inadvertent presence of small air bubbles in the insulin vials: expansion of 
bubbles might influence insulin delivery. Care must be taken to remove 
such air bubbles as much as possible before starting to use the vials in a 
pump or for injections.
Safety measures
Trekking at altitude is often associated with conditions of low-hygiene and 
scarcity of (adequate) medical care. Therefore, basic therapeutic supplies 
C
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Table 2   Attention points for physically active subjects with diabetes at altitude
Predeparture: 
- Inform and instruct fellow travelers and expedition leaders of your diabetes and 
its treatment, including emergency medical treatment  (e.g. glucagon injection).
- Obtain information about local medical aid and (diabetic) resources.
- Consult your physician when planning high altitude travel (including an ophthal-
mologist in case of very high and extreme altitude travel).
- Make yourself familiar with diabetes management in the environment (cold, 
terrain) and with the intensity of exercise anticipated at altitude.
- Obtain adequate clothing for all conditions and test it prior to departure.
- Take spare supplies including short acting insulin. (Fig 3)
At altitude:
- Stay in close contact with fellow hikers/travelers
- Anticipate frequent blood glucose monitoring and correct glucose accordingly.
- Insulin requirements and oral antihyperglycemic dosages may be decreased 
due to exercise and appetite loss.
- Insulin doses may be increased especially in case of high altitude illnesses, 
rapid ascents and at higher (extreme) altitudes.
- Prevent BGMs, pumps, catheters and insulin from freezing.
- Take adequate fluids and nutrition high in carbohydrates in case of prolonged 
exercise at altitude.
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should be carried. Medical emergencies often require expensive helicopter 
assistance and not only altitude, but many other factors hamper a successful 
helicopter rescue. Adequate insurance coverage should be arranged 
before departure. It is of vital importance to notify travel companions and 
guides of the hiker’s diabetes and to teach them how to recognize (severe) 
hypo- and hyperglycemia. Travel companions should be able to measure 
blood glucose and should be instructed how to administer glucose or inject 
insulin and glucagon. Furthermore, carrying an emergency medical kit with 
instructions in a common, easily accessible place is of vital importance. 
(Fig 3)
Figure 3   Diabetes travel supplies and recommendations for altitude 
activities of multiple days duration
All items should be taken in sufficient quantities (triple the normal amount), easy accessible and 
in separate rucksacks (e.g. subject and fellow traveler). A third pack should be stored at a timely 
reachable place (e.g. hotel, base camp).
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Conclusions and recommendations
Subjects with diabetes should not be discouraged to take part in activities 
at altitude. Most likely, active and sensible subjects with well-controlled, 
uncomplicated diabetes will not experience major problems at high, or even 
very high altitudes, provided that they take sufficient time to acclimatize. 
However, factors including diabetic complications and co-morbidities, 
exposure to very high- and extreme- altitudes or extreme conditions 
(especially cold exposure), can complicate successful altitude travel and 
demand careful preparation and planning of diabetes management. 
Important both for and treating physician is to check for contra-indications 
for altitude travel, to promote adequate self management skills and 
understanding of diabetes regulation, and to compose an individualized 
plan that limits risks and includes treatment adjustments. Recommenda-
tions for altitude travel for subjects with diabetes and their treating physician 
are listed in Figure 3 and Table 2.
 Clearly, the presence of diabetes can increase the potential dangers 
of extreme altitude travel. Still, even the highest mountains in the world can 
be conquered by subjects with diabetes as evidenced by several subjects 
with diabetes successfully summiting Mt. Everest. Despite the potential 
difficulties, the accomplishment of summiting a mountain, finishing a hiking trail 
or just enjoying a skiing holiday, will definitely boost a sense of achievement 
and well being in the individual with diabetes.
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Due to increased numbers of people with diabetes taking part in extreme 
sports (e.g. high-altitude trekking) reliable handheld blood glucose meters 
(BGMs) are necessary. Accurate blood glucose measurement under 
extreme conditions is paramount for safe recreation at altitude. Prior studies 
reported bias in blood glucose measurements using different BGMs at high 
altitude. We hypothesize that glucose-oxidase based BGMs are more 
influenced by the lower atmospheric oxygen pressure at altitude than 
glucose dehydrogenase based BGMs.
Methodology/ Principal Findings: 
Glucose measurements at simulated altitude of nine BGMs (six glucose 
dehydrogenase and three glucose oxidase BGMs) were compared to 
glucose measurement on a similar BGM at sea level and to a laboratory 
glucose reference method. Venous blood samples of four different glucose 
levels were used. Moreover, two glucose oxidase and two glucose dehydro- 
genase BGMs were evaluated at different altitudes on Mount Kilimanjaro. 
Accuracy criteria were set at a bias <15% from reference glucose (when 
>6.5mmol/L) and < 1mmol/L from reference glucose (when <6.5 mmol/L). 
No significant difference was observed between measurements at 
simulated altitude and sea level for either glucose oxidase based BGMs or 
glucose dehydrogenase based BGMsas a group phenomenon. Two GDH 
based BGMs did not meet set performance criteria. Most BGMs are 
generally overestimating the true glucose concentration at high altitude. 
Conclusion: 
At simulated high altitude all tested BGMs, including glucose oxidase based 
BGMs, did not show influence of low atmospheric oxygen pressure. All BGMs, 
except for two GDH based BGMs, performed within predefined criteria. At true 
high altitude one GDH based BGM had best precision and accuracy.
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Introduction
Regular exercise and a healthy life style should be part of daily life of 
everybody, but definitely of any person with diabetes mellitus. Minimal 
requirements for exercise have been formulated, with a minimum of five 
times weekly 30 minutes of vigorous exercise or brisk walking. However, 
increasing numbers of people with diabetes do participate in more strenuous 
forms of physical activity, amongst others high-altitude trekking and mountain 
climbing. These kinds of activities do pose special challenges to subjects 
with diabetes mellitus treated with insulin. Glucose levels have to be kept 
under good control, and it is a challenge to find a balance between energy 
intake, energy expenditure, blood glucose levels, and insulin requirements. 
In general, frequent assessment of blood glucose levels will be necessary 
to allow proper adjustments. 
 Therefore, both accuracy and easy accessibility of frequent blood 
glucose measurements in subjects with type 1 diabetes mellitus are paramount 
for a safe activity at high altitude. 
 Previous studies have examined the accuracy and reliability of various 
glucose meters at (simulated) altitudes up to 5,000 m. These and other 
studies with type 1 diabetes mellitus patients indicated a considerable subset of 
the handheld blood glucose meters (BGMs) to be unreliable at high altitude 
(1-6). One could hypothesize that glucose oxidase (GOX) BGMs, which use 
oxygen as one of the substrates, would underestimate true glucose values 
since less oxygen is available under hypobaric conditions. This effect 
has been demonstrated by some (5). Others have demonstrated oxygen 
independent BGMs using glucose dehydrogenase (GDH), to perform better 
under hypobaric conditions and GOX based BGMs to underestimate true 
blood glucose levels (1). However, these studies were limited by field- or 
simulated altitude settings only (3-5), test protocols using only GOX based 
BGMs (3), test protocols up to simulated altitudes < 4500m (3-5) or with 
outdated material (3,4). 
Since we planned an expedition to climb Mount Kilimanjaro with a team of 
people with type 1 diabetes mellitus, we were in need of the most reliable 
handheld BGMs up to 6000m altitude. The purpose of this study was to 
investigate whether modern GDH or GOX based BGMs are reliable under 




 We hypothesized, that GDH based BGMs would be more accurate 
than GOX based BGMs at high altitude, since GDH based BGMs are by 
definition less oxygen dependent in their reaction than GOX based BGMs.
Methods
Two experiments were performed; First, all BGMs were tested at simulated 
altitudes in a hypobaric chamber. Second, a selection of GOX and GDH 
based BGMs in the first experiment were used during the ascent of Mount 
Kilimanjaro (5895m). the local ethics committee of the Isala Clinics Zwolle, 
the Netherlands, approved the study protocol and all participants gave 
written informed consent. 
Hypobaric chamber experiment
We used a hypobaric chamber of the Dutch Airforce Research facility in 
Soesterberg, The Netherlands. Six GDH and three GOX based BGMs were 
tested at simulated altitudes: sea level, 2000m, 3000m, 4000m and 5000m 
while temperature (20° C) and humidity were kept constant. GDH based 
BGMs used were; Freestyle Mini and Precision X-ceed  (both Abbott 
Diabetes Care, USA), Hemocue 201+ (Quest Diagnostics U.K.), Accu-Chek 
Aviva and Accu-Chek Compact Plus (both Roche Diagnostics, Switzerland) 
and the Contour Link (Bayer, Germany). GOX based BGMs were; Glucocard 
Memory (Menarini Diagnostics, Italy) Statstrip (Nova Biomedical, USA) and 
the Klinion (Klinion Diabetes Care, Medeco the Netherlands). All BGMs 
used were new - i.e. the same BGM was not extensively used for medical 
practice before the experiments took place - to prevent errors from wear 
and tear. Venous blood drawn from a healthy individual spiked to a glucose 
concentration of 5, 10, 15 and 20 mmol/L was used as substrate to test 
BGMs. True glucose values were determined with the laboratory certified 
Glucose Hexokinase (GHex) based method (Roche Diagnostics, Manheim, 
Germany). This GHex method is aligned with the GC-MS glucose reference 
method. BGMs were simultaneously tested inside and outside the hypobaric 
chamber, and samples were tested in duplicate. 
 To prevent glucose variation due to time-dependent glycolysis by cellular 
uptake in blood samples (5-7% per hour (7), a blood sample was prepared 
for GHex reference testing using a perchloric acid preparation method. The 
latter was done at the time spiked glucose samples were prepared – prior 
to BGM and GHex testing. These blood samples were used for both GHex 
and BGM glucose testing under normobaric and hypobaric conditions.
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Field experiment
On Mount Kilimanjaro testing took place at incremental altitudes (range 
1300-4600m) using capillary blood samples from eight subjects with type 1 
diabetes and eight healthy control subjects. Care was taken to take a full 
droplet of blood from a subject’s warm and clean index finger. Four BGMs, 
two GDH based BGMs (Accu-Chek Compact Plus and Contour) and two 
GOX based BGMs (Klinion and Glucocard) were used. Samples were 
tested at temperatures ranging from ±10-30°C using one single sample of 
each subject. GHex reference testing was not available at altitude. Instead, 
standard reference solutions ( glucose range 2.4 – 4.1 ; 4.4 – 6.7 and 14.0 
– 17.9 mmol/L; NOVA biomedical, USA) were used to test within-BGM 
performance at different altitudes. These control solutions are made for the 
Statstrip BGM and were primarily used to observe possible consistent 
biases in BGMs within that same BGM (precision) with repeated measures 
at different altitudes. For between BGM performance comparison the 
best-tested BGM from the hypobaric experiment –the GDH based 
Accu-Chek Compact Plus- was used as a reference. No air humidity was 
measured a altitude. 
Analysis and statistics 
Performance criteria for BGMs were set at a difference of ±1 mmol/L of the 
reference method when , <6.5 mmol/L, or ±15% when the reference sample 
read ≥6.5 mmol/L (Dutch Organisation of Applied Physics and Science 
(‘‘TNO’’) guideline, the Netherlands). Furthermore, Clarke’s error grid 
analysis was used to determine clinically relevant accuracy. (8) The error 
grid plots the reference glucose and the glucose measured by the BGM on 
a x-y plot. The grid is divided into 5 zones (A–E) of clinical accuracy and 
corresponding treatment assumptions to correct the glucose value. Zone A 
represents the target glucose range and glucose values are clinically 
accurate; Zone B represents glucose values that deviate >15% from the 
reference glucose leading to no or benign treatment; Zone C glucose values 
would lead to overcorrection of acceptable glucose values causing hyper- 
or hypoglycemia; Zone D represents glucose values that could lead to 
dangerous misdetection and failure to treat; Zone E glucose values are 
opposite from the reference glucose leading to very dangerous treatment 
decisions. Values in zone A and B are considered clinically acceptable. 
Glucose measured by BGMs is presented in means (mmol/L) ± SEM 




method is presented in percentage (%) and it’s range. Overestimation is 




Each sample was tested in duplicate under hypobaric and normobaric 
conditions simultaneously and results are presented as the mean glucose 
levels with absolute (mmol/L) or relative (%) bias from GHex glucose 
determination.
 Four of six tested GDH and all three GOX based BGMs performed 
within predefined performance criteria of ± 1.0 mmol/L when reference 
glucose was <6.5 mmol/L and ± 15% when reference glucose was > 6.5 
mmol/L at all simulated altitudes. There were no mechanical failures due to 
hypobaric conditions.
 One GDH based BGM (Freestyle mini) showed biases (range 15.2 to 
18.5%) outside of predefined criteria for 7 out of 20 tested glucose samples 
at simulated altitudes of 2000m and 3000m. Also, this BGM showed biases 
outside of predefined criteria at 4 out of 20 sea level readings (range 16.0 to 
18.5%). 
 Furthermore, another GDH based BGM (Precision X-ceed) only 
showed biases outside of predefined criteria at sea level for 5, 10 and 15 
mmol/L glucose samples (Table 1). In general, under hypobaric conditions 
(at simulated altitude) both the GOX and GDH based BGMs tended to 
overestimate glucose levels compared to normobaric conditions (bias range; 
GDH BGMs: -8.2 to +16.9 % and GOX BGMs: 0 to +10.8%)  (Figure 1, 2 and 
Table 1, 2). Table 1 and 2 demonstrate the relative bias (%) of the 10 mmol/L 
test sample, and are representative for the remaining tested glucose samples 
(5, 15 and 20 mmol/L).
As a group phenomenon no significant difference was observed between 
GOX- and GDH-BGMs under hypobaric conditions (Bias at 2000-5000m 
5.8 ± 7.9 %; (range:    -5.0 to +19.1 %) vs. 7.5 ± 6.5 % (range: -3.5 to + 22.1) 




























































































































































































































































































































































































































































Indeed, differences observed were seen in all tested glucose concentrations 
and were therefore not sample dependent. 
 Moreover, no trend in bias was seen for the individual BGMs with 
increasing simulated altitude. However, one GDH-based BGM performed better 
under hypobaric than under normobaric conditions (Precision Xceed).
The best performing BGM under hypo- and normobaric conditions and at 
all glucose concentrations tested was the GDH based BGM Accu-chek 
Compact Plus. When further assessing the specific results of the Accu-chek 
Compact Plus, there was a trend of greater overestimation of 10 and 15 
mmol/L glucose samples at higher simulated altitudes. Furthermore, the 
smallest of biases was found in the 20 mmol/L sample. However, the bias 
of this BGM (bias range -1.1 to 6.7% at all glucose concentrations and 
simulated altitudes) was well within predefined criteria for acceptable bias 
and within meter variation was minimal. Moreover, the meter was user- 
friendly, which is important, especially under extreme conditions such as 
high altitude mountaineering. 
Field experiment
Three standard glucose control solutions were used as a crude reference 
method of BGM performance at Mt Kilimanjaro at altitudes of 1300m, 
3000m, 3700m and 4600m . Also one single sample of capillary blood of 
Table 2   Relative bias (%) of GOX based BGMs compared to the 
Hexokinase laboratory reference method at different altitudes  
(10 mmol/L glucose sample)

















0 10.05 12.6 9.5 -5.8 5.2 2.9 5.2
2000 9.73 14.7 10.8 -7.5 0.8 3.7 3.7
3000 9.38 11.1 5.8 -2.5 3.4 -5.3 4.8
4000 8.93 4.5 6.1 -0.8 0.8 3.5 6.1
5000 8.50 2.3 5.6 -2.4 0.0 4.5 6.6
Note: normobaric BGMs stay at sea level. (normo= bias under normobaric conditions (sea level); 
hypo= bias under hypobaric conditions (simulated altitude), * = reference method.
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eight subjects with type 1 diabetes mellitus and eight healthy control subjects 
was used to test BGMs at altitudes of 1300m, 3000m, 3770m, 3900m and 
4600m altitude.  
 Measurements with the standard glucose control solutions demonstrated 
consistent results of all BGMs except for the Klinion GOX based BGM which 
showed a large within BGM variance at different altitudes in all glucose 
C
hapter 3
Figure 1   Error grid analysis of 5, 10, 15 and 20 mmol/L glucose testing 
samples of BGMs (y-axis) against reference (GHex) (x-axis) at 
sea level (mmol/L)
Note: Leftward deviation from dashed line means overestimation of true glucose by tested BGM 
compared to GHex reference glucose and vice versa. No differences were noted outside of 
predefined criteria due to testing conditions at sealevel (0 m) in and outside the hypobaric 
chamber. 
Black diamonds = Contour; Black squares = Accu Chek Aviva; Black circles = Accuchek 
Compact Plus; Black triangles = Freestyle Mini; Black Asterixes = Precision; Black stripes = 
Hemocue; White squares = Klinion; White circles = Statstrip; White diamonds = Glucocard; 
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ranges tested. (Table 3) However, when analyzing BGM accuracy in relation 
to the glucose solutions reference measurements one GOX based BGM 
(Glucocard) consistently underestimated true glucose measurement 
especially in the lower glucose range (2.4 to 4.4 mmol/L). These results 
correlated with results previously obtained in the hypobaric chamber. 
Figure 2   Error grid analysis of 5, 10, 15 and 20 mmol/L glucose testing 
samples of BGMs (y- axis) against reference (GHex) (x-axis) at 
5000m simulated altitude (mmol/L)
Note: Leftward deviation from dashed line means overestimation of true glucose by tested BGM 
compared to GHex reference glucose and vice versa. 
Black diamonds = Contour; Black squares = Accu Chek Aviva; Black circles = Accuchek 
Compact Plus; Black triangles = Freestyle Mini; Black Asterixes = Precision; Black stripes = 
Hemocue; 
White squares = Klinion; White circles = Statstrip; White diamonds = Glucocard; Dashed line 
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 When comparing BGMs on Mount Kilimanjaro with the best tested 
BGM in the hypobaric chamber (Accuchek Compact Plus; a GDH based 
BGM) for capillary glucose samples of subjects with type 1 diabetes mellitus 
and healthy controls at altitudes ranging 1300-4600m, a total of 228 paired 
glucose measurements were analyzed. Of these, 47 (21%) were outside of 
set performance criteria primarily observed in the 3.6 to 5.2 mmol/L mean 
glucose range, and specifically due to an overestimation. (Fig 3.) In 
comparison to the reference BGM, the Glucocard, a GOX based BGM, 
performed better than the Contour (GDH) and the Klinion (GOX) BGMs. (3 
vs. 10 vs. 8% of bias outside performance criteria respectively). Most BGM 
performance criteria violations were observed at altitudes of 3000-3900m .
C
hapter 3
Table 3   GOX and GDH based BGMs on Mount Kilimanjaro at different 
altitudes tested with standard glucose solutions
Altitude Control  
solution
GDH BGM GOX BGM 
(m) Glucose 
(mmol/L)




1300 m 2.4 – 4.1 3.9 2.7 4.6 1.9
4.4 – 6.7 5.6 5.5 6.0 4.7
14.0 – 17.9 14.7 15.7 17.5 14.7
3000 m 2.4 – 4.1 3.9 3.0 3.0 1.6
4.4 -6.7 5.9 5.6 5.6 4.3
14.0-17.9 14.9 16.6 15.5 14.2
3700 m 2.4-4.1 3.9 2.5 3.2 1.8
4.4-6.7 5.4 5.7 5.9 4.4
14.0-17.9 14.5 15.5 16.4 13.8
4600 m 2.4-4.1 3.8 3.1 2.6 1.4
4.4-6.7 6.0 5.9 4.9 4.2
14.0-17.9 14.9 16.2 13.9 14.0
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Discussion
The present study was conducted to test accuracy and reliability of GOX 
and GDH based BGMs at simulated and true high altitude. We hypothesized 
that oxygen independent GDH based BGMs would be more reliable and 
accurate at high altitude. In contrast to previous reports and our hypothesis, 
Figure 3   Error grid analysis of glucose samples of all (healthy controls 
and diabetes type 1) subjects measured by GOX- and GDH-BGMs 
(y-axis) at different altitudes on Mount Kilimanjaro (range 1300- 
4600m) compared to Accuchek BGM glucose as a reference 
method (x-axis); (mmol/L)
Note: leftward deviation from dashed line indicates overestimation of glucose measured by 
BGM and rightward deviation means underestimation by BGM compared to Accu-Chek BGM. 
Black diamonds = Contour; White squares = Klinion; White diamonds = Glucocard; Dashed 
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no significant differences were observed between GOX- and GDH-based 
BGMs at simulated high altitude in all tested glucose ranges. 
 At true high altitude within-meter variation and accuracy compared to 
standard reference glucose solutions was better in the GDH based BGMs, 
and best in the Accu-Chek Compact Plus BGM, independent from glucose 
solution used. 
 In general, most BGMs tended to overestimate blood glucose at high 
altitude.  
At simulated high altitude one GDH based BGM performed better under 
hypobaric conditions (Precision Xceed), possibly due to in-meter failure of 
the normobaric BGM. This is suggested by the fact that under normobaric 
conditions (sea level) this BGM showed constant biases close to 15% in the 
5, 10 and 15 mmol/L glucose samples. Furthermore, the most inaccurate 
BGM in all glucose ranges was the GDH based Freestyle Mini (28% of total 
glucose readings > +15% bias) without an apparent effect of altitude. 
Lastly, there was a time dependent glucose lowering effect seen in the 
reference samples (GHex) possibly due to cellular uptake despite perchloric 
acid preparation of samples. (Table 1, 2) As expected, a parallel decrement 
in glucose was observed when testing all BGMs.
 At true high altitude, the GOX based Glucocard BGM had good 
within-meter  variation and was reasonably accurate compared to the 
reference BGM. However, when testing with standard reference glucose 
solutions, it constantly showed underestimation of the lowest glucose 
reference sample and was at the low end of the other reference samples. 
This is not well explained by chemical technique used as the other GOX 
based BGM (Klinion) did not show this phenomenon. A possible explanation 
might be that substances in the reference glucose solution or errors in test 
strips interfered with glucose measurement in this meter. (9)
 Overestimation of glucose by BGMs at true altitude could have dangerous 
consequences when hypoglycemia is falsely not shown by BGM readings 
and hypoglycemic symptoms might not be fully sensed due to extreme 
conditions. At the hyperglycemic range, the therapeutic decisions made 
due to overestimation of true blood glucose have less consequences than 
in the hypoglycemic range, where not treating hypoglycemia could lead to 
life threatening conditions.  In this perspective,  the findings of underestimation 
by the Glucocard GOX based BGM in the low glycemic range are not 




of glucose by BGMs at simulated altitude is truly present at true altitude this 
might lead to dangerous situations. However, at simulated altitude 
overestimation was limited to 17 (9%) of all measurements, all of which fell 
in the lower B zone of the error grid leading to no or benign treatment errors.
Research of BGMs at simulated high altitude up to 4000m by Gautier and 
co-workers has reported underestimation up to -28.9 % using venous blood 
samples of glucose ranges from 1.5 up to 26.3 mmol/L. However, this study 
did not differentiate between GOX or GDH based BGMs and BGMs used 
are outdated today. (4) Furthermore, Öberg and Östenson tested four GDH 
and one GOX based BGM at simulated and true high altitude up to 4500 
and 5895m respectively. Their study reported overestimation ranging from 
6.5 up to 15 % of the GOX based BGM at normo- and hyperglycemic 
glucose levels at 4500 and 2500m. GDH based BGMs performed better 
and overestimated true glucose levels by 0.8 to 6.5 % (1).  Interestingly, two 
similar GDH based BGMs were used and bias observed did not correspond 
with our study; the Contour (GDH based) BGM in their study showed an 
underestimation (-1.9 to -4.2%) and the Freestyle (GDH based) BGM only 
showed a bias of + 0.8% of both ~5.8 and ~16.5 mmol/L glucose samples. 
When GDH based BGMs were tested at true high altitude a wide range of 
bias was reported and no reference method was used. 
 Our results differ from the findings in previous research. First, we did 
not find a significant method-related difference between GOX and GDH 
based BGMs at simulated high altitude. Second, although not compared to 
a laboratory reference method, we did not find a wide range of bias in GOX 
and GDH based BGMs up to 4600m at true high altitude. 
 A possible explanation for the first difference observed in contrast to 
the study of Gautier and co-workers (4) might be improved oxygen-based 
technique and sensitivity of the reagent  for oxygen. This is reflected by the 
fact that it takes less time to read out glucose test strips results now than it 
took thirteen years ago, suggesting that GOX based BGMs need less 
oxygen in order to show a proper reaction. 
 In our study, BGMs were tested at simulated high altitude under constant 
temperature and humidity, using a laboratory reference method. Previous 
research reported low temperatures and humidity influence accuracy of 
BGMs independent of altitude (1-2). This might have compromised field 
research at true high altitude and explained the wide range of bias in cold 
conditions at 5895m in the other studies. (1,2). Since at 4600m we tested 
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BGM’s at 28° C, the difference in temperature might explain this contrasting 
result. 
This study has limitations that might influence its results. 
 First, on Mount Kilimanjaro we could only test BGM’s on within meter 
variation and relative bias compared to the best tested BGM, but not on true 
bias due to the lack of a laboratory reference method at high altitude. Also, 
the reference solution used was not compared to a laboratory reference 
method upon return from altitude. However, BGMs showed consistent 
findings that correlated well with results obtained with the hypobaric chamber 
experiment. 
 Second, on Mount Kilimanjaro blood glucose levels of tested BGMs 
were compared to the best performing BGM as a reference method based 
on results in a hypobaric chamber under constant environmental conditions. 
One could speculate that alternating temperatures and humidity on a 
mountain might influence the accuracy of tested BGMs and the accuracy of 
the reference BGM in particular, thereby compromising results. However, 
when testing with standard glucose solutions, the reference BGM showed 
best accuracy and within meter variation (Table 3). Moreover, in our study 
we tested BGMs at temperatures ranging from 10 to 28 °C and these are 
well within the range of temperatures stated by BGM manufacturers to 
provide reliable glucose measurements. 
 Based on the tests in the hypobaric chamber and at true high altitude 
we concluded that the Accu-check Compact Plus GDH based BGM was 
most accurate at simulated altitude and most precise at true high altitude. 
Conclusion
No differences were observed between GDH and GOX based BGMs at 
simulated altitude up to 5000m. All of the tested BGMs, except for two GDH 
based BGMs, performed within defined criteria for acceptable accuracy at 
simulated altitude. In general, at simulated high altitude BGMs tend to 
overestimate true glucose levels. At true high altitude GDH based BGMs 
performed better in relation to within-meter variation and accuracy. 
 If a similar effect of overestimation is present at true high altitude this 
could have dangerous consequences in the normo- and hypoglycemic range. 




methods with measurement of humidity and temperature as possible 
confounders are warranted.
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Increased insulin requirements  
during exercise at very high altitude 
in type 1 diabetes
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Safe, very high altitude trekking in subjects with type 1 diabetes requires 
understanding of glucose regulation at high altitude. We investigated insulin 
requirements, energy expenditure, and glucose levels at very high altitude 
in relation to acute mountain sickness (AMS) symptoms in individuals with 
type 1 diabetes.
Research Design and Methods: 
Eight individuals with complication-free type 1 diabetes took part in a 
14-day expedition to Mount Meru (4562 m) and Mount Kilimanjaro (5895 m) 
in Tanzania. Daily insulin doses, glucose levels, energy expenditure and 
acute mountain sickness symptoms were determined. Also, energy 
expenditure, and AMS symptoms were compared with a healthy control 
group.
Results: 
We found a positive relation between AMS symptoms and insulin requirements 
(r = 0.78; P = 0.041) and AMS symptoms and glucose levels (r = 0.86; 
P = 0.014) for Mount Kilimanjaro. Compared with sea level, insulin doses 
tended to decrease by 14.2% [19.7] (median ± [interquartile range]) 
(P =0.41) whereas glucose levels remained stable up to 5000m altitude. 
However, at altitudes >5000m, insulin dose was unchanged (36.8 ± 17 vs. 
37.6 ± 19.1 international units [mean ± SD] P =0.75), but glucose levels 
(7.5 ± 0.6 vs. 9.5 ± 0.8 mmol/L [mean ± SD] P =0.067) and AMS scores 
(1.3 ± 1.6 vs. 4.4 ± 4 points [mean ± SD] P =0.091) tended to increase. 
Energy expenditure and AMS symptoms were comparable in bith groups 
(P = 0.84).
Conclusions: 
Our data indicate that in complication-free individuals with type 1 diabetes, 
insulin requirements tend to increase at altitudes above 5000m despite high 
energy expenditure. This change may be explained, at least partly, by AMS.
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Introduction
An increasing number of people with type 1 diabetes mellitus participate in 
extreme physical activity, such as very high altitude trekking defined as 
trekking at altitudes between 3500 and 5500m (11,500-18,000 ft) (1). Very 
high altitude trekking poses specific demands on individuals with type 1 
diabetes mellitus, because many physiological processes, including glucose 
metabolism, energy expenditure, and insulin requirements, differ at altitude 
compared with sea level. (2)
 In individuals without diabetes, exercise at altitude initially elicits an 
increase in both glucose and insulin. However, after 3 weeks at 4,300 m, resting 
glucose levels and glucose levels during exercise decrease compared with 
sea level values, whereas insulin levels return to, and remain at sea level 
values. This suggests decreased glucose mobilization or increased insulin 
sensitivity as a result of acclimatization to high altitude (3,4). 
 In individuals with type 1 diabetes, the increase in glucose uptake by 
skeletal muscle in response to aerobic exercise at sea level is comparable 
to subjects without diabetes (5). However, because individuals with type 1 
diabetes, by definition, lack the ability to automatically adjust insulin levels 
and have defective counter-regulatory mechanisms (6), the initial response 
to exercise at high altitude will be different from that of healthy individuals. 
 Furthermore, all individuals at very high altitude are at risk for developing 
acute mountain sickness (AMS), which, in its early stages, is characterized 
by headache, depressed appetite, gastrointestinal symptoms, fatigue, and 
sleeping problems. AMS is accompanied by increased sympathetic activity 
and an increase in plasma catecholamines that could result in a deterioration 
of glycemic control (7). 
 It is difficult to predict individual insulin requirements and glucose 
profiles in response to exercise at very high altitude in individuals with type 
1 diabetes. In addition, AMS may deteriorate glycemic control. These factors 
could therefore compromise safe trekking at very high altitude. 
 To our knowledge, no study has yet assessed a possible relationship 
between the occurrence of AMS and hyperglycemia in type 1 diabetes. 
Furthermore, whether
 Insulin requirements increase or decrease in response to very high 
altitude in type 1 diabetes remains subject to debate (8-10). 
 Therefore, in this study, we determined daily insulin dosages and glucose 




compared daily energy expenditure and AMS symptoms in subjects with 
type 1 diabetes with those of a healthy control group. 
Research design and methods
Subjects 
Eight patient with complication-free type 1 diabetes were recruited by 
advertisement and selected to take part in the “Bas van de Goor Foundation 
Kilimanjaro Challenge”(11). Non-medical criteria for selection were personal 
motivation, and willingness to function in a team. 
 Medical exclusion criteria were the presence of complications (retinopathy, 
neuropathy, nephropathy), uncontrolled hypertension (systolic blood pressure 
>150 mmHg or diastolic blood pressure >90 mmHg), severe hypoglycaemia 
unawareness, cardiac disease (abnormal electrocardiogram, implantable 
cardioverter defibrillator or pacemaker, cardio-myopathy, coronary or clinically 
relevant valvular  disease), peripheral arterial insufficiency, smoking or use 
of illicit drugs. 
 The control group consisted of nine healthy individuals (four MDs, one 
clinical chemist, one laboratory technician, one echocardiographer and two 
research assistants) and all were subjected to the same criteria and training 
program as the type 1 diabetes group. 
 Before the expedition, all participants underwent a physical examination, 
maximal exertion cycle ergometer testing, electrocardiography, echocardio-
graphy and laboratory testing and were given general training advice. The 
research protocol was approved by the local ethics committee of the Isala 
Clinics, Zwolle, the Netherlands, and all subjects gave written informed 
consent.
Itinerary
After arrival in Arusha, Tanzania, (altitude 1254 m) a 3-day ascent of Mount 
Meru (alt. 4568 m) was made to facilitate acclimatization to altitude. 
Subsequently, all subjects remained at 1254 m altitude for one day and 
continued for the 7-day ascent of Mount Kilimanjaro (altitude 5895 m), 
taking the Machame route (12) . 
Measurements 
Daily insulin dosages were recorded from subcutaneous insulin pumps 
(MiniMed Paradigm MMT 770, Medtronic Inc. Minneapolis MN [n=6] and 
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Accu Chek Spirit, Roche Diagnostics, Basel, Switzerland [n=1]), and 
manual recording by one subject using a four times daily insulin injection 
regimen. All subjects with diabetes regulated their own glucose levels and, 
in principle, determined their own insulin doses. Daily glucose levels were 
recorded by the diabetes group using continuous glucose monitoring 
(CGM) system (MiniMed Paradigm Real Time, Medtronic Inc.) and handheld 
blood glucose meters (BGMs) (Accu Chek Compact Plus, Roche 
Diagnostics). The BGMs used were successfully  tested for accuracy at very 
high altitude (5000 m) as previously reported (13) and tested regularly at 
different altitudes using  standard reference glucose solutions (NOVA 
Biomedical, Waltham, MA). Per subject, per day, a total of 17 h 42 min ± 1 
hr 12 min data of CGM were available for analysis (mean ± SD) CGM 
calibrations with handheld BGMs were performed four (six) times daily 
(median [IQR]).
 Energy expenditure was monitored in all subjects using a right upper 
armband estimating energy expenditure from various physiological and 
movement parameters monitored. (SenseWear Pro Armband, Bodymedia, 
Pittsburg, PA) 
 AMS score was recorded daily in all subjects according to the Lake 
Louise Score. This score is composed of five items graded from 0 (not 
present) to 3 (severe): headache, gastro-intestinal symptoms, dizziness or 
light headedness, difficulty sleeping, and fatigue or weakness. A diagnosis 
of AMS is based on the presence of headache, at least one other symptom, 
and a total score of ≥ 4 (14). 
Statistical analysis
Differences between two means were tested by Student t tests for data with 
normal distribution. Mean glucose was calculated by area under the curve 
analysis from CGM data. Also, the time subjects spent in hyper- and 
hypoglycemia, defined as episodes with glucose levels >10 mmol/L and 
<3.5 mmol/L, respectively, was calculated by CGM data analysis. 
Correlations were calculated using Spearman ρ analyses for data that was 
not normally distributed. For comparisons between groups in time, mixed 
repeated measures ANOVA was used for data that were normally distributed. 
The SPSS personal software package (version 16.0; SPSS, Chicago, IL) 
was used for statistical analysis. A P value of <0.05 was considered 







Baseline characteristics of all tested subjects are listed in Table 1. Apart 
from younger age and HbA1C levels, participants with diabetes were 
comparable to the control group. 
 During the ascent of Mount Meru two subjects of the diabetes group 
did not reach the summit because of viral gastro enteritis in one and AMS in 
the other. One subject reached camp two at 3,580 m altitude and one 
subject returned to camp one at 2,514 m altitude. These subjects were still 
included in the analysis, because both eventually reached the summit of 
Mount Kilimanjaro. 
 During the climb of Mount Kilimanjaro, all participants with type 1 
diabetes reached the summit without major problems. One subject from the 
non-diabetes group stayed at base camp due to knee problems, after 
successfully summiting mount Meru. The altitude profile of the expedition is 
presented in Fig. 1 (shaded area). 
Insulin doses
Daily insulin dosages are depicted in Fig. 1 (top). During the ascents of both 
mount Meru and mount Kilimanjaro, mean insulin dose decreased non-
significantly with a subsequent return to baseline values on resting days. 
Although there was substantial inter-individual variation, the insulin dose 
was reduced, albeit not significantly: -14.2 ± 19.2% (median ± IQR) 
(P =0.41) (Fig. 2).When analyzed over the whole expedition period, insulin 
dose tended to be lower at higher altitude (r = -0.51, P = 0.054).
Glucose
Mean daily glucose measured by CGM is depicted in Fig. 1 (middle). 
Glucose levels tended to increase, compared with baseline (1254m), during 
the ascent of Mount Meru (P = 0.086) but remained elevated even after the 
descent to 1254m (P = 0.002; day 1 vs. day 6). During the ascent of Mount 
Kilimanjaro, glucose levels initially decreased nonsignificantly (P = 0.079). 
However, glucose levels increased steeply to their highest level on the 
summit day (day 1 vs. day 12, P = 0.020). We found no relation between 




Table 1   Baseline characteristics of study participants.
Type 1 diabetes Control particpants
N (male/female) 8 (5/3) 9 (4/5)
Age (years) 31.6 ± 5.3 42.1 ± 9.9*
HbA1C (%) 6.8 ± 0.6 5.2 ± 0.4*
Diabetes duration (years) 10.4 ± 8.1 n.a.
Blood pressure (mmHg) 117 / 69 ± 5.9 / 3.3 118 / 75 ± 11.9 / 9.2
BMI (kg/m2) 23.9 ±1.9 23.7 ± 1.8
Acetazolamide use (yes/no) 6/2 7/2
Data are presented ± SD. n.a., not applicable. * P < 0.05.
Figure 1   Mean insulin dosage (black circles; top), mean glucose from 
CGM (black squares; middle) and mean AMS score per day 
(black triangles: downward: diabetes group, upward; control 
group; bottom) during the expedition; left Y axis. Altitude profile 
of expedition (gray line, shaded area); right y-axis. 
Note; altitude presented on expedition days is the highest altitude reached that specific day. 
AMS scores comprise seven subjects with type 1 diabetes. Data are presented as means ± SD.
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Time spent per day in hyperglycemia tended to increase on Mt Meru 
compared with baseline values (212 ± 228 min [sea level] vs. 284 ± 405 
min [day 3], P =0.076), subsequently decreased nonsignificnatly on Mount 
Kilimanjaro (127 ± 168 min [day 11], P =0.47), but peaked on the summit 
day (500 ± 568 min [sea level vs. day 12], P =0.041, Friedman analysis, 
median ± IQR). Time per day in hypoglycaemia did not differ between sea 
level and any altitude (11 ± 31 vs. 0 ± 54 min [median ± IQR], P = 0.9, 
Friedman analysis). None of the subjects required help of a second party 
for hypoglycemic episodes.
Acute mountain sickness
As expected, mean AMS scores increased in parallel with altitude in both 
groups (sea level vs. 4,562 m [P=0.015] and sea level vs. 5,895 m [P =0.019]) 
and were strongly correlated; r = 0.92 (P =0.0001) (Fig. 1, bottom). There 
were no significant differences in AMS scores between the diabetes group 
and the control group (P = 0.79). 
 When analyzing both ascents separately for possible effects of acclima-
tization, there was a strong relation between AMS and glucose levels for 
Mount Kilimanjaro (r =0.86; P =0.014). Also, for Mount Kilimanjaro, we 
found a positive relation between insulin doses and AMS scores (r = 0.78; 
Figure 2   Relative change in daily insulin dose compared with sea level 
doses during the expedition. (mean ± SD; %)
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P = 0.041). However, there was no relation between AMS and glucose 
levels over the whole expedition period (r = 0.15; P = 0.60). 
Energy expenditure 
Energy expenditure increased significantly at altitude, 3,012 ± 578 (day 6) 
vs. 5,044 ± 937 (day 12) cal/day (mean ± SD) (P = 0.0001), and followed 
the same trend as the altitude profile (Fig. 3). Energy expenditure was 
comparable between the diabetes group and the control group (P = 0.57).
Conclusions
This study investigated the relationships among daily insulin dosages, 
glucose profiles and AMS symptoms in response to exercise at very high 
altitude in subjects with complication-free type 1 diabetes. As anticipated, 
insulin dosages initially tended to decrease while glucose levels remained 
fairly stable at altitude. However, during the the final ascent (day 12), glucose 
levels increased sharply in parallel to an increase in AMS scores but insulin 
doses did not change. Taken together, these results are in accordance 
with increased insulin requirements when extreme altitudes (> 5000m) are 
C
hapter 4
Figure 3   Energy expenditure per day of the type 1 diabetes group (black 
circles) and the control group (black squares) (left y-axis) during 
the expedition in relation to the altitude profile (gray line, shaded 
area; right y-axis). Day 6 is a day of rest in between ascents
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reached (day 12). On the final ascent, the increments in AMS symptoms and 
mean glucose are borderline significant. However, the significant increase 
in time in hyperglycemia and the positive relations between AMS and mean 
glucose levels, and AMS and insulin doses, support the notion of increased 
insulin requirements at extreme altitude, possibly related to AMS.
 The increased glucose levels (day 12)  cannot be attributed to an increased 
carbohydrate intake, because higher anorexia scores on the Lake Louise 
Questionnaire suggested markedly reduced caloric intake at altitudes 
> 4500m (data not shown). In addition, reduced exercise-stimulated glucose 
uptake is unlikely  because energy expenditure increased in response to 
exercise at altitude. The fact that increments in glucose , together with 
unchanged insulin doses, were accompanied by parallel increments in 
AMS scores suggests a shared causative factor.
 Even after partial restoration of gluco-regulatory hormones levels because 
of acclimatization, ascent to higher altitudes will elicit increments in gluo- 
regulatory hormones (3). Furthermore, AMS in itself is related to increments 
of counter-regulatory hormones (7). Therefore, it seems likely that after an 
initial acclimatization to altitudes of up to ± 4,500 m, increments in AMS and 
altitude on day 12, again, induced a state of insulin resistance by increments 
in counterregulatory hormones. 
Previous expeditions with individuals with type 1 diabetes have shown diverging 
results (8-10). Moore et al. (10) have reported decrements in insulin dosages 
on Mount Kilimanjaro of up to 50%. This exepedition had a very low summit 
seccess rate and was complicated by cases with keto-acidosis. This suggests 
insulin underdosing. In our study, insulin dose was initially decreased by 
approximately 15-20% (Fig. 2). However, it is likely that above a critical 
altitude of approximately 5,000 m this decreased insulin dose becomes 
inadequate as glucose levels increase. A ciritical altitude of approximately 
5,000 m might also explain why for Mount Meru we did not find a relation 
between AMS and glucose levels.
 Admettla et al. (9) found increased insulin requirements at altitudes 
above 5000 m when adjusting for carbohydrate intake in a group of type 1 
diabetic climbers on Mount Aconcagua (6962 m). Pavan et al. (8) reported 
increased insulin requirements in eight climbers with type1 diabetes on 
Mount Cho Oyu (8,201 m.) and increased HbA1C levels in type diabetic 
subjects and healthy controls after this 39-day expedition. Thus, most 
reported studies seem to be in line with the concept that at extreme (≥ 5,500 
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m) and even very high (3,500 - 5,500 m) altitudes, glucose levels and insulin 
requirements increase despite the high energy expenditure and lower 
carbohydrate intake. 
 Our study has clinical implications. At very high altitude, we would 
recommend climbers with type 1 diabetes to maintain or only slightly 
decrease insulin doses despite strenuous exercise and reduced caloric 
intake. Also, if more symptoms of AMS occur, one should expect to see an 
increase in insulin requirements. 
 Although the use of acetazolamide is not recommended in patients 
with type 1 diabetes because of the percieved risk of keto-acidosis (9), six 
of eight subjects with diabetes in our study used the drug without 
complications.
 This study has limitations. First, we did not monitor caloric intake 
because we were not informed in advance what type of food would be 
provided. Also, it was difficult to estimate carbohydrate contents of local 
foods. Howeverm higher anorexia scores on the Lake Louise Questionnaire 
suggest markedly reduced caloric intake at altitudes ≥ 4,500 m. Furthermore, 
because of ethical and financial constraints, it was not feasible to use CGM 
devices to measure glucose continuously in the control group. Insulin 
requirements can hardly be determined in subjects without diabetes while 
exercising at very high altitude. Therefore, it was not possible to compare 
between groups for insulin requirements and glucose levels. 
 Second, acetazolamide, which was used by ±75% of all subjects in 
both groups, could have influenced AMS scores and insulin doses at very 
high altitude. Acetazolamide helps to prevent AMS and thus could attenuate 
counter-regulatory hormonal reponses associated with high altitude and 
AMS. As far as we know, this has not been investigated in humans, so the 
degree of interference remains speculative. Because of the small number of 
subjects who did not use acetazolamide (Table 1), we could not statistically 
analyze whether acetazolamide use influenced  insulin requirements or not. 
However, we could not discover any consistent pattern between acetazolamide 
users and nonusers regarding insulin requirements. Finally, we were unable 
to measure counterregulatory hormone levels because of local limitations 
of blood sampling, handling, and storage.
 One strength of our study is the use of continuous measurement of 
energy expenditure and glucose monitoring at very high and extreme 
altitudes, which provides detailed information on glucose trends and 




altitudes and provides the subject with diabetes with instant access of 
glucose levels and trends.
 In summary, in individuals with type 1 diabetes, insulin requirements 
tend to increase during very high altitude trekking despite high energy 
expenditure and reduced caloric intake. This change may be explained, at 
least partly, by AMS. The role of AMS and counterregulatory hormones 
warrants further investigation. 
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Metabolic effects of  
high altitude trekking in patients  
with type 2 diabetes
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Little is known regarding the metabolic effects of high altitude trekking in 
type 2 diabetes. We investigated the effects of high altitude trekking 
preceded by exercise training on glucose levels, lipids and insulin sensitivity 
in patients with type 2 diabetes.
Research Design and Methods: 
Thirteen individuals with type 2 diabetes took part in a 13 day expedition to 
the summit of Mount Toubkal (4,167m), Morocco, after six months exercise 
training. Prior to the expedition, participants received an individualized 
training advice based on maximal exertion ergometer testing. During the 
exercise training and at high altitude, energy expenditure, body weight, 
fasting glucose, HbA1C, lipids and insulin sensitivity (HOMA-IR) were 
determined. We used continuous glucose monitoring (CGM) and measured 
acute mountain sickness scores.
Results: 
Training reduced fasting glucose (-0.7 ± 0.9 mmol/L; P = 0.026), the need 
for anti-hyperglycemic medication and increased exercise capacity (+0.3 
± 0.3 W/kg; P = 0.005). High altitude trekking improved fastig insulin 
concentrations (-3.8 ± 3.2 μU/L; P = 0.04) insulin sensitivity (HOMA-IR) 
(-1.57 ± 1.70; P = 0.017), total cholesterol (-1.2 ± 1.4 mmol/L; P = 0.014) 
and LDL-cholesterol (-0.5 ± 0.9 mmol/L; P = 0.012) compared to values 
prior to the start of exercise training. HbA1C levels did not change. The 
frequency and duration of hyper- or hypoglycemic episodes (measured by 
CGM)  remained unchanged at high altitude compared to sea level. All 
participants reached the summit at 4167 m.
Conclusion: 
 High altitude trekking preceeded by exercise training is feasible for patients 
with type 2 diabetes. It improves blood glucose levels, lipids and fasting 
insulin concentrations and HOMA-IR while glucose controls is maintained. 
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Introduction
An increasing number of people with diabetes mellitus undertake trekkings 
at high altitude.(1-3) These trekkings under conditions of hypobaric hypoxia 
are considered to be strenuous exercise and are therefore a physical challenge. 
Adequate preparation and regular exercise to establish a reasonable level 
of physical fitness, are a requisite. Exercise is considered an important 
cornerstone in the treatment of patients with type 2 diabetes. At sea level, 
regular exercise is associated with improved glycemic control and insulin 
sensitivity.(4) However, the effects of exercise at sea level might differ 
substantially from exercise effects at altitude.
The International Mountaineering and Climbing Federation – the UIAA 
(Union Internationale des Associations d’Alpinisme) - states that type 2 
diabetes should not pose a problem at high altitude, and that being at 
altitude per se has no influence on diabetes. (5) However, a number of studies 
in type 1 diabetes and healthy subjects showed that exercise at very high 
altitude can initially lead to hyperglycemia. (6-8) This is possibly related to 
the need for acclimatization, acute mountain sickness and/or increments in 
glucose counter regulatory hormones.(2,6,9) On the other hand, increased 
glucose uptake due to exercise, in combination with the use of  antihyper-
glycemic agents, particularly sulfonylureas and insulin, can lead to an 
increased risk of hypoglycemia.(10,11) Also, suppressed appetite associated 
with high altitude could lead to reduced intake of carbohydrates and a 
further increase in the risk of hypoglycemic events. (12)
 There are no data about the safety and metabolic effects in subjects 
with type 2 diabetes that undertake trekkings at high (1,500-3,500 m) and 
very high (3,500-5,500) altitude. Therefore, we investigated the effects of 
a 13-day high altitude trekking expedition to Mount Toubkal (Morocco; 
4,167m) preceded by a preparatory exercise program, on glucose levels, 






Subjects with type 2 diabetes were recruited by advertisement and selected 
to take part in the “Bas van de Goor Foundation Atlas Diabetes Challenge”.
(13) Inclusion criteria were: type 2 diabetes mellitus, age < 70 years, 
treatment with diet, insulin and/or oral anti-hyperglycemic agents, personal 
motivation and willingness to function in a team. 
 All participants underwent maximal exertion cycle ergometer testing , 
ECG, echocardiography and laboratory tests at baseline (day -270). The 
graded cycle ergometer test to exertion was used to determine maximal 
workload capacity (Wattmax) and estimate VO2max according to an equation 
as described by Storer et al. (14) Maximal exertion cycle ergometer testing 
and laboratory tests were repeated after a six months exercise training 
program at the start of  the high altitude trekking expedition (day 0). Medical 
exclusion criteria were the presence of symptomatic or severe complications 
(proliferative retinopathy, neuropathy, nephropathy), uncontrolled hyper- 
tension (systolic blood pressure >165 mmHg and/or diastolic blood 
pressure >95 mmHg), cardiac disease (abnormal electrocardiogram (in 
rest or during maximal exertion cycle ergometer testing), implantable 
cardiac defibrillator or pacemaker, cardio-myopathy, coronary or clinically 
relevant valvular disease), peripheral arterial insufficiency, past CVA or TIA, 
smoking or use of illicit drugs and/or a body mass index (BMI) > 35 kg/m2 
at the start of the high altitude trekking expedition (day 0). Patients’ diabetes 
care providers (general practitioners and internists) were notified by letter of 
their patient’s participation in the study. They were requested to continue 
diabetes care as usual. The research protocol was approved by the local 
ethics committee of the Isala Clinics, Zwolle, The Netherlands. All subjects 
gave written informed consent.
Physical activity and food intake 
Participants received a written training program at the start of the training 
period (day -180).This training program was composed of two endurance 
and two resistance training sessions, with a total duration of 3.5 - 6 hours 
per week. The program aimed at achieving a normal estimated maximal 
workload capacity (Wattmax) (15) and at improving general physical fitness 
during a six month training period until the start of the expedition (day 0). 
Participants trained individually and training was not supervised by an 
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investigator. Energy expenditure was monitored with a right upper armband 
(SenseWear Pro ArmbandTM , Bodymedia, Pittsburgh, USA) during one 
week every month. This armband estimates energy expenditure from 
various physiological and movement parameters monitored.(16) Energy 
expenditure was continuously monitored during high altitude trekking.
 We determined weight, height and body mass index (BMI: weight (kg)/
height (m)2) at the start of the training period (day -180), at the start of  the 
expedition (day 0;) and on expedition days 9 (3200m alt.) and 12 (450m alt.). 
Glucose and laboratory analysis
During the six month exercise training period, participants measured fasting 
capillary blood glucoses during one week every month. Calibrated, new, 
handheld blood glucose meters (Accu Chek Compact Plus, Roche 
Diagnostics) were used. This type of blood glucose meter had been 
previously tested for accuracy and reliability at high altitude.(17) Two months 
prior to the expedition (day -60), participants were instructed to start using 
a continuous blood glucose monitoring system (CGMS) (Paradigm 
MiniMed, Medtronic, USA) in the same week as capillary blood glucose 
measurements and energy expenditure assessment. Participants calibrated 
the CGMS four times daily with the handheld blood glucose meter. During 
the expedition, participants measured capillary blood glucose at least four 
times daily and used CGMS continuously. A similar type of CGMS proved 
to be reliable during barometric pressure changes. (18)
 Fasting glucose and plasma insulin (Bi-INS Immuno RadioMetric Assay, 
Cisbio Assays, France) were determined six months prior to the high altitude 
trekking expedition (day -180), at the start of the expedition (876m), on day 
9 (3200m) and on day 12 (450m) Homeostasis model assessment of insulin 
resistance (HOMA-IR) was calculated as a measure of insulin resistance 
using the formula: fasting insulin (mU/L) x fasting glucose (mmol/L)] / 22.5. 
(19) Subjects treated with insulin were excluded from HOMA-IR and fasting 
glucose analysis. HbA1C, (Ultra2-A1C, affinity chromatography, Trinity Biotech 
diagnostics, Bray, Ireland)  plasma cholesterol, HDL-c, triglycerides (Enzymatic 
in vitro assay, Roche diagnostics, Almere, the Netherlands) and LDL-c 
(calculated by the Friedewald formula) were determined six months prior to 
the high altitude trekking expedition at the start of the expedition and at the 





The presence of acute mountain sickness (AMS) symptoms was scored 
daily (at high altitude only) in all subjects according to the Lake Louise 
Questionnaire. This score is composed of five items graded from 0 (not 
present) to 3 (severe): headache, gastro-intestinal symptoms, dizziness or 
light headedness, difficulty sleeping, fatigue or weakness. A diagnosis of 
AMS is made on the presence of headache, at least one other symptom, 
and a total score of ≥ 4. (20)
Itinerary of the trekking expedition
After arrival in Morocco (876m) participants made trekkings for 5-6 hours 
through uneven rocky terrain on day 1 and 2 to get acclimatized and familiar 
with the terrain. Thereafter, an 8-day ascent to the summit of Mt. Toubkal 
(4,167m) was made. Participants carried a rucksack (content weight between 
5 and 10 kgs) and made trekkings ranging from 5-8 hours walking up- and 
downhill with an altitude gain ranging from 350 to 1350 m per day. The 
terrain consisted of rocky paths and temperature ranged from  ± 1 to 32 ºC. 
Participants slept in basic mountain huts or tents. Days 0, 9 and 12 were 
resting days when laboratory tests and biometric measurements took place.
Statistical analysis
The SPSS personal software package (version 16.0; SPSS, Chicago) was 
used for statistical analysis. Repeated measures ANOVA with post hoc 
Bonferroni testing was used for normally distributed data. Partial correlations 
were calculated to test relations between different independent variables 
and glucose levels. Student T tests were performed to test differences 
between two means for normally distributed data. Time in hypo- and 
hyperglycemia and mean glucose were calculated from area under the 
curve (AUC) analysis of continuously monitored glucose data. Friedman 
ANOVA and Wilcoxon signed rank post-hoc tests were used for non 
parametric repeated measures analysis. A P-value of <0.05 was considered 
statistically significant. Data are presented as means ± SD unless stated 
otherwise.  
Results
Thirteen patients with type 2 diabetes mellitus participated in the study. 




Table 1   Characteristics of studied subjects and effect of training at sea 
level (day -180 -- day 0) and trekking at altitude (day 0 –day 12) 
Day -180 Day 0 Day 9 Day 12
0m 876m 3200m 450m
Age (yr) 48.2 ± 9.7 - - -
Male/Female (n) 8/5 (13) - - -
BMI (kg/m2) 27.5 ± 4.1 27.1 ± 4.0 26.8 ± 3.9 26.8 ± 4.0
Weight (kg) 85.4 ± 12.4 83.9 ± 12.9 83.1 ± 11.4 83.1 ± 11.6
Duration Diabetes (yrs) 6.3 ± 3.9 - - -
Max. Workload (W/kg) 2.6 ± 0.8 2.9 ± 0.8* - -
VO2max (ml/min/kg)
 † 33.6 ± 7.7 36.6 ± 7.9* - -
% predicted VO2max 
‡ 106.4 ± 21.6 112.6 ± 22.3* - -
Syst. BP (mmHg) 130.1 ± 18.8 129.4 ± 14.3 138.1 ± 19.7 -
Diast. BP (mmHg) 87.5 ± 13.6 84.7 ± 10.9 88.8 ± 12.6 -
HbA1C (%) 6.6 ± 0.8 6.6 ± 0.9 - 6.6 ± 0.9
HOMA-IR 3.4 ± 1.8 3.8 ± 1.8 1.9 ± 0.8§ 2.7 ± 1.2
Cholesterol (mmol/L) 4.6 ± 1.1 4.5 ± 1.2 - 3.8 ± 0.8Ⅱ¶
HDL (mmol/L) 1.4 ± 0.6 1.4 ± 0.6 - 1.3 ± 0.4
LDL (mmol/L) 2.3 ± 1.0 2.5 ± 1.0 - 1.9 ± 0.7Ⅱ
Triglycerides (mmol/L) 2.2 ± 0.9£ 1.5 ± 0.8# - 1.2 ± 0.4¶
Note: Day 9 corresponds to tests performed at 3200m alt. while the maximum altitude reached 
was 4,167m (summit) that day. To convert VO2 (ml/min/kg)  to Metabolic Equivalents (METs) 
divide by 3.5.
*  p<0.01 vs. day -180 
£  measured at day 270
†  VO2max calculated from maximal workload capacity (Watt) using a formula described by 
Storer. (14)
‡  Percentage of normal predicted VO2max estimated using a formula described by Fairbarn. (31)
§  p<0.05 vs. day 0 and day 12
Ⅱ  p<0.05 vs. day 0
¶  p<0.01 vs. day -270
#  p<0.05 vs. day -270
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Effects of the six months training period at sea level
Glucose levels    
During the training period two subjects could stop their anti-hyperglycemic 
treatment (one sulfonylurea derivant and one thiozolidinedione) and five 
subjects could reduce the daily dose of anti-hyperglycemic medication 
(insulin or tablets). (Table 2) The decision to stop or reduce the dosage of 
anti-hyperglycemic agents was made by the patient’s diabetes care provider 
and based on glucose measurements and HbA1C. Despite these reductions 
in the use of medication, fasting glucose decreased slightly from 7.6 ± 1.5  to 
6.9 ± 1.2 mmol/l; P = 0.026. (day -180 vs. day 0) (Fig. 1) but HbA1C levels 
remained unchanged (P = 0.73). (Table 1) 
 Measured time by CGMS in both hyperglycemia (defined as glucose 
levels >10 mmol/L) and time in hypoglycemia (defined as glucose levels <4 
mmol/L) did not change during the last two months of the training period; 
101 ± 140 vs. 140 ± 247 min./day; P = 0.13 and 9 ± 41 vs. 42 ± 67 min/day; 
P = 0.21, respectively. (median ± IQ range) 
 HOMA-IR remained unchanged during the training period (P = 0.23). 
(Table 1)
Lipids
Fasting plasma triglycerides decreased from 2.2 ± 0.9 (day -270) to 1.6 ± 
0.6 mmol/L (day 0) (P = 0.025), whereas LDL, HDL and cholesterol did not 
change. (Table 1) We found no difference in any of the plasma lipids 
between subjects using statins (n = 6) and subjects who did not (n = 7). 
(P = 0.54)
Energy expenditure and body weight
During the training period, daily energy expenditure increased from 2997 ± 
386 to 3361 ± 358 kCal/day; (day -180 vs. day -60) (P = 0.01)(Fig. 1) but 
mean body weight did not change (P = 0.26). Maximal workload increased 
from 2.6 ± 0.8 to 2.9 ± 0.8 W/kg. (P = 0.003). (Table 1)
 
Effects of trekking at high altitude (expedition)
All participants in the expedition reached the summit of Mount Toubkal 
(4,167m). No major health problems occurred; three subjects had gastro- 
enteritis on the fourth and fifth day of the expedition and were treated with 
loperamide, ciprofloxacin and metoclopramide for a short period.
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Glucose levels
During the expedition, mean fasting glucose was lower in the second half 
compared to the first half at altitude (7.1 ± 1.2 mmol/L. vs. 6.6 ± 0.9 mmol/L, 
P = 0.022) but did not differ from sea level (6.9 ± 1.2 mmol/L; Fig. 1) 
The area under the curve for glucose and the time (median ± interquartile 
range) at sea level versus altitude in hyperglycemia (74 ± 251 vs. 147 ± 
388 min/day, P = 0.20) and hypoglycaemia (0 ± 29 vs. 0 ± 66 min/day, 
P = 0.43) remained unchanged. 
 We found a substantial improvement in insulin sensitivity at 3,200m 
altitude (day 9: 1.9 ± 0.8) compared to lower altitudes (day 0: 3.8 ± 1.8, 
P = 0.013 and day 12: 2.7 ± 1.2, P = 0.024) (Table 1). 
C
hapter 5
Table 2   Anti-hyperglycemic medication used by the number (n) of 
participants and changes during the training period (day -180 – 
day 0) and during high altitude trekking (day 0 – day 12).  
Medication use Day -180 Day 0 Day 9 Day 12
0 m 876 m 3200m 450m
Insulin (n) 3 3 3 3
Metformin (n) 8 8 7 7
SU derivate (n) 5 3 3 3
Thiazolidinedione (n) 1 0 0 0
DPP4 inhibitor (n) 1 1 1 1
Note: Metformin was discontinued during the expedition in 1 insulin using subject as a result of 




































































































































































































































































































































































High altitude trekking lead to decreased cholesterol and LDL whereas 
triglycerides and HDL did not change (day 0 vs. day 12). (Table 1) We did 
not find any relation between plasma triglycerides (r =.17, P = 0.25),  LDL 
(r = -.009; P = 0.95) or cholesterol (r = -.22; P = 0.13) and energy expenditure. 
Again, we found no difference between subjects using statins (n = 6) and 
those who did not (n=7). (P > 0.05 for all lipids)
Energy expenditure 
Energy expenditure increased at altitude (P < 0.01, for trend) and peaked 
on days of greatest altitude gain: day 4; 2,300 to 3,550m and day 8; 2,300 
to 3,600m (4366 ± 718 and 4166 ± 831 kCal/day, respectively; both P < 0.01, 
compared to day -180) (Fig.1) Bodyweight remained stable at altitude; 
83.9 ± 12.9 vs. 83.1 ± 11.6 kg; (day 0 vs. day 12) (P = 0.68).
AMS and cardio-respiratory responses 
Acute mountain sickness (AMS) symptom scores were low and none of the 
participants was diagnosed with AMS. Highest AMS symptom scores were 
reached on day 4 (1 ± 3.2 points) when participants climbed strenuously 
from 2,300 to 3,550 m. Blood pressure remained stable at altitude (P = 0.27 
for systolic blood pressure). (Table 1)  Oxygen saturation decreased at 
altitude; 97.4 ± 1.8 (day 0; 876m) to 92.9 ± 2.4 (day 9; 3,200m) to 91.5 ± 2.4 
(day 10; 4,167m) % O2sat (P < 0.001). 
Discussion
Our study indicates that patients with complication-free type 2 diabetes can 
succesfully and safely take part in high altitude trekking after adequate 
preparation. 
 The results of the training period show reductions in plasma triglycerides, 
fasting glucose, antihyperglycemic medication and body weight, while 
workload capacity increased. These effects are most likely associated 
with the increased physical activity as reflected by the increased energy 
expenditure. Most of our results are in accordance with earlier studies in 
which, increased physical activity, without substantial weight loss, was shown to 
reduce visceral fat mass, decrease plasma triglycerides and HbA1C levels, 




we did not find decrements in HbA1C levels or insulin resistance as calculated 
by HOMA-IR. This might be explained by the fact that physical fitness at 
inclusion ranged widely. Some unfit participants improved substatially while 
those who were already fit only marginally improved. This is shown by the 
moderate increase in workload capacity and estimated VO2max. (Table 1) 
 Furthermore, the need for glucose lowering medication was reduced in 
5 out of 10 participants (insulin users excluded) with already good glycemic 
control as shown by the HbA1C levels ≤ 7 %. (Table 1) Since HbA1c levels did 
not change, the lowering of this medication can be regarded as improvement 
of glycemic control in these patients. 
 During the expedition at high altitude we observed a substantial 
improvement in HOMA-IR and lipids while body weight and food intake 
(data not shown) remained stable. 
 Exposure to high altitude can initially lead to higher levels of insulin, 
glucose and counter-regulatory hormones. These elevated levels restore to 
baseline levels as a result of acclimatization after about one week at high 
altitude.(8,24) In subjects with type 1 diabetes mellitus, increased insulin 
requirements are reported at extremely high altitude (>5500m), possibly 
related to AMS. (6,7,25) In our study, mean glucose, time in hyper- and 
hypoglycemia remained stable, indicating no substantial glycemic 
disregulation at altitude. Furthermore, although the prevalence of acute 
mountain sickness at approximately 3,600m varies between  34.9 - 57.2%, 
(26-28) none of the participants in our study suffered from AMS. The gradual 
ascent and the fact that we only resided at altitudes above 3,000 m on days 
8-11, could explain the stable glucose profiles and low AMS scores.
The substantial improvement in insulin resistance, as determined by 
HOMA-IR, at altitude was driven by a decrease in fasting insulin levels on 
days 9 (6.5 ± 2.5) and 12 (8.7 ± 3.8 mU/L), while fasting glucose levels 
remained fairly stable. Fasting insulin levels were significantly lower during 
the high altitude trekking expedition compared with levels at the start (day 
-180; 12.5 ± 5.9) and at the end of the training period (day 0; 12.5 ± 5.0 
mU/L);(P < 0.05). Because insulin users were excluded from analysis and 
oral anti-hyperglycemic medication and dietary intake remained unchanged 
the most likely explanation is increased exercise-stimulated glucose uptake. 
However, in the absence of a direct measure of insulin sensitivity, increased 
insulin- or hypoxia-stimulated glucose uptake cannot be excluded. 
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 Participants exercised for more than seven hours (exercise defined as 
minutes of physical activity > 3 METs) the day prior to fasting insulin level 
determination at high altitude (421 ± 146 kCal on day 8). Although exact 
data are lacking about physical activity on the days prior to fasting insulin 
determination at sea level, the exercise volume was significantly higher on 
day 8 compared to day 11, possibly explaining the difference in fasting 
insulin levels.
 Hypoxia stimulated glucose uptake has been found in vitro and in vivo 
and could hypothetically play a role since lowest fasting insulin levels 
(combined with stable fasting glucose levels) were found at highest 
altitudes, hence lowest oxygen saturation SpO2: 92.9 ± 2.4 % (day 9; 
3,200m)
 At sea level, previous studies involving aerobic exercise without dietary 
changes in type 2 diabetes mellitus show decrements in triglycerides, while 
cholesterol, LDL-c and HDL-c remain unchanged.(29) Also in our study we 
found an improvement in lipids that is most likely explained by exercise. (Fig 1) 
In addition, the improved insulin sensitivity and glucose levels could have 
had a direct lowering effect on triglycerides. There are no previous studies 
on lipid changes at high altitude in subjects with diabetes, but Ferezou et al. 
reported reduced plasma cholesterol, LDL-c and triglyceride levels in 
healthy subjects at 4800m.(30) The latter is in accordance with our findings. 
Our study implies that there are no objections for subjects with complica-
tion-free type 2 diabetes and normal cardiac exercise tests to participate in 
high altitude trekking. Beneficial effects are improvement of glucose levels, 
plasma lipids and insulin sensitivity. Regarding glucose levels, we would 
consider any subject with type 2 diabetes capable of safely exercising at 
high altitude, irrespective of the type of oral hypoglycemic medication. 
Although referring to a small number of subjects, the use of sulfonylureas 
did not seem to lead to an increased risk of hypoglycemia.
 This study has limitations. Because of the uncontrolled study design, it 
is not clear whether the improved fasting glucose and HOMA-IR were due 
to the increased energy expenditure, to the hypoxic conditions at altitude or 
to other factors. HOMA-IR is validated for studies with large samples (31), 
so these results should be interpreted with caution. The research setting 
precluded the use of a direct measure of insulin sensitivity and limited the 
number of patients. 
 A strength of our study is the use of continuous measurement of energy 




on glucose trends and exercise intensity. Its feedback contributed positively 
to lifestyle changes. Also, providing participants with a training and lifestyle 
advice is what happens in daily practice of diabetes care providers. This 
form of monitoring provides some insight into whether patients change their 
level of physical activity or not. 
In conclusion, high altitude trekking is feasible for complication-free 
subjects with type 2 diabetes mellitus after a preparatory training phase. 
Beyond the objective improvement in blood glucose, lipids, and fasting 
insulin the successful accomplishment of a summit may have substantial 
beneficial psychologic effects. 
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To prospectively assess the effects of an exercise intervention on organ- 
specific fat accumulation and cardiac function in type 2 diabetes mellitus. 
Materials and Methods: 
Written informed consent was obtained from all participants and the study 
protocol was approved by the medical ethics committee. The study followed 
12 patients with type 2 diabetes mellitus (seven men; mean age 46 ± 2 
years [standard error]) before and after 6 months of moderate-intensity 
exercise program, followed by a high-altitude trekking expedition with 
exercise of long duration. Abdominal, epicardial and paracardial fat volume 
and cardiac function were measured using magnetic resonance (MR) 
imaging.  Cardiac function was quantified with cardiac MR, and images 
were analyzed by a researcher who was supervised by a senior researcher 
(4 and 21 years respective experience in cardiac MR). Hepatic, myocardial 
and intramyocellular triglyceride (TG) content were measured with proton-MR 
spectroscopy at 1.5 and 7 Tesla. Two-tailed paired t-tests were used for 
statistical analysis.
Results: 
Exercise reduced visceral abdominal fat volume from 348 ± 57 ml (mean ± 
SE) to 219 ± 33ml (P< 0.01),and subcutaneous abdominal fat volume 
remained unchanged (P = 0.9). Exercise decreased hepatic TG content 
from 6.8 ± 2.3% to 4.6 ± 1.6% (P < 0.01) and paracardial fat volume from 
4.6 ± 0.9 to 3.7 ± 0.8 ml (P = 0.02). Exercise did not change epicardial fat 
volume (P = 0.9), myocardial TG content (P = 0.9), intramyocellular lipid 
content (P = 0.3) or cardiac function (P = 0.5). 
Conclusion: 
A 6-month exercise intervention in type 2 diabetes decreases hepatic 
triglyceride content, visceral abdominal and paracardial fat volume, which 
are associated with increased cardiovascular risk, but cardiac  function was 
unaffected. Tissue-specific exercise-induced changes in body fat distribution 
in type 2 diabetes mellitus were demonstrated in this study.
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Advances in Knowledge 
• 6 months of exercise training decreases visceral abdominal fat (348 ± 57 
ml to 219 ± 33ml;P< 0.01) and hepatic triglyceride (TG) content (6.8 ± 
2.3% to 4.6 ± 1.6% (P < 0.01) in 12 patients with type 2 diabetes mellitus 
as measured by MR imaging and proton MR spectroscopy
• Paracardial fat decreases in response to 6 months exercise training in 
patients with type 2 diabetes mellitus (4.6 ± 0.9 to 3.7 ± 0.8 ml; P < 0.05), 
but epicardial fat and myocardial TG content did not.
• Exercise capacity increased in response to 6 months of exercise training 
in patients with type 2 diabetes mellitus (oxygen uptake maximum: 33.0 
± 2.2 mL/kg/min to 36.1 ± 2.3 mL/kg/min; P < 0.05), but myocardial TG 
content and cardiac function did not change.
Implications for Patient Care
• Dietary interventions or substantial weight loss did not seem to be a 
requisite for beneficial reductions in visceral abdominal, paracardial, and 
hepatic fat volume in patients with type 2 diabetes mellitus.
Introduction
In patients with type 2 diabetes mellitus, both aerobic and resistance exercise 
have been shown to improve metabolic control and reduce cardiovascular 
risk. Therefore it is recommended that patients with type 2 diabetes mellitus 
perform exercise at a moderate intensity for a minimum of 150 minutes per 
week (1).
 Metabolic pathways involved in the pathogenesis of insulin resistance 
and cardiovascular risk are complex. Insulin resistance is associated with 
increased lipolysis from the adipose tissue. The increased flux of fatty acids 
can be taken up by different organs, including in the liver, in the heart and in 
muscle (2). The accumulation of triglycerides (TGs) in tissues, other than 
adipose tissue, is called ectopic fat accumulation. Ectopic fat accumulation 
in the muscle and liver are involved in pathophysiologic insulin resistance 
(3-5). Pericardial fat is the fat around the heart that can be divided in 
the epicardial en paracardial fat layer. Hepatic steatosis, myocardial TG 
accumulation and pericardial fat have been associated with cardiovascular 
complications (2;6;7). Furthermore, myocardial TG accumulation has been 




Therefore, strategies to limit ectopic fat accumulation are rational approaches 
to improve glucose homeostasis and potentially reduce cardiovascular risk. 
Most intervention studies have focused on visceral and subcutaneous fat; 
however, to our knowledge, little is known about the effect of exercise alone 
without diet on ectopic fat accumulation in type 2 diabetes mellitus patients. 
Several studies have shown an association between epicardial fat and 
visceral fat volume (8;9). If this association holds a causal relationship, we 
expect that an exercise-induced decrease in visceral abdominal fat will be 
accompanied by a decrease in epicardial fat volume. Lastly, exercise in 
healthy and obese subjects showed that hepatic triglyceride content 
decreases (10;11).
 The purpose of our study was to prospectively assess the effects of an 
exercise intervention on organ-specific fat accumulation and cardiac function 
in type 2 diabetes mellitus patients. 
Materials and Methods
Patients and study design
Written informed consent was obtained from all participants, and the study 
protocol was approved by our medical ethics committee. Twelve patients 
(seven men, five women; patient age 46 ± 2 [standard error]) with type 2 
diabetes mellitus were included. Patients were recruited by advertisement 
to take part in the Atlas Diabetes Challenge (14), a trekking expedition to 
Mount Toubkal, Morocco organized by the Bas van de Goor Foundation, for 
which exercise training was required. At inclusion, (90 days before start of 
training; Fig 1), all patients underwent screening that consisted of physical 
examination, electrocardiography (ECG), echocardiography, maximal exertion 
cycle ergometer testing and blood analysis. Exclusion criteria were patients 
older than 70 years, diabetic complications (ie, retinopathy, neuropathy, or 
nephropathy), hypertension (systolic blood pressure >165 mmHg and/or 
diastolic blood pressure >95 mmHg), body mass index greater than 35kg/
m2, smoking, known cardiac disease (ie, abnormal ECG, cardiomyopathy, 
or coronary or valvular disease), use of drugs, or any contraindication for 
magnetic resonance (MR) imaging.
 Patients underwent a 6-month individualized training program, followed 
by a 12-day trekking expedition to Mount Toubkal (elevation, 4167 m) in 
Morocco. Trekking consisted of moderate intensity exercise (walks of 
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approximately 4-7 hours daily), of which 4 days were spent above 3000-m 
elevation. Patients received a written training program 6 months prior to the 
expedition, and were advised to perform two endurance and two resistance 
training sessions per week for a total of 3.5-6 hours per week. The aims 
of the program were to achieve a normal estimated workload capacity 
(Wattmax) and to improve general physical fitness. Patients trained themselves 
without supervision, but they kept in contact with the expedition physicians. 
Patients recorded their food intake and energy expenditure for 1 week per 
month during the 6-month training program and continuously during the 
expedition by using a web-based dietary program and a physical activity 
monitor (SenseWear Pro Armband; BodyMedia; Pittsburgh, Pa) (16). At inclusion 
and after the training period, the maximal exercise capacity was determined 
using an incremental cycle ergometer test. Maximum oxygen uptake (VO2 
max) was calculated (15). Patients underwent MR examinations on two 
occasions: at 7 days before the start of training and 200 days after the start 
of training (Fig 1). At least 4 hours after the last meal, MR measurements 
were obtained, blood was drawn, and anthropometric  measurements (ie, 
body weight and blood pressure) were taken. 
Subcutaneous and visceral abdominal fat
A 1.5 Tesla MR imager (Gyroscan ACS-NT 15; Philips Medical Systems, 
Best, The Netherlands) was used for all MR imaging. Patients were examined 
in a supine position. Abdominal fat was imaged using a turbo spin-echo 
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Figure 1   Timeline of the study.Screening was performed 90 days before 
the start of the training program. The training program consisted 
of a 6-month individualized exercise program, followed by a 
12-day trekking expedition to Mount Toubkal in Morocco.  
An MR examination was performed approximately 1 week before 











imaging sequence (17). Three 10 mm thick transverse sections were imaged 
at the fifth lumbar vertebrae during breath-holds (Fig 2). Imaging parameters 
were as follows: repetition time msec/ echo time msec 168/11; flip angle, 
90 degrees. Contours were drawn around the visceral and subcutaneous 
abdominal fat deposits using MASS® software (Medis, medical Imaging 
Systems, Leiden, the Netherlands). The area of each section was multiplied 
by the section thickness to estimate the volume, and the volumes of all three 
slices were summed. 
 All MR imaging and MR spectroscopy acquisition at 1.5 Tesla was 
performed by J.T.J, R.W.v.d.M., and S.H. (4,8, and 8 years of respective 
experience in MR imaging and MR spectroscopy), and processing was 
performed by J.T.J., who was supervised by H.J.L. (21 years of experience 
in MR imaging and MR spectroscopy).
Epicardial and paracardial fat quantification
The heart was examined by using gated ECG breath holds with a multi-shot 
turbo spin echo sequence in a four-chamber view orientation (Fig 2). Water 
was suppressed using spectral inversion recovery. Imaging parameters 
were: ≥1000/8.6; flip angle, 90 degrees; section thickness, 4 mm; 251 x 256 
matrix. Contours were drawn around the epicardial and paracardial fat 
surrounding the ventricles and atria by using software (MASS; Medis 
Medical Imaging Systems). The number of pixels was converted to square 
centimeters and multiplied by the section thickness to obtain volume. 
Proton MR spectroscopy of myocardial and hepatic TG content
1.5 Tesla hydrogen-proton MR spectroscopy (Gyroscan ACS- NT 15; Philips 
Medical Systems, Best, The Netherlands) was used to quantify myocardial 
and hepatic triglyceride (TG) content (Figure 3 and 4)(18;19). Myocardial 
and hepatic hydrogen-proton single-voxel MR spectroscopic data were 
acquired using a point resolved spectroscopy sequence. A voxel was 
placed in the liver and myocardial interventricular septum respectively. 
ECG triggered and respiratory pencil-beam navigator were used during 
acquisition (21). A water-suppressed spectrum for TG signal resonances 
and a spectrum without water suppression (for internal standard) were 
obtained. The imaging parameters were (repetition time, ≥) 3000/26. For the 
water suppressed spectrum, 1024 data points were obtained and averaged 
over 128 acquisitions with a 1000 Hz spectral width. For the non-suppressed 
spectrum, repetition time was 10000 msec and only four signal averages 
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were acquired. MR user interface software (jMRUI version 2.2, Leuven, 
Belgium), with prior knowledge files, was used to fit the spectra as previously 
decribed (19). The triglyceride content was calculated as [(amplitude of the 
TG signal/ amplitude of water signal) x 100]. 
C
hapter 6
Figure 2   Top: Quantification of (upper figures) epicardial (red) and 
paracardial fat (green) volume and (lower figures) visceral (red) 
and subcutaneous (green) abdominal fat. For the abdominal fat, 
only one transverse section is shown; three sections were 
imaged. The area of fat of each individual section was multiplied 
by the section thickness to estimate the volume, and the 
volumes of all three sections were summed. 
Bottom: Box and whisker plot of relative changes in epicardial 
and paracardial (11 patients) and visceral and subcutaneous 
(Subc.) abdominal fat volume (12 patients) after 6 months of 
exercise compared with before start of training (12 patients; 
seven men, five women; mean age, 46 years ± 2). * = P < .05 
change after exercise compared with baseline.
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Proton MR spectroscopy of intramyocellular lipid content
Localized proton hydrogen-MR spectroscopy was performed in the left 
tibialis anterior muscle on a 7-T whole-body MR imiging system (Philips 
Healthcare, Best, the Netherlands) to ensure optimal separation of intra-
myocellular lipid (IMCL) and extramyocellular lipid signals by using a using 
a stimulated echo acquisition mode sequence with VAPOR water 
suppression with the following parameters: 2000/22; mixing time, 28msec; 
voxel size 10 x 10 x 10 mm. Unsuppressed water spectra were recorded with 
the same parameters. The voxel was placed in the muscle on transverse 
and sagittal T1-weighted images of the lower leg by avoiding vascular 
structures, tendon plates and visible fat (Fig 4). Software (jMRUI version 2.2; 
MRUI) was used for postprocessing. Signals were fitted for creatine, trime-
thylamonium, lipids at 2.4 ppm, and six resonances for IMCL and extramyo-
cellular lipid (around 2.2 ppm, 2ppm, 1.45 ppm, 1.3 ppm, 1.1 ppm, and 0.8 
ppm). The average separation between IMCL water and fat (CH2) and extra-
myocellular lipid CH2 was 0.22 ppm ± 0.03. All values were corrected for 
T2 relaxation times (IMCL, 80 msec; water, 30 msec). Ratios of the CH2 
resonance of IMCL at 1.3 ppm were calculated relative to the water peak. 
Acquisition and postprocessing of the spectra at 7 T was performed by 
R.L.W., H.E.K., and A.G.W. (4,12, and 12 years of experience, respectively, in 
spectroscopy).
Left ventricular cardiac function
The heart was imaged from apex to base during breath-holds in short axis 
view, with a sensitivity-encoded balanced steady-state free precession 
sequence. Imaging parameters were as follows: 3.4/1.7 ; flip angle of 35 
degrees, field of view 400mm2; section thickness, 10 mm with a 0-mm gap; 
256x256 matrix (15). To assess systolic function, epicardial and endocardial 
contours were manually drawn with software (MASS: Medis Medical 
Systems) (20) . Left ventricular (LV) end-diastolic and end-systolic volume, 
ejection fraction, cardiac output and LV mass were determined as measures 
of systolic function. For assessment of LV diastolic function, transmitral flow 
was measured, using ECG-gated gradient-echo sequence with a velocity 
sensitivity of 100 cm/sec. Imaging parameters wer as follows: 14/4.8; flip 
angle, 20 degrees, section thickness, 8 mm; field of view, 350 mm2; 256x256 
matrix. Analytic software (FLOW; Medis Medical Systems) was used to 
create velocity versus time curves and to assess the peak velocity of the 
early diastole (E) and atrial contraction (A). The peak deceleration gradient 
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of E, the E/A peak ratio and LV filling pressures in early diastole- trial 
contraction were determined (21;22).
Assays
Serum C-peptide was measured with an automated immunoluminometric 
assay on an analyzer (Immulite 2500; Siemens Diagnostics, Breda, The 
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Figure 3   Top: Graph of placement of voxel for quantification of hepatic  
TG content and two representative proton MR spectra before 
and after exercise in one patient. A water-suppressed spectrum 
for TG signal resonances and a spectrum without water 
suppression as internal standard were obtained. Box in  
the image represents the voxel placed in the liver to assess the 
MR spectra. Imaging parameters were 3000/26. 
Bottom: Box and whisker plot shows relative changes in body 
weight, hepatic TG content, and alanine aminotransferase 
(ALAT) after 6 months of exercise compared with baseline  
(12 patients; seven men, five women; mean age, 46 years ± 2). 








































Figure 4   Top: Image of voxel placement for quantification of IMCLs in left 
anterior tibialis muscle and myocardial TG content in the cardiac 
septum. The box in the top image represents the placement of 
the voxel for myocardial assessment of MR spectra. Graph 
represents two representative proton MR spectra for IMCLs and 
myocardial TG content before and after exercise in one patient. 
Dotted line compares both spectral peaks; they are similar 
before and after training. For the myocardial TG content,  
a water-suppressed spectrum for TG signal resonances and a 
spectrum without water suppression for the internal standard 
were obtained. Myocardial TG content imaging parameters were 
3000/26. IMCL imaging parameters were 2000/22. 
Bottom: Box and whisker plot of relative changes in IMCLs, 
myocardial TG content, end-diastolic volume (EDV), and stroke 
volume (SV) after 6 months of exercise compared with baseline 
(12 patients; seven men, five women; mean age, 46 years ± 2). 
































Netherlands). Glycated hemoglobin values were measured with a semi 
automated high performance liquid chromatography machine (Primus Ultra 2; 
Ordia, Leiden, the Netherlands). Serum aspartate aminotransferase, alanine 
aminotransferase, gamma-glutamyltransferase, cholesterol and TGs were 
measured using a chemistry analyzer (Modular P800; Roche Diagnostics, 
Mannheim, Germany).
Statistical analysis
All statistical analyses were performed by using statistical software (SPSS 
17.0; SPSS, Chicago, Ill). Non-normally distributed data were log-trans-
formed and checked for normality after transformation. We used two-tailed 
paired t tests to compare the two study conditions. A two-tailed P value of 




Table 1   Clinical and biochemical characteristics before and after 6 




(200 days after start of training)
Weight (kg) 88.0 ± 3.9 83.7 ± 3.4* 
Body mass index (kg/m2) 28.7 ± 1.2 27.3 ± 1.1*
GGT (U/L) 35.1 ± 7.1 34.1 ± 5.5
ASAT (U/L) 29.8 ± 2.9 24.8 ± 4.0
ALAT (U/L) 32.8 ± 2.5 25.6 ± 3.1*
Glucose (mmol/L) 7.5 ± 1.0 7.0 ± 0.7
HbA1c (%) 6.7 ± 0.3 6.5 ± 0.3
C-peptide (nmol/L) 0.8 ± 0.1 0.8 ± 0.2
Cholesterol (mmol/L) 4.8 ± 0.3 4.6 ± 0.3
HDL (mmol/L) 1.5 ± 0.2 1.5 ± 0.1
Cholesterol/HDL ratio 3.9 ± 0.4 3.3 ± 0.3*
LDL (mmol/L 2.8 ± 0.3 2.7 ± 0.3
Triglycerides (mmol/L) 1.5 ± 0.2 1.5 ± 0.2
Note: Patient cohort was seven men, five women; age, 46 years ± 2,; diabetes duration, 6.1 years ± 
1.4; height 1.75 m ± 0.02. Data are mean ± standard error. ALAT= alanine aminotransferase, ASAT= 
aspartate aminotransferase, GGT= gamma-glutamyltransferase, HbA1c= glycated hemoglobin; 
HDL=high-density lipoprotein, * P < 0.05 after exercise compared to baseline.
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Results
Clinical and biochemical characteristics
The baseline characteristics are shown in Table 1. Mean energy expenditure 
increased from 2965 ± 111 at day 0 to 3439 ± 152 kCal/day at day 192 
(P < 0.01) (Fig 1). Maximum oxygen uptake increased from 33.0 ± 2.2 at 
the beginning of the training to 36.1 ± 2.3 ml/kg/min at 180 days after start 
of training (P < 0.01) (Fig 1).
 Exercise intensity  did not differ during the study period (P = 0.96), however, 
mean daily exercise duration increased substantially during the trekking 
expedition copared with the training period (138 ± 43 vs. 291 ± 63 min/day; 
P < 0.001). 
 At start of the training, seven patients used metformin, three patients 
used  a sulfonyl ureum derivate, three patients used insulin and one patient 
used a dipeptidyl-peptidase-4 inhibitor. During the training period and before 
the expedition, one patient stopped using the sulfonyl ureum derivate. Self 
reported caloric intake did not change during the exercise period (P = 0.22), 
nor did the composition of the diet change over the exercise period. Body 
mass index decreased from 28.7±1.2 at the start of the training to 27.3±1.1 
kg/m2 at the 200 days after the start of the training (P<0.001). No significant 
changes in γ-glutamyltransferase (P = 0.8), aspartate aminotransferase 
(P = 0.2),  Glycated haemoglobin (P = 0.5),  or C-peptide levels (P = 0.8)
occurred (Table 1). Cholesterol (P = 0.3), high-density lipoprotein (HDL; 
P = 0.4), and TG (P = 0.8) concentrations did not change during the training 
period, but there was a decrease in the cholesterol-to-HDL ratio (3.9 ± 0.4 
at the start of training to 3.3 ± 0.3 at 200 days after the start of the training 
(P = 0.01).
Fat compartments
Visceral abdominal fat volume significantly decreased from 348 ± 57 at the 
start of the training to 219 ± 33 ml at 200 days after the start of the training 
(P < 0.01) (Table 2). Subcutaneous abdominal fat volume (Table 2) remained 
unchanged in terms of statistical significance (P = 0.9). Accordingly, the 
ratio between visceral and subcutaneous fat decreased significantly from 
0.53 ± 0.11 at teh starts of the training to 0.34±0.06 at 200 days after the 
starts of the training (P < 0.01). Due to motion artifacts, epi- and paracardial 
fat of one patient could not be measured. Exercise reduced the paracardial 
fat volume from 4.6 ± 0.9 to 3.7 ± 0.8 ml in 11 patients (P = 0.02), and the 
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hepatic TG content was reduced from 6.8 ± 2.3 at baseline to 4.6 ± 1.6 
after the expedition (P < 0.01). Exercise did not affect myocardial TG content 
(P =0.9), IMCL (P =0.3), or epicardial fat volume (P =0.9, Table 2). 
 No significant correlation was found between the decrease in weight 
and the decrease in visceral abdominal fat (P = 0.5), paracardial fat (P = 0.3) 
or hepatic TG content (P = 0.9). 
 The relative changes in the previously mentioned fat compartments are 
depicted in Figures 2, 3, and 4.
Myocardial function
Systolic and diastolic blood pressure, heart rate, left ventricular mass and 
diastolic function (early diastole-atrial (E/A) contraction peak flow and early 
diastole deceleration peak) remained unchanged (Table 3). Ejection fraction, 
56 ± 1 at the start of the training to 58 ± 1% at 200 days after the start of 
the training; P = 0.06), cardiac output, and cardiac index did not change. 
C
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Table 2   Fat compartments at baseline and after 6 months of exercise in 
12 patients with type 2 diabetes mellitus 
Fat compartments Baseline 
(start of training)
After exercise 
(200 days after start  
of training)
Visceral abdominal fat (ml) 348±57 219±33*
Subcutaneous abdominal fat (ml) 699±71 704±74
Ratio visceral / subcutaneous fat 0.53±0.11 0.34±0.06*
Epicardial fat (ml) (n=11) 4.7±0.4 4.7±0.4
Paracardial fat (ml) (n=11) 4.6±0.9 3.7±0.8*
Hepatic TG content (%) 6.8±2.3 4.6±1.6*
Myocardial TG content (%) 0.61±0.13 0.60±0.13
IMCL/H20 (%) 0.58±0.12 0.68±0.11
Note: Data are as mean ± standard error. IMCL/H2O = ratio intramyocellular lipids and water in 
left tibialis anterior muscle. * P<0.05 after exercise compared to baseline.
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Discussion
Our study took place in a real life setting, and was composed of a 6-month 
training period of moderate-intesity exercise followed by a trekking expedition 
with prolonged moderate-intensity exercise. This caused a greater than 
20% decrease in visceral fat, hepatic TG content and paracardial fat in 
patients with type 2 diabetes mellitus, but we did not observe changes in 
subcutaneous abdominal fat, myocardial or intramyocellular TG content, 
epicardial fat volume, or cardiac function.
Epicardial and paracardial fat
Because epicardial fat and visceral abdominal fat underwent cross-sec-
tional correlation (8;9), we hypothesized that both fat compartments would 
be similarly affected by exercise. 
 Interestingly, our 6-month exercise program decreased visceral abdominal 
fat and paracardial fat, but did not change epicardial fat volume in patients 
with type 2 diabetes mellitus. Recent studies (23;24) have shown that 
paracardial fat volume is a better predictor of cardiovascular risk than 
epicardial fat, and therefore a decrease in paracardial fat might indicate a 
decreased cardiovascular risk.  Kim et al. (25) found a significant reduction 
in epicardial fat in obese men after a 12-week exercise program, and the 
change in epicardial fat correlated with the change in visceral fat. One study 
in pigs (26) showed that the epicardial fat around the coronary arteries and 
the epicardial fat around the myocardium respond differently with respect to 
the expression of inflammatory genes. Therefore, epicardial fat may show 
regional differences in its response to exercise. Interestingly, Sicari et al. 
(23) found a cross-sectional correlation between visceral and paracardial 
fat volume, but not epicardial fat volumes. Apparently, exercise in patients 
with type 2 diabetes has a disparate effect on visceral and epicardial 
adipose tissue, which resulted in a decrease in visceral and paracardial fat 
without a change in epicardial fat in our study. 
Hepatic triglyceride content
At baseline, patients had a mean hepatic TG content of 6.8%. Hepatic 
steatosis is defined as a TG content greater than 5.6% measured with hy-
drogen-proton MR spectroscopy (27).  We found that exercise decreased 
hepatic TG content by 26% in patients with type 2 diabetes mellitus, and 
thereby reducing their hepatic TG content to normal values. This decrease 
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was accompanied by a decrease in alanin aminotransferase. Previous 
studies reported on the effects of exercise on hepatic TG content, but only 
in patients without diabetes (10). To our knowledge, the exact mechanism 
behind the exercise-induced reduction in hepatic TG content is not clear. 
Although patients in our study lost some weight, we found no significant 
correlation between changes in body weight and changes in hepatic TG 
content. The decrease in hepatic TG content may be due to a diminished 
flow of free fatty acids from the visceral adipose tissue, in accordance with 
the portal hypothesis (28). However, reduction in hepatic TG content has 
also been described without a reduction in visceral fat (11). Our results 
indicate that the liver is not a passive bystander, which adapts to changes 
in fatty acid metabolism. Rector et al. (29) showed that sudden cessation of 
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Table 3   Hemodynamics and cardiac function at baseline and after 6 




(200 days after the start  
of training)
Hemodynamics
Systolic blood pressure (mmHg) 142±7 142±7
Diastolic blood pressure (mmHg) 87±4 83±4
Heartrate (per minute) 71±2 68±2
Cardiac dimensions and function
LV mass (g) 103±8 107±9
LV mass index (g/m2) 50±3 53±4
LV end-diastolic volume (ml) 176±9 179±9
LV end-systolic volume (ml) 77±4 76±4
LV stroke volume (ml|) 99±5 103±5
Ejection fraction (%) 56±1 58±1
Cardiac index (l/min/m2) 3.1±0.1 3.1±0.1
E/A peak flow 1.45±0.16 1.31±0.11
E deceleration peak (ml/s2 x10-3) 3.9±4.3 3.9±3.4
E/Ea 10.8±0.64 11.4±0.71
Note: Data are mean ± standard error. A = diastolic atrial contraction, E = early diastolic filling 
phase, E/Ea = estimate of left ventricular filling pressure, LV = left ventricular.
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daily physical activity in hyperphagic or obese rats resulted in stimulation of 
biochemical pathways known to initiate hepatic steatosis, including 
decreased hepatic mitochondrial oxidative capacity, increased hepatic 
expression of de novo lipogenesis proteins, and increased hepatic malo-
nyl-coenzyme A. 
IMCL and myocardial TG content
Data regarding the effects of exercise on IMCL content in insulin-resistant 
patients are inconsistent. A 16-week moderate-intensity exercise program 
in obese, insulin-resistant patients increased IMCL (11); however, two 
studies of 10 -12 weeks of exercise in overweight men and patients with type 
2 diabetes mellitus found no change in IMCL (14;15). We found no effect of 
a 6-months exercise program on IMCL.  
 To our knowledge, only two studies have examined the effects of 
exercise on myocardial TG content. Twelve weeks of exercise decreased 
myocardial TG content in healthy obese patients (30), but it did not decrease 
myocardial TG content in patients with type 2 diabetes mellitus (31). Our 
study confirms and extends the latter result. 
 Previously, an association was found between myocardial TG content 
and diastolic cardiac function (12;17). In our study, exercise did not change 
myocardial TG content, and we found no change in systolic or diastolic 
function. Similarly, one year of training in patients with type 2 diabetes 
mellitus (32) and 12 weeks of training in patients who were overweight (30) 
showed no significant changes in myocardial function; however, in the latter 
study, ejection fraction increased by 2%. 
The major limitation of our study is the small number of patients. Patients 
act as their own control. Despite this small patient number, our data show 
statistically significant changes in fat distribution with exercise. Secondly, 
diet could have varied between patients; we did not control for this. Finally 
there were interindividual differences in the exercise duration and intensity 
during the training and trekking expedition. Though exercise intensity did 
not differ during the study, mean exercise duration increased substantially 
during the trekking expedition compared with the training period. Further- 
more, factors related to altitude, such as hypoxia, may have influenced the 
results. Many studies that examine the dynamics of ectopic fat accumulation 
focus on the effects of diet or combined diet and exercise on weight loss in 
relation to changes in imaging parameters. In our study, patients did lose 
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some weight, without specifically attempting to diet. Therefore, we assume 
that their weight loss was achieved only by training.
In conclusion, a 6-month exercise training regimen, without changes in diet, 
decreased hepatic TG content, and visceral abdominal and paracardial fat 
volume in patients with type 2 diabetes mellitus. These fat compartments 
are all associated with increased cardiovascular risk. Subcutaneous fat, 
epicardial fat, and intramyocellular and myocardial TG content did not change. 
Therefore, our study demonstrated tissue-specific exercise- induced changes 
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Subjects with diabetes are encouraged to engage in any form of physical 
activity, and an increasing number visits the mountains for various activities. 
Mountain activities have gained popularity and several subjects with 
diabetes have even successfully summited Mount Everest, the world’s 
highest mountain. Furthermore, recent experimental studies show that 
exercise under hypoxic conditions may benefit peripheral glucose uptake 
and support weight control in subjects with type 2 diabetes mellitus (T2DM).
 At present, knowledge of safe and successful management of diabetes 
during exercise at altitude is limited and literature provides variable information 
on both beneficial and potentially hazardous effects of trekking at altitude. 
The aim of this thesis was to gain more insight into the safety, technical 
challenges and metabolic changes associated with trekking at altitude in either 
type 1 diabetes mellitus (T1DM) or T2DM. Data obtained prior to, during, and 
after two mountain expeditions, one including subjects with T1DM, and one 
including subjects with T2DM, form the basis of the present thesis.
First, we extensively searched the literature and described the current 
knowledge of high altitude travel in subjects with diabetes mellitus in 
chapter 2. One of the most important findings of this review is that for active 
and well prepared, complication-free subjects with either T1DM of T2DM, 
there seem to be no objections to travel to very high (3500 -5500m) and 
even extreme altitudes (>5500m). Nevertheless, there are many factors that 
need to be accounted for and require precautionary actions. In addition, 
there are gaps in current literature and there is a need for controlled 
studies at true or simulated altitude. Available knowledge mainly refers to 
uncomplicated T1DM, while data about T2DM are virtually lacking. Although 
some subjects with diabetes have travelled to extreme altitudes without 
major problems, one can imagine that several organ functions or regulatory 
systems affected by diabetes can limit or complicate altitude exposure. 
Below, the various challenges are summarized.
 Diabetes and its complications can affect normal physiological responses 
to hypobaric hypoxia and may limit high altitude exposure. For example, 
diabetic complications, such as proliferative diabetic retinopathy or peripheral 
sensory neuropathy, as well as coronary artery disease, may even be 
extremely hazardous, especially at very high and extreme altitudes. On the 
other hand, well-trained and complication-free subjects with diabetes seem 
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to be comparable to their non-diabetic counterparts regarding maximal 
exercise capacity and cardio-pulmonary function at sea level. Compared to 
their non-diabetic fellow hikers, subjects with T1DM appear to be equally 
affected by acute mountain sickness. However, prevention and treatment of 
acute mountain sickness can be problematic in the individual with diabetes. 
Prophylactic and therapeutic regimens, such as dexamethasone and 
acetazolamide, may result in hyperglycemic deregulation or even (hypothetically) 
diabetic ketoacidosis. 
 Gluco-regulation is affected by hypoxia. This is related to a rise in 
sympathetic nervous system activity and gluco-counter regulatory hormones, 
which, after acclimatization, partly restore to sea level values. Additional 
factors such as decreased appetite, unpredictable meals, acute mountain 
sickness and cold (potentially resulting in slow resorption of subcutaneous 
insulin and malfunctioning of blood glucose meters) can complicate 
 gluco-regulation at altitude. Based on all these considerations, we provide 
pre-travel recommendations including medical consultation and basic 
medical supplies. Adequate knowledge of glucose regulation and possible 
altitude-related complications, meticulous planning, and a thorough 
preparation are amongst the basic precautions. When these precautions 
are met, patients with diabetes are capable of conquering the world’s 
highest mountains. 
Frequent monitoring of blood glucose during exercise under constantly 
changing conditions at altitude, is a requisite for safe high altitude travel. In 
chapter 3 we investigated whether modern handheld capillary blood 
glucose meters are affected by hypobaric hypoxia. We tested six glucose 
dehydrogenase and three glucose oxidase based blood glucose meters in 
a hypobaric chamber (simulated altitude) and compared the results to 
those obtained outside the chamber (normobaric; sea level) and to a 
laboratory glucose reference method. Thereafter, we tested two glucose 
oxidase based, and two glucose dehydrogenase based blood glucose 
meters at true altitude on Mount Kilimanjaro, Tanzania. 
 We found similar results between measurements obtained by the 
glucose oxidase based, compared to the glucose dehydrogenase based 
blood glucose meters, both at simulated altitude and at sea level. Two 
glucose dehydrogenase based blood glucose meters did not meet set 
performance criteria independent from hypobaric hypoxia. In general, most 
blood glucose meters overestimated true blood glucose concentration at 
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simulated altitude. At true high altitude, a glucose dehydrogenase based 
blood glucose meter had the best precision and accuracy. 
 Thus, current handheld blood glucose meter technology is sufficiently 
reliable and accurate for measuring blood glucose under hypoxic conditions. 
It should be noted that during our studies in the hypobaric chamber, both 
air humidity and temperature were kept within the normal range. In the field 
study, temperature was within the normal range and air humidity was not 
measured. Therefore, amongst others, the low temperatures and air humidity 
often encountered at altitude, may still affect the accuracy and reliability of 
blood glucose meters.
Having an overview of current knowledge regarding the effects of altitude in 
diabetes (chapter 2) and having researched the best blood glucose meter 
for altitude travel (chapter 3), we set out on two altitude expeditions with 
subjects with T1DM (chapter 4) and T2DM (chapter 5). 
Chapter 4 describes the mean daily insulin requirements and results of the 
continuously monitored glucose profiles in eight, complication-free subjects 
with T1DM during trekking at high and extreme altitude. Also, we compared 
energy expenditure and symptoms of acute mountain sickness between 
subjects with T1DM and non-diabetic fellow climbers. 
 We found that above altitudes of 5000m, acute mountain sickness 
symptoms and blood glucose concentrations tended to increase. This 
occurred while mean insulin dose was essentially unchanged. There was a 
positive correlation between acute mountain sickness and insulin requirements 
and between acute mountain sickness and blood glucose concentrations 
during the ascent of mount Kilimanjaro. These results indicate that at 
extreme altitude (>5500m) hyperglycemia was present in subjects with 
T1DM, despite lower caloric intake and very high energy expenditure. These 
higher blood glucose levels seem to be related to acute mountain sickness 
and, possibly, increments in adrenergic-sympathetic activity.
 In our study, subjects with T1DM were equally affected by acute mountain 
sickness and had comparable energy expenditure as their non-diabetic 
fellow climbers. Energy expenditure was high, increased in parallel to 
altitude, and peaked on days of summit attempts. 
 Importantly, we did not find severe glycemic deregulation or clinical 
keto-acidosis at altitude despite the use of acetazolamide in 6 out of 8 
subjects with diabetes. 
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 Furthermore, the continuous glucose monitoring system that was used 
to investigate glycemic control during this expedition, functioned without 
major problems and was found to be a very useful tool to anticipate on 
glycemic changes under extreme conditions. 
The majority of subjects with diabetes nowadays has T2DM; these subjects 
often are less active, have a higher body mass index and have more diabe-
tes-related co-morbidity as opposed to subjects with T1DM. There is a 
paucity of data regarding the effects of altitude in subjects with T2DM. 
Experimental studies have shown that exercise and, acute, mild hypoxia 
have an additive effect on peripheral glucose uptake in T2DM. In contrast, 
altitude can also cause hyperglycemia (chapter 4). 
 In chapter 5 we investigated the effects of high altitude trekking preceded 
by exercise training on concentrations of blood glucose, HbA1C percentage, 
homeostasis model assessment of insulin resistance (HOMA-IR), blood 
lipids, energy expenditure, caloric intake, body weight and the occurrence 
of acute mountain sickness in subjects with complication-free T2DM. 
Thirteen individuals with T2DM took part in the Atlas Diabetes Challenge: a 
twelve-day expedition to the summit of Mount Toubkal (4167m), Morocco, 
after six months of preparatory exercise training at sea level. 
We found that the preparatory training resulted in an increased mean daily 
energy expenditure and improved maximal exercise capacity while reported 
caloric intake remained unchanged. Also, the preparatory training reduced 
fasting glucose and allowed a reduction in the use of anti hyperglycemic 
medication (either a lower dose or even the complete discontinuation of 
some medication) , whereas HbA1C percentage, HOMA-IR, body weight 
and the concentration of circulating lipids remained unchanged. Trekking at 
altitude improved HOMA-IR (at 3200m altitude) and concentrations of total 
cholesterol and LDL-cholesterol compared to values prior to the start of the 
expedition. Importantly, the frequency and duration of hyper- or hypo- 
glycemic episodes (as measured by continuous glucose monitoring) 
remained unchanged at high altitude compared to sea level, and all 
participants reached the summit. Despite increased energy expenditure, 
both caloric intake and body weight remained stable at altitude and did not 
differ from sea level. 
 These results show that high altitude trekking is feasible for prepared 
subjects with uncomplicated T2DM, and that this intermediate-term change 
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in exercise activities is associated with an improvement of HOMA-IR 
(reflecting a decrease in insulin resistance), blood glucose and lipids.
The Atlas Diabetes Challenge consisted of 6 months preparatory training 
followed by a 12-day trekking expedition. Over the whole study period, 
exercise – without changes in reported caloric intake – led to a slight, but 
significant, change in body weight and a decrease in blood glucose and 
lipid concentrations. As visceral fat and (ectopic) fat deposition in the heart, 
liver and skeletal muscle are associated with insulin resistance, T2DM and 
cardiovascular disease, we hypothesized that these metabolic changes 
observed after training, would be associated with a change in body fat 
distribution in general, and with ectopic fat accumulation in particular. This 
hypothesis was tested by measuring (ectopic) body fat volumes before and 
at the end of the Atlas Diabetes Challenge. 
 In chapter 6 we describe the effects of exercise on ectopic fat 
deposition, as assessed by magnetic resonance imaging and magnetic 
resonance spectroscopy, in subjects with T2DM participating in the Atlas 
Diabetes Challenge. In addition, given that ectopic fat deposition in the 
heart is related to diastolic dysfunction, we also assessed cardiac function.
We found that 6 months of exercise (including a trekking expedition) led to 
reductions of 37% in visceral abdominal fat volume, 26% in hepatic TG 
content and 20% in paracardial fat volume, in the absence of reported 
dietary changes. These changes did not correlate with the - 4.8% change in 
body mass. In contrast, subcutaneous abdominal, epicardial, myocardial 
and intra-myocellular fat volumes remained unchanged. There was a trend 
towards an increased left ventricular ejection fraction without any changes 
in diastolic cardiac function. The circulating concentrations of alanine ami-
notransferase (ALAT) and the cholesterol-to-HDL ratio also decreased 
while there were no changes in the concentrations of LDL cholesterol, 
triglycerides, aspartate aminotransferase (ASAT), or γ-glutamyltransferase 
(γGT).  
 Based on these findings, we concluded that exercise in subjects with 
T2DM induces tissue-specific changes in body fat distribution. Exercise 
seems to have beneficial effects on paracardial, visceral abdominal and 
hepatic fat deposition, not related to weight loss and in the absence of 
dietary changes. 
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General conclusions and discussion
Taken together, the results obtained in this thesis can be summarized in a 
number of findings:
1. Modern, glucose oxidase- and glucose dehydrogenase-based handheld 
blood glucose meters are sufficiently accurate under conditions of 
hypobaric hypoxia. 
Apparently, technology has improved, and currently both glucose dehydro - 
genase and glucose oxidase based blood glucose meters are not significantly 
affected by hypobaric hypoxia per se. However, temperature and air humidity 
still may affect accurate capillary blood glucose measurements at high altitude. 
2. Safe and successful high altitude trekking is feasible for subjects with 
uncomplicated T1DM as well as T2DM, and is not associated with major 
glycemic deregulations. 
It should be acknowledged, however, that all the participants in our two 
expeditions were free from diabetic complications, screened for cardio- 
vascular disease and accompanied by a medical team. Therefore, the above 
mentioned statement may not be applicable to subjects with complications 
and/or cardiovascular abnormalities.
3. Subjects with uncomplicated T1DM and T2DM are equally affected by 
acute mountain sickness compared to non-diabetic individuals. 
In this thesis, findings were most evident in T1DM, which is in line with and 
extends the findings of previous studies in T1DM. Although we may not 
have travelled high, or ascended fast enough to provoke more pronounced 
symptoms of acute mountain sickness, it seems that up to 4000m altitude, 
AMS affects both subjects with, and without T2DM, similarly.
4. At extreme altitude, hyperglycemia in subjects with T1DM can occur 
despite high energy expenditure and similar caloric intake when the 
apparently needed increase in insulin doses is not sufficiently anti - 
cipated. This hyperglycemia is associated with the occurrence of acute 
mountain sickness. 
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5. At high altitude, HOMA-IR is decreased in subjects with uncomplicated 
T2DM. 
The finding that hypobaric hypoxia can lead to hyperglycemia in T1DM, 
whereas it seems to improve blood glucose and HOMA-IR in subjects with 
T2DM, is fascinating. In our studies these apparently opposing effects of 
hypobaric hypoxia on blood glucose may be explained by several factors.
First, in the Kilimanjaro Challenge the partly acclimatized participants 
reached extreme altitude (> 5500m) and ascended close to 1500m in one 
day. This led to higher symptom scores of acute mountain sickness in most 
subjects both with and without T1DM. In contrast, AMS symptom scores in 
the participants of the Atlas Challenge were very low and most ascents 
were gradual and did not comprise very high or even extreme altitudes. 
 Acute mountain sickness is considered to lead to increments in 
sympatho- adrenergic activity. This increased sympatho adrenergic activity 
counteracts the actions of insulin by inhibition of glucose uptake by tissues 
and by mobilizing glucose through glycogenolysis and gluconeogenesis. 
Thus, the presence of acute mountain sickness may partly explain these 
disparate effects of hypoxia. 
 Second, independent from the presence of AMS, hypobaric hypoxia 
initially induces increments in both insulin and glucose concentrations, 
increased responses to glucose loading and increments in sympathetic 
activity, as expressed by increments in sympathetic nerve activity and 
concentrations of both noradrenalin and adrenalin. Also, it has been shown 
that central inhibition of the sympathetic nervous system by clonidine - a 
combined central blocker of noradrenalin and peripheral alfa-2 receptor 
agonist- prevents both hypoxia induced insulin resistance, (as shown by 
hyperinsulinemic euglycemic clamping) and hypoxia induced increments in 
plasma noradrenalin concentrations. Thus, it seems that both hypoxia and 
AMS elicit at least a temporary state of insulin resistance through increased 
sympathetic activity.
 Third, whether an individual exercises or rests probably plays an 
important role. It can be reasoned that up to a certain level of hypobaric 
hypoxia, the additive effect of insulin-independent skeletal muscle glucose 
uptake through both hypoxia and muscle contraction, may overcome the 
gluco-counterregulatory mechanisms at altitude mentioned above. However, 
even in rest, acute altitude exposure to ≈ 3000m has been shown to induce 
lower blood glucose concentrations in subjects with T2DM. This suggests 
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that up to 3000m hypoxia stimulated glucose uptake may outweigh gluco- 
counter regulatory mechanisms.
 Fourth, the time spent at altitude is crucial as it has been shown that 
concentrations of adrenalin, noradrenalin, insulin, and blood glucose all 
change due to altitude acclimatization after days to weeks at a similar 
altitude. Subsequently, glucose mobilization and glucose disposal in response 
to exercise change as time at altitude passes. 
 Altogether, the apparently opposing effect of hypobaric hypoxia on 
glucose regulation in subjects with T1DM and T2DM can be explained by 
the length and the degree of hypoxic exposure (acclimatization and altitude 
reached), exercise and the presence of AMS.
6. High altitude trekking leads to increments in energy expenditure as 
compared to normal daily activities at sea level. In our studies, trekking 
consisted of low intensity exercise of long duration as measured by an 
upper arm physical activity monitor. (In contrast to the measured low 
intensity exercise, subjectively, the intensity feels strenuous due to 
hypobaric hypoxia.)
The increased energy expenditure measured at altitude can be explained 
by several factors. Most likely, this is explained by the longer duration of (low 
intensity) exercise during trekking at altitude as compared to the often 
shorter duration exercise bouts at sea level. Whether there was an additive 
effect of hypobaric hypoxia that increased energy expenditure even further 
is unknown, but also unlikely. It has previously been shown that although 
exercise feels more strenuous, the absolute energy expenditure for the 
same workload is equal at altitude and at sea level. Lastly, we assumed the 
sensewear arm band activity monitors  to be accurate both under normoxic 
and hypoxic conditions, however, to our knowledge, this has not been tested. 
7. Six months of unsupervised exercise training and a 12-day high altitude 
trekking expedition can elicit decrements in visceral abdominal, 
paracardial and intra-hepatic fat volumes in the absence of reported 
dietary changes in subjects with T2DM. 
8. In subjects with T2DM, beneficial changes in body fat distribution, 
circulating lipid concentrations and anti-hyperglycemic medication 
occur in response to exercise in the absence of substantial weight loss.
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It is intriguing that these beneficial changes in body fat distribution occur in 
the absence of reported dietary changes. This implies that solely exercise 
can induce these changes in visceral and ectopic fat distribution. However, 
the effect of hypoxia per se on these changes remains unclear as we did 
not measure body fat distribution at the end of the training period at sea 
level just prior to the altitude expedition. 
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Practical advices: a combination of evidence 
and expert opinion
Part of the information, as published in the medical journal Diabetes Care, 
is repeated in this short overview. In general, advices can be quite 
comprehensive, but the individual’s own responsibility needs to be 
emphasized, and the relative lack of evidence based standard advices for 
solving possible problems should be mentioned.
Still, problems can be either prevented or faced with some confidence 
when preparations are made, and measures are taken to improve safety 
during the trip. (see Table 1 and Fig 1 below)
Table 1   Points of attention for physically active subjects with diabetes at 
altitude
Predeparture: 
- Inform and instruct fellow travelers and expedition leaders of your diabetes and 
its treatment, including emergency medical treatment  (e.g. glucagon injection).
- Obtain information about local medical aid and (diabetic) resources.
- Consult your physician when planning high altitude travel (including an ophthal-
mologist in case of very high and extreme altitude travel).
- Make yourself familiar with diabetes management in the environment (cold, 
terrain) and with the intensity of exercise anticipated at altitude.
- Obtain adequate clothing for all conditions and test it prior to departure.
- Take spare supplies including short acting insulin. 
At altitude:
- Stay in close contact with fellow hikers/travelers
- Anticipate frequent blood glucose monitoring and correct glucose accordingly.
- Insulin requirements and oral antihyperglycemic dosages may be decreased 
due to exercise and appetite loss.
- Insulin doses may be increased especially in case of high altitude illnesses, 
rapid ascents and at higher (extreme) altitudes.
- Prevent BGMs, pumps, catheters and insulin from freezing.




Trekking at altitude is often associated with conditions of low-hygiene and 
scarcity of (adequate) medical care. Therefore, basic therapeutic supplies 
should be carried. Adequate insurance coverage should be arranged 
before departure. It is of vital importance to notify travel companions and 
guides of the hiker’s diabetes and to teach them how to recognize (severe) 
hypo- and hyperglycemia. Travel companions should be able to measure 
blood glucose and should be instructed how to administer glucose or inject 
insulin and glucagon. Furthermore, carrying an emergency medical kit with 
instructions in a common, easily accessible place is of vital importance.
 All items (see Fig 1) should be taken in sufficient quantities (e.g. triple 
the normal amount), easy accessible and in separate rucksacks (e.g. 
subject and fellow traveler). A third pack should be stored at a timely 
reachable place (e.g. hotel, base camp). 
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Figure 1   Diabetic travel supplies and recommendations for activities at 
altitude of longer duration
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Future perspectives in research
While our studies add knowledge towards the safety, technical challenges 
and metabolic changes associated with trekking at altitude in type 1 diabetes 
mellitus (T1DM) and T2DM, several gaps in knowledge remain.
Regarding blood glucose meters, it still needs to be determined whether the 
combination of low temperature and hypoxia will affect performance. In addition, 
air humidity may be relevant. Additional measurements and comparisons 
at different altitudes and temperature and perhaps levels of humidity are 
required. 
An intriguing finding of our studies is the apparently opposing effect of high 
altitude (hypobaric hypoxia) exposure on glucose regulation in subjects 
with T1DM and T2DM. While in T1DM hypobaric hypoxia can lead to hyper-
glycemia, it seems to improve blood glucose and HOMA-IR in subjects with 
T2DM. Above, under item 5, a number of potential explanations is provided; 
the length of hypoxic exposure (i.e. the degree of acclimatization) and the 
extent of hypoxia (i.e. the actual altitude reached), the exercise intensity and 
the exercise duration and the presence of AMS. These factors seem to 
share a common pathway as they all affect the activity of the sympathetic 
nervous system. More detailed investigations including accurate measurements 
of sympathetic nervous system activity, for example by (non- and) invasive 
measurements (heart rate variability, baro-receptor sensitivity, micro-
neurography) and catecholamine levels in combination with detailed 
information concerning glucose metabolism may yield valuable information on 
the exact relationship between these two key regulatory systems. In addition, 
it would be interesting to further research the possible disparate effect of 
hypoxia on glucose metabolism in both subjects without and subjects with 
diabetes; either type 1 or type 2 diabetes.
Hypoxic exposure frequently leads to weight loss induced by a negative 
energy balance. Reduced appetite is common at altitude and may be part 
of the constitutional symptoms of AMS and/or due to changes in hormones 
involved in satiety regulation, but the exact mechanisms remain unknown. 
T2DM is associated with increased ectopic fat deposition and accumulation 
of fat in the visceral abdominal cavity, which seems to be more sensitive to 
lipolysis induced by catecholamines. Therefore, it would be interesting to 
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investigate whether exercise during short term moderate altitude exposure 
(true altitude or simulated in a hypobaric chamber) results in the preferential 
reduction of the visceral abdominal fat compartment and whether this 
relates to a reduction in (ectopic) fat mass, and improvements in adipokines, 
lipids and insulin resistance. 
 In our study, 6 out of 8 patients with T1DM used acetazolamide, 
apparently without adverse effects, but more data are needed to conclude 
that the use of acetazolamide is safe for patients with T1DM and does not 
increase the risk to develop ketoacidosis.
 While it is notoriously difficult to obtain research data in patients with 
diabetes trekking at high altitude, it is at the same time extremely rewarding 
to enable patients to experience the magnificence of mountains and the 
serenity of nature. 
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Suikerziekte (Diabetes Mellitus) is een ziekte die zich kenmerkt door een te hoog 
suikergehalte (glucose) in het bloed (hyperglycemie). Dit wordt veroorzaakt 
door afwezigheid van insuline, een hormoon gemaakt door de alvleesklier, 
bij type 1 diabetes, of door verminderde productie en/of gevoeligheid voor 
insuline bij type 2 diabetes. Diabetes mellitus is geassocieerd met hart- en 
vaatziekten en kan negatieve gevolgen hebben (complicaties) zoals het 
verminderd werken van de nieren (nierinsufficiëntie), zenuwen (neuropathie), 
ogen (retinopathie) en bloedvaten. 
 Lichamelijke inspanning is voor mensen met diabetes van groot 
belang. Het verbetert de gevoeligheid van het lichaam voor insuline en de 
opname van glucose uit het bloed. Lichaamsbeweging leidt zo tot betere 
glucosewaarden, een lagere insuline- of bloedsuiker verlagende medicatie 
behoefte en een verminderde kans op complicaties. Ook draagt lichamelijke 
inspanning bij aan het voorkomen en verlagen van o.a. overgewicht, hart- 
en vaatziekten, hoge bloeddruk, hoge cholesterol waarden in het bloed, 
depressie en vele andere aandoeningen die samen hangen met diabetes. 
 Steeds meer mensen bezoeken (hoog-)gebergten en zijn daar lichamelijk 
actief. Hoe groter de  hoogte die men bezoekt, hoe lager de zuurstofspanning 
in de lucht (“ijlere lucht”). Dit heeft tot gevolg dat ook de zuurstofopname uit de 
lucht moeilijker wordt en de zuurstofspanning in het bloed afneemt (hypoxie). 
Het lichaam reageert op deze hypoxie door o.a. een snellere hartslag, een 
snellere ademhaling, het vrijmaken van stress- hormonen en het activeren 
van het onwillekeurige (sympatische) zenuwstelsel. Dit zenuwstelsel speelt 
een rol bij de regulatie van de bloeddruk, de hart- en ademfrequentie en stelt 
het lichaam in staat lichamelijke arbeid te verrichten. Deze reacties van het 
lichaam worden versterkt wanneer er sprake is van lichamelijke inspanning; 
immers voor lichaamsbeweging is meer zuurstof nodig. Verblijft men langere 
tijd op hoogte dan past het lichaam zich aan en nemen een aantal van de 
bovengenoemde reacties af; het lichaam went aan de hoogte (acclimatisatie). 
Zeker tijdens inspanning bij langduriger verblijf op hoogte blijft er echter 
sprake van hogere concentraties van stresshormonen in het bloed en hogere 
activiteit van het sympatische zenuwstelsel. Bovendien is er bij mensen zonder 
diabetes op hoogte aanvankelijk meer insuline nodig om de bloedsuiker 
normaal te houden: m.a.w. er lijkt sprake te zijn van een verminderde insuline 
gevoeligheid en/of relatief hogere bloedsuikerwaarden. Ook de omstandigheden 
in de bergen kunnen problemen geven. Denk aan koude en afwezige of 
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beperkte medische hulp, maar ook aan het optreden van hoogteziekte: een 
aandoening waarvan de kenmerken variëren van hoofdpijn en misselijkheid 
tot benauwdheid, bewustzijnsverlies en overlijden.
 Er is maar weinig bekend over de effecten van lichamelijke inspanning 
op hoogte bij mensen met diabetes. Men kan zich voorstellen dat zuurstof 
gebrek, hoogteziekte en stress negatieve gevolgen hebben voor mensen 
met diabetes en dat de bloedsuikerwaarden sterk kunnen stijgen ten gevolge 
van hogere concentraties van stresshormonen in het bloed en hogere activiteit 
van het onwillekeurige zenuwstelsel. Echter, uit experimenteel onderzoek blijkt 
dat juist zuurstofgebrek ook kan zorgen voor een verbeterde opname van 
suiker (glucose) uit de bloedbaan en zodoende bijdraagt aan een lagere 
bloedsuikerwaarde. 
De doelstelling van dit proefschrift was het verkrijgen van meer kennis over 
de veiligheid, de technische uitdagingen en de veranderingen in de suiker- 
en vetstofwisseling ten gevolge van trektochten in (hoog)gebergten bij mensen 
met diabetes. Metingen voor, tijdens en na twee hoogte expedities waarvan 
de deelnemers type 1 of type 2 diabetes hadden, vormen de basis van dit 
proefschrift. 
In hoofdstuk 2 beschrijven we de huidige kennis uit medische studies van 
het gaan naar en verblijven op (grote) hoogten met diabetes. Er blijken geen 
duidelijke redenen te zijn waarom iemand met diabetes zonder complicaties 
en met een goede instelling van bloedsuikerwaarden, niet naar zeer grote 
(3500-5500m) en zelfs extreme hoogte (>5500m) zou kunnen reizen. Wel 
zijn er vele factoren die het reizen naar grote hoogten voor iemand met 
diabetes moelijker en gevaarlijker maken en is bezoek aan artsen evenals 
een zeer goede voorbereiding noodzakelijk voor vertrek. Men kan zich 
voorstellen dat diabetes zelf en de mogelijke complicaties ervan lichamelijke 
inspanning op hoogte en de aanpassing aan een lagere zuurstofspanning 
bemoeilijken (bijvoorbeeld het slechter voelen van koude door neuropathie 
en daardoor bevriezing van vingers). De meeste medisch wetenschappelijke 
literatuur betreft het effect van hoogte op mensen met diabetes type 1, 
maar over diabetes type 2 is weinig bekend. Mensen met type 1 diabetes 
lijken echter niet gevoeliger voor hoogteziekte te zijn dan mensen zonder 
diabetes en ook zij behaalden de top van extreem hoge bergen waaronder 
de Mt. Everest: ’s werelds hoogste top (8848m). Wel is er sprake van hogere 
bloedsuikers op zeer grote hoogte en kunnen hoogte gerelateerde zaken 
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zoals verlies van eetlust, langdurige inspanning, koude, bevriezing van 
insuline en bloedsuikermeters (waardoor deze niet meer werken), leiden tot 
uiteenlopende bloedsuikerwaarden en complicaties. Ook het voorkomen 
en het behandelen van hoogteziekte met medicatie kan mogelijk ernstige 
verhoging van bloedsuikerwaarden geven. Daarom beschrijven we welke 
voorzorgsmaatregelen en voorbereidingen nodig zijn om het reizen naar 
grote hoogten met diabetes zo verantwoord mogelijk te maken. Een aantal 
voorwaarden hiervoor zijn een goede kennis van de gevolgen van inspanning 
en omgevingsfactoren op bloedsuikerwaarden, het bezoek aan een arts 
voorafgaand aan de bergtocht, een goede instelling van zijn/haar diabetes 
en het frequent controleren van de bloedsuiker. 
 Om dit laatste te kunnen doen is een nauwkeurige en betrouwbare 
bloed suikermeter nodig welke goed functioneert op grote hoogte. 
 In hoodstuk 3 beschrijven we de effecten van hoogte (hypoxie) op de 
nauwkeurigheid van verschillende bloedsuikermeters. Sommige bloed-
suikermeters (glucose oxidase meters) zijn afhankelijk van zuurstof voor de 
bepaling van het suikergehalte in het bloed, andere meters (glucose 
dehydrogenase meters) niet. Een lage luchtdruk en zuurstofspanning (i.e. 
hoogte) werden nagebootst in een grote tank op de luchtmachtbasis te 
Soesterberg.  Een negental bloedsuikermeters werd simultaan getest met 
bloedmonsters van verschillende glucose concentraties, zowel binnen 
(hoogte) en buiten de tank (zee niveau). Wij vonden geen verschillen tussen 
de glucose oxidase en de glucose dehydrogenase meters op verschillende 
hoogten en op zee niveau. Wel bleken de meeste meters de ware bloed-
suikerwaarde te overschatten op grote hoogte. Voor en tijdens een veld -
onderzoek op werkelijke hoogte (Mt. Kilimanjaro) was een dehydrogenase 
type bloedsuikermeter het meest nauwkeurig en betrouwbaar. Het zou 
kunnen dat niet de lage zuurstofspanning op hoogte, maar andere zaken 
zoals de lage temperatuur en luchtvochtigheid de nauwkeurigheid van de 
moderne bloedsuikermeters beïnvloeden.
 Na de beschikbare kennis te hebben samengevat (hoofdstuk 2) en 
een betrouwbare bloedsuikermeter te hebben getest (hoofdstuk 3) volgden 
twee expedities naar hooggebergten waarvan de resultaten beschreven 
staan in hoofdstuk 4 en 5. 
 In hoofdstuk 4 beschrijven we het effect van inspanning en hoogte op 
de bloedsuikerwaarden en het energie verbruik tijdens een expeditie met 8 
deelnemers met type 1 diabetes naar Mt. Meru (4562m) en Mt. Kilimanjaro 
(5895m). De bloedsuikerwaarden werden met een bloedsuikermeter gemeten 
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(met een vingerprik), maar ook met een continu glucose monitoring systeem dat 
de onderhuidse glucose waarden meet middels een onderhuids geplaatste 
sensor. Deze sensor zendt de glucose waarden door naar de insuline pomp 
waar vervolgens de glucosewaarden op het display als een grafiek zijn af te 
lezen. Ook werd middels een armband op basis van verschillende 
parameters het dagelijkse energieverbruik (kilocalorieën per dag (kCal/
dag)) gemeten. Het geschatte dagelijkse energie verbruik steeg fors op 
dagen van het klimmen naar grotere hoogten, maar verschilde niet tussen 
mensen met en mensen zonder diabetes type 1. De symptomen van 
hoogteziekte werden gescoord op een gestandaardiseerde vragenlijst 
(Lake Louise Questionnaire). Er was geen verschil in het optreden van 
(symptomen) van hoogteziekte tussen beide groepen. Boven 5000m 
hoogte vonden we stijgende glucosewaarden terwijl de dagelijkse insuline 
dosis gelijk bleef. Ook namen de symptomen van hoogteziekte boven deze 
hoogte toe. Er bleek een positieve relatie te zijn tussen bloedsuikerwaarden 
en hoogteziekte en tussen hoogteziekte en insuline doses. Extreme hoogte 
lijkt dus aanleiding te geven tot hogere bloedsuikerwaarden bij mensen met 
type 1 diabetes terwijl de insuline dosering gelijk, de inspanning hoger, en 
de voedselinname lager was in vergelijking met lagere hoogten. Mogelijk 
dat dit te maken heeft met een toename van stresshormonen en een 
toegenomen activiteit van het onwillekeurige zenuwstelsel bij hoogteziekte 
en/of het bereiken van grotere hoogten waardoor de insuline dosering 
hoger  zou moeten zijn dan men mogelijk verwacht. Deze toenamen van 
stress hormonen en het onwillekeurige zenuwstelsel zouden een vorm van 
insulineresistentie kunnen geven en onze bevindingen kunnen verklaren. 
De continue onderhuidse glucosesensor functioneerde goed op hoogte en 
over de gehele expeditie liet deze geen forse ontregeling van glucosewaarden 
zien in vergelijking met zee niveau.   
In hoofdstuk 5 beschrijven we de effecten van inspanning op zee niveau en 
inspanning op hoogte bij mensen met type 2 diabetes. Het grootste deel 
van de mensen met diabetes heeft type 2 diabetes. Type 2 diabetes is 
geassocieerd met overgewicht, een lagere conditie en de aanwezigheid 
van diabetes gerelateerde aandoeningen en complicaties. Over de effecten 
van inspanning bij type 2 diabetes onder een lagere zuurstofspanning 
(zoals op hoogte) is uit experimenteel onderzoek bekend dat dit de 
glucose opname uit het bloed kan bevorderen en zodoende leidt tot lagere 
bloedsuikerwaarden. Dit terwijl juist hogere bloedsuikers werden gevonden 
139
bij mensen met type 1 diabetes bij verblijf en inspanning op grote hoogte. 
(hoofdstuk 4).
 We onderzochten het effect van een 12- daagse trektocht in het Atlas 
gebergte in Marokko welke werd voorafgegaan door een 6 maanden durende 
trainingsperiode op zee niveau. 
 Bloedsuiker waarden, HbA1C % (~ gemiddelde bloedsuikerwaarde over 
3 maanden), 
geschatte insuline gevoeligheid (HOMA-IR), energie verbruik, voedsel 
inname, vetstofwisseling (o.a. cholesterol) in het bloed, lichaamsgewicht en 
symptomen van hoogte ziekte werden gemeten bij 13 mensen met type 2 
diabetes.  
 Wij vonden dat een 12-daagse expeditie naar Mt Toubkal (4167m) geen 
verandering gaf van bloedsuikerwaarden bij mensen met type 2 diabetes 
zonder complicaties. Wel was de nuchtere insuline spiegel op 3200m 
gedaald terwijl de bloedsuikerwaarden stabiel bleven t.o.v. lagere hoogten 
en zeeniveau; een fenomeen dat mogelijk past bij een toegenomen insuli-
negevoeligheid. Er trad geen hoogteziekte op en alle deelnemers haalden 
de top. In vergelijking met de start van de expeditie was het totale cholesterol 
en het LDL-cholesterol (“slechte cholesterol”) gedaald en bleven de voedsel 
inname en het gewicht stabiel. Zes maanden voor de expeditie ontvingen 
de deelnemers een trainingsadvies en werd hun inspanningsvermogen 
getest. Na 6 maanden voorbereiding, nog voor de hoogte expeditie, waren 
het dagelijkse energieverbruik en het inspanningsvermogen toegenomen 
en was de nuchtere bloedsuikerwaarde gedaald. Het gewicht nam 
nauwelijks af, de voedselinname veranderde niet en de gemiddelde bloed-
suikerwaarde (HbA1C) en ook de geschatte insulinegevoeligheid (HOMA-IR) 
bleven stabiel. Concluderend laten de resultaten van deze studie zien dat 
het maken van trektochten op grote hoogte haalbaar is voor mensen met 
diabetes type 2 en gunstige effecten heeft op de bloedsuiker-, insuline- en 
cholesterolwaarden. 
 De trainingsperiode van 6 maanden en de bovengenoemde expeditie 
werden gebruikt om de effecten van lichamelijke inspanning op de verdeling 
van lichaamsvet te onderzoeken bij mensen met type 2 diabetes. Type 2 
diabetes gaat namelijk gepaard met overgewicht en de opslag van 
lichaamsvet, niet alleen in normaal onderhuids vetweefsel, maar ook in 
organen en ander weefsel (ectopisch vet) zoals de lever, het hart, de 
skeletspieren en rondom de buikorganen. Dit ectopisch vet kan de functie 
van deze organen negatief beïnvloeden, is betrokken bij een verminderde 
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werking van insuline op deze weefsels en is geassocieerd met hart- en 
vaatziekten. 
 In hoofdstuk 6 worden de effecten beschreven van lichamelijke inspanning 
op ectopische vetverdeling in de deelnemers van de bovengenoemde 
expeditie. De hoeveelheid vet in en om het hart, in de lever, in een spier van 
het onderbeen, in de buikholte en onder de buikhuid werden gemeten met 
behulp van een magneetscan (MRI: Magnetic Resonance Imaging en MRS: 
Magnetic Resonance Spectroscopy). Ook werd de functie van het hart 
middels een MRI scan gemeten. 
 Wij vonden dat zes maanden lichaamsbeweging en een hoogte expeditie 
leidde tot afname van het vet in de lever en de buikholte en rondom het 
hart. Ook stoffen in het bloed welke een aanwijzing kunnen zijn voor lever-
ontsteking door vervetting van de lever (ALAT) waren verminderd na 6 
maanden training. Het lichaamsgewicht was gedaald met 4.8%, echter 
deze afname was niet gerelateerd aan de veranderingen in de gemeten 
vetcompartimenten. Concluderend lijkt een interventie op basis van lichaams-
beweging zonder dieet de opslag van ectopisch vet in specifieke, maar niet 
alle, vetcompartimenten te verminderen. 
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Conclusies en Algemene Beschouwing
De bevindingen van de onderzoeken beschreven in dit proefschrift kunnen 
als volgt worden samengevat:
1. Moderne, bloedsuikermeters met glucose oxidase- of glucose dehydro-
genase-techniek zijn voldoende nauwkeurig onder omstandigheden 
van verlaagde luchtdruk en zuurstofspanning (hoogte) tot 5000m hoogte.
 
In vergelijking met eerdere studies lijkt de huidige technologie verbeterd te 
zijn en blijken beide typen bloedsuikermeters (meters met glucose dehydro -
-genase en glucose oxidase techniek) niet beïnvloed te worden door de 
effecten van hoogte per se. Het kan echter wel zo zijn dat de (lage) lucht-
vochtigheid en koude op (grote) hoogte nauwkeurige bepaling van de 
bloedsuiker door bloedsuikermeters beïnvloedt. 
2. Het maken van bergtochten door hooggebergten is haalbaar en voldoende 
veilig voor mensen met diabetes mits deze goed zijn voorbereid, geen 
complicaties of belangrijke hart- en vaatziekten hebben. Het maken 
van trektochten op hoogten tot 5000m leidt niet tot grote verstoring van 
de bloedsuikers. 
3. Mensen met ongecompliceerde type 1 of type 2 diabetes krijgen niet vaker 
hoogteziekte dan mensen zonder diabetes.
Deze bevindingen sluiten aan bij eerder, beperkt onderzoek bij mensen met 
type 1 diabetes. Voor diabetes type 2 lijkt hetzelfde te gelden, maar het is 
mogelijk dat in onze studie er geen hoogteziekte optrad omdat we zeer 
geleidelijk zijn gestegen en geen extreme hoogte hebben bereikt. 
4. Hoge bloedsuikerwaarden kunnen optreden op extreme hoogte (> 5500m) 
en lijken gerelateerd te zijn aan hoogteziekte bij mensen met type 1 
diabetes. Deze hogere bloedsuikers treden op ondanks een verminderde 
inname van voedsel, een hogere energieverbruik door lichamelijk 
inspanning en onveranderde insuline doseringen. 
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5. Op grote hoogte (3200m) nemen de nuchtere insulineconcentraties in 
het bloed en de HOMA-IR, een maat voor insuline resistentie, af bij 
mensen met type 2 diabetes.
De twee bovenstaande bevindingen lijken elkaar tegen te spreken. Namelijk, 
extreme hoogte leidt tot hogere bloedsuikerwaarden bij mensen met type 1 
diabetes, maar grote hoogte leidt tot relatief lagere bloedsuikerwaarden 
(t.o.v. de insulinebehoefte) bij mensen met type 2 diabetes. Dit kan mogelijk 
worden verklaard door een aantal mechanismen. 
 Ten eerste kan men dit verklaren door het verschil in hoogte. Tijdens 
de beklimming van de Kilimanjaro behaalden de deelnemers met type 1 
diabetes extreme hoogte (>5500m) en stegen zij van 4500m naar 5895m 
in minder dan een dag. Een snelle stijging naar grotere hoogte en slechts 
een gedeeltelijke acclimatisatie leidde tot een toename van hoogteziekte 
symptomen bij de meeste deelnemers met en zonder diabetes type 1. 
Daarentegen waren er nauwelijks symptomen van hoogteziekte tijdens de 
beklimming van Mt. Toubkal (4167m) en extreme hoogte en snelle stijgingen 
in hoogte werden niet bereikt. Hoogteziekte (AMS) gaat gepaard met een 
toename van onwillekeurige (sympatische) zenuwstelsel activiteit en het 
vrijkomen van stresshormonen. Beiden remmen de werking van insuline 
door de opname van glucose uit de bloedbaan te verminderen en de afgifte 
van glucose aan de bloedbaan te vergroten. Dus het optreden van hoogte- 
ziekte zou een verklaring kunnen zijn waarom hogere bloedsuikerwaarden 
werden gevonden in de studie met diabetes type 1 en niet in de studie met 
diabetes type 2.
 Ten tweede leidt ook zuurstoftekort, of hypoxie, tot initiële verhoging van 
de bloedsuikerwaarden en insuline concentratie in het bloed, on afhankelijk 
van het optreden van hoogteziekte. Dit past bij een staat van insuline 
resistentie (het minder gevoelig zijn van weefsels voor de effecten van 
insuline). Ook stresshormonen zoals nor- en adrenaline en de (sympatische) 
zenuwactiviteit nemen toe onder hypoxische omstandigheden. Als men deze 
zenuwactiviteit onder hypoxische omstandigheden remt met medicijnen 
dan treden deze insuline resistentie en toename van noradrenaline in het 
bloed niet op. Concluderend lijken dus zowel hoogte ziekte (AMS) als 
hoogte (hypoxie) een tijdelijke staat van insulineresistentie te geven door 
toename van sympatische zenuwactiviteit en stresshormonen.
 Ten derde speelt het al dan niet lichamelijk actief zijn een belangrijke 
rol. Men kan zich voorstellen dat zowel lichaamsbeweging als een lagere 
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zuurstof spanning (hypoxie) tot op zekere hoogten de opname van suiker 
uit de bloedbaan versterken. Deze mechanismen van verbeterde opname 
van bloedsuiker in de skeletspier zouden de mechanismen die de bloedsuiker 
doen stijgen (verhoogde zenuwactiviteit en afgifte van stresshormonen) tot 
een zekere mate van hypoxie, c.q. tot een bepaalde hoogte, kunnen 
overtreffen. Stopt men met de lichamelijke inspanning en valt zodoende 
een van de twee stimuli voor verbeterde opname van bloedsuiker weg, dan 
zou het kunnen dat de bloedsuikerverhogende mechanismen weer de 
overhand krijgen. Echter, ook zonder lichaamsbeweging blijkt een acute en 
tijdelijke blootstelling aan een hoogte van +/- 3000m lagere bloedsuiker-
waarden te kunnen geven in experimenteel onderzoek. Mogelijk dat dus 
andere zaken dan hoogte, hoogteziekte en inspanning nog een rol spleen. 
 Ten vierde, de duur van hoogte-expositie is cruciaal omdat uit eerdere 
studies met mensen zonder diabetes bleek dat de concentraties van  nor- 
en adrenaline, insuline, en glucose in het bloed  na een aantal dagen van 
stijging ook weer dalen bij langer verblijf op eenzelfde hoogte. Hierdoor zal 
ook het vrijkomen van glucose naar de bloedbaan en de opname van 
glucose uit de bloedbaan bij inspanning veranderen. 
 Samenvattend kunnen de schijnbaar tegengestelde effecten van bloot- 
stelling aan hoogte op de bloedsuiker huishouding bij mensen met type 1 
en type 2 diabetes in onze studies waarschijnlijk verklaard worden door 
de duur van het verblijf op hoogte (mate van acclimatisatie), de hoogte zelf 
(mate van hypoxie), de duur en de intensiteit van de inspanning en de 
aanwezigheid van hoogteziekte. 
6. Het maken van trektochten in hooggebergten leidt tot een groter dageljks 
energieverbruik door lichaamsbeweging t.o.v. activiteiten op zee niveau. 
De inspanning is van een lage intensiteit maar een langere duur. (Echter, 
door de ijlere lucht op hoogte lijkt de inspanningintensiteit groter dan op 
zeeniveau.)
Dat het dagelijkse energie verbruik op hoogte hoger is dan op zee niveau 
wordt hoogstwaarschijnlijk verklaard doordat men zich langer inspande: 
urenlange wandeltochten met dalingen en stijgingen die normaal op zee 
niveau tijdens de voorbereiding niet werden gemaakt. Of de lagere zuur-
stofspanning (hypoxie) een rol speelde in de gevonden toename in dagelijks 
energie verbruik is niet duidelijk, maar ook niet aannemelijk. 
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Ook al voelt de geleverde inspanning voor een bepaalde activiteit (Wattage) 
zwaarder op hoogte, de hoeveelheid verbruikte energie voor deze activiteit 
blijft gelijk op zeeniveau en hoogte. Tot slot moet opgemerkt worden dat 
we hebben aangenomen dat de sensewear armband op hoogte net zo 
nauwkeurig het dagelijks energieverbuik mat als op zeeniveau, maar dit is 
nooit wetenschappelijk onderzocht. 
7. Zes maanden lichamelijke training en een trektocht in het hooggebergte 
kan een afname geven van levervet, vet rond de buikorganen en rondom 
het hart bij mensen met type 2 diabetes zonder dat veranderingen in 
dieet gerapporteerd werden. 
 
8. Afname van (ectopisch) vet in het lichaam, cholesterol en vetten in de 
bloedbaan en de noodzaak voor bloedsuiker verlagende medicatie 
traden op na lichamelijke inspanning en waren niet geassocieerd met 
de afname van lichaamsgewicht.
Het is erg interessant dat de afname van vet in de verschillende lichaams- 
delen en organen optrad zonder dat de proefpersonen rapporteerden dat ze 
hun eetpatroon hadden veranderd. Dit zou betekenen dat deze veranderingen 
alleen door een toename van lichaamsbeweging werden veroorzaakt. Het 
effect van hoogte (hypoxie) op deze veranderingen kan echter een rol 
hebben gespeeld. Om dit met grotere zekerheid vast te stellen hadden 
we echter de MRI metingen aan het einde van de 6 maanden trainingsperiode, 
net voor de expeditie, moeten herhalen.  
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Praktische adviezen 
Hieronder volgen praktische adviezen en informatie voor mensen met 
diabetes die naar hoogte willen gaan of op hoogte actief zijn. Een klimmer 
of wandelaar dient zich bewust te zijn van zijn of haar eigen verantwoordelijk -
heid tijdens, en bij voorbereiding van, activiteiten op hoogte. 
 Er is weinig informatie dat gestoeld is op medisch onderzoek en de 
meeste informatie bestaat uit ervaringen van experts en “gezond verstand”. 
Een deel staat ook beschreven in hoofdstuk 2. De meeste problemen kunnen 
voorkomen worden door een goede voorbereiding. (zie Tabel 1 en Figuur 1 
hieronder)
Tabel 1   Aandachtspunten voor mensen met diabetes tijdens activiteiten 
op hoogte 
Voor vertrek: 
- Informeer en instrueer medereizigers en de expeditie leiders over jouw 
 diabetes en hoe te handelen in geval van medische nood (bijv. glucagon 
injectie  toedienen).
- wees op de hoogte van lokale medische zorg en verkrijgbare (diabetes) 
 hulpmiddelen en medicatie.
- bezoek je eigen arts/specialist als je naar (grote) hoogte gaat (denk aan een 
bezoek aan de oogarts wanneer je naar zeer grote of extreme hoogte gaat).
- Train jezelf en anticipeer op de te verwachten omstandigheden op hoogte 
(koude, moeilijk terrein, regen) zorg dat je in goede lichamelijke conditie bent.
- Zorg voor goede kleding voor alle weersomstandigheden en test deze voor vertrek.
- Neem reserve voorraden mee van alle diabetes benodigdheden.
Op hoogte:
- Blijf dichtbij medereizigers/-wandelaars
- Wees voorbereid op frequente bloedsuikermetingen en correctie van afwijkende 
glucosewaarden.
- Lagere doseringen van insuline en orale bloedsuiker verlagende medicatie 
kunnen nodig zijn door inspanning en verlies van eetlust op hoogte.
- Hogere insulin doseringen kunnen nodig zijn in geval van hoogteziekten, 
snelle stijging naar grotere hoogten en op extreme hoogten. 
- Voorkom dat bloedsuikermeters, insulinepompen, catheters and insuline 
 bevriezen.
- Neem voldoende drank en koolhydraatrijke voeding mee in geval van lange 
inspanning op hoogte. 
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Bij het maken van bergtochten is er vaak sprake van lagere hygiene en 
afwezigheid of moeilijk te bereiken medische zorg. Neem daarom een basis-
uitrusting mee om eerste hulp te kunnen verzorgen. Zorg ook voor een 
goede verzekering welke eventuele noodmaatregelen of opname in een 
buitenlans ziekenhuis dekt. Medereizigers en gidsen dienen op de hoogte 
te zijn van het feit dat de wandelaar/reiziger diabetes heeft en zij moeten 
hypo- en hyperglycemieen (hoge en lage bloedsuikers) leren herkennen. 
In geval van nood dienen zij ook bloedsuikers te kunnen meten en middels 
glucose, glucagon of insuline toediening te kunnen behandelen. Daarom 
dienen deze medische hulpmiddelen ook voor medewandelaars/reizigers 
makkelijk te vinden te zijn in de rugzak van de reiziger met diabetes of bij de 
gids. 
 Neem alle benodigdheden in voldoende hoeveelheden mee (bij voorkeur 
3 maal zoveel)
Figuur 1   Reisbenodigdheden en aanbevelingen voor mensen met 
diabetes bij activiteiten van langere duur op hoogte
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 Zorg dat men er gemakkelijk bij kan en doe ze in verschillende rug- 
zakken. Zorg dat een derde voorraad achterblijft in het basiskamp of hotel. 
Toekomstig onderzoek
Onze studies dragen bij aan de kennis over de veiligheid, technische 
aspecten (betrouwbaarheid van bloedsuikermeters) en metabole veranderingen 
welke plaatsvinden bij het maken van trektochten op hoogte bij mensen 
met type 1 en type 2 diabetes. Maar er zijn nog steeds belangrijke zaken 
welke verder onderzoek behoeven. 
Het kunnen vertrouwen op een bloedsuikermeter is van essentieel belang 
voor iemand met diabetes m.n. tijdens inspanning op hoogte en bijbehorende 
factoren die de bloedsuiker kunnen verstoren. 
 Het is echter nog niet duidelijk of het koude, luchtvochtigheid, de 
combinatie van beide of de combinatie met hypoxie (hoogte) is die de 
 betrouwbaarheid van bloedsuikermeters het meest beïnvloed. Om dit goed te 
onderzoeken zou herhaling van onze experimenten met variabele temperatuur 
en luchtvochtigheid nodig zijn. 
Een interessante bevinding van onze studies is het feit dat hoogte (hypobare 
hypoxie) verschillende en ogenschijnlijk tegenstrijdige effecten heeft op 
de bloedsuiker waarden van mensen met type 1 (T1DM) en type 2 (T2DM). 
Terwijl bij T1DM hypobare hypoxie tot hoge bloedsuikers kan leiden 
(hyperglycemie), lijkt hypobare hypoxie de bloedsuikerwaarden en de 
insuline gevoeligheid bij T2DM te verbeteren. Eerder noemden we onder 
punt 5 hierboven, al een aantal mogelijke verklaringen voor deze bevinding: 
de lengte van het verblijf op hoogte (de mate van acclimatisatie) en de mate 
van hypoxie (de bereikte hoogte), de aanwezigheid van hoogteziekte en de 
mate en duur van inspanning. Al deze factoren lijken eenzelfde factor te delen, 
namelijk dat ze allemaal effect hebben op de activiteit van het sympatische 
zenwstelsel. 
 Om dit verder te ontrafelen zou verder onderzoek moeten plaatsvinden 
met gedetailleerde en nauwkeurige metingen van sympatische zenuwstelsel 
activiteit, bijvoorbeeld door (non- en ook) invasieve metingen (hartslag 
variabiliteit, baro-receptor gevoeligheid, microneurografie), meting van 
catecholamine (stress hormonen) spiegels en glucose waarden. Door dit 
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op hoogte en op zee niveau, bij inspanning en in rust, bij mensen met en 
zonder diabetes (T1DM en T2DM) te meten kan men de relatie tussen deze 
parameters onderzoeken.  
Verblijf en activiteiten op hoogte leiden vaak tot verlies van lichaamsgewicht. 
Het verlies van eetlust wordt veel gerapporteerd en zou dit deels kunnen 
verklaren. Eetlustverlies zou onderdeel kunnen zijn van de symptomen van 
hoogteziekte (AMS) of mogelijk verklaard kunnen worden door veranderingen 
in hormonen die het verzadigingsgevoel reguleren in het lichaam. T2DM 
hangt samen met een verhoogde opslag van vetweefsel in organen en in 
de buikholte (ectopisch vet) in plaats van opslag in het onderhuidse vet- 
weefsel. De afbraak van het vet in de buikholte lijkt gevoeliger te zijn voor 
catecholaminen (stresshormonen) welke mede op hoogte in hogere 
concentraties worden vrijgemaakt. 
 Het zou daarom interessant zijn om te onderzoeken of lichaamsbeweging 
onder hypoxische omstandigheden (op hoogte of in een hypobare kamer) 
van kortere duur resulteert in afname van vetmassa in de buikholte en van 
ectopisch vet. Dit zou op zijn beurt weer kunnen leiden tot verbeterde 
insuline gevoeligheid, cholesterolwaarden en nuchtere bloedsuikers.  
Verder gebruikten 6 van de 8 mensen met T1DM acetazolamide ter 
voorkoming van hoogteziekte tijdens de beklimming van Mt. Kilimanjaro 
zonder dat zij last leken te hebben van een in theorie mogelijk gevaarlijke 
bijwerking (het optreden van verzuring van het bloed; ketoacidose). Of 
acetazolamide werkelijk kan leiden tot ketoacidose is echter nooit bij mensen 
met diabetes onderzocht. Verdere studies hiernaar zouden het veilig 
gebruik kunnen vergemakkelijken en mogelijk daarmee kunnen resulteren 
in het succesvol behandelen en voorkomen van hoogteziekte bij mensen 
met diabetes.   
Tot slot is het erg lastig goede gecontroleerde studies uit te voeren in de 
bergen. Dit neemt niet weg dat het erg veel voldoening oplevert om mensen 
met diabetes door middel van onderzoek naar de top van een berg te 
kunnen helpen en daarmee te kunnen laten genieten van niet alleen de 
natuur, maar ook van een toename in zelfvertrouwen en motivatie om een 
gezonde leefstijl na te streven.
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Dankwoord 
Eindelijk is het zover! Tijdens het verrichten van onderzoek en het schrijven 
van de artikelen heb ik me vaak op dit moment verheugd: mijn boekje is af 
en ik kan de mensen die ertoe hebben bijgedragen bedanken. 
 Hoe kan ik anders dan de vergelijking maken van promoveren met de 
beklimming van een berg. Het vraagt een gedegen voorbereiding en 
gedurende je reis kom je erachter dat je dingen vergeten bent of misschien 
beter een andere route had kunnen nemen. Het enthousiasme en het 
plezier nemen toe naarmate jij en je teammaten verder omhoog en dichter 
bij de top, de eindbestemming, komen. Af en toe zitten de “weersomstan-
digheden” fors tegen wat de beklimming vertraagt en veel extra energie 
kost. Het laatste stuk is het zwaarste deel met kou, ademnood, afnemende 
energie en vermoeidheid. Als dan het einde in zicht is gaat het weer 
makkelijker en kun je uiteindelijk genieten van de behaalde top en het 
plezier van een gezamenlijke prestatie. Op geen enkele top stond ik alleen 
en geen beklimming of onderzoek was mogelijk zonder allen die mij hielpen. 
Tijdens de afdaling, als de benevelende invloed van het zuurstof gebrek 
afneemt, realiseer je je dit laatste maar al te goed. Daarom een woord van 
dank aan alle directe en indirecte betrokkenen bij dit proefschrift. 
In 2008 begon dit avontuur doordat Hanneke Joosten mij in contact bracht 
met Henk Bilo, mijn latere promotor. Hierna volgden beklimmingen, protocollen, 
mails, telefoontjes, congressen, trainingsweekenden en nog veel meer; 
kortom mijn promotietraject! Hanneke, allereerst dus veel dank aan jou als 
“initiator” van dit leuke avontuur. 
Zonder proefpersonen bestaat er geen onderzoek. Heel veel dank aan alle 
“Challengers”. Jullie deelname was niet zonder moeite: mailen wat je doet 
en gegeten hebt een hele week, 24-uur lang piepjes en alarmen door het 
dragen van een energie armband, insulinepomp, continue glucose- en ECG- 
registratie apparatuur tijdens het beklimmen van een berg, en dat terwijl de 
zuurstofkraan maar half open staat! Jullie lieten zien dat leven met diabetes 
voor een ieder anders is, maar verlegden allen jullie grenzen en gingen de 
uitdaging aan. Bedankt voor jullie inzet, doorzettingsvermogen, ideeën en 
gezelligheid. 
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Prof. Dr. H.J.G. Bilo, beste Henk, ik herinner me nog goed dat ik ’s ochtends 
in de Isala Klinieken voor het eerst met je sprak over ons onderzoek. Direct 
ontwapenend met jouw handelsmerk: sandalen en bretels, enthousiast, vol 
met ideeën en met een vriendelijke en praktische aanpak. Als promotor ben 
je een soort vaderfiguur en wist je op de juiste momenten altijd weer even 
te polsen of alles goed verliep; het onderzoek, de artikelen, maar vooral, je 
had altijd oog voor de mens achter de promovendus. Ongelofelijk veel dank 
voor je adviezen, geduld, aanstekelijke enthousiasme, humor en je holistische 
benadering. Om in jouw woorden te blijven: ik houd je graag als “makker”, 
inclusief de bijbehorende hug! 
Prof. Dr. C.J. Tack, beste Cees, ik klopte bij jou aan na de eerste beklimming 
en experimenten met de vraag of jij me als promotor wilde begeleiden 
vanuit Nijmegen. Ook al was je fysiek niet betrokken bij de beklimmingen, 
wetenschappelijk ging dat gelukkig snel. In het bijzonder wil ik je danken 
voor je begeleiding, commentaar en manier van wetenschappelijk schrijven. 
Het was leerzaam te zien dat het nog duidelijker verwoorden en presenteren 
van onderzoeksgegevens tot mooie publicaties leidde. Veel dank voor je 
inspanningen, in het bijzonder die in het laatste deel van mijn promotie-
traject en het mogelijk maken van een Nijmeegse promotie. 
Prof. Dr. R.O.B. Gans, beste Rijk, letterlijk en figuurlijk wat meer op afstand 
maar zeker niet minder gewaardeerd. Wetenschappelijk en fysiek ben je 
ontzettend fit en dit vertaalde zich altijd in helder commentaar en advies: de ene 
keer in  de vorm van een fles ORS op 4500m hoogte (welke mij letterlijk weer op 
de been hielp) de andere keren in snelle correctie van mijn artikelen begeleid 
van structureel commentaar (bij voorkeur gekenmerkt door de correctie tekens 
van jouw Apple software). Heel veel dank voor jouw begeleiding en gedeelde 
sportieve en wetenschappelijke momenten. Loop je nog een keer mee naar 
de finish in Central Park?
Prof. dr. E.J.P. de Koning, beste Eelco, jou heb ik tijdens mijn promotie 
traject professor zien worden en dat verbaasd me niets. Verbeteren van 
onderzoeksvoorstellen, combineren van ons “metabole” onderzoek met de 
radiologische expertise van het LUMC, reviseren van mijn manuscripten; 
ik kon met jouw opbouwende commentaar en tips mijn artikelen naar een 
hoger niveau te tillen. Heel veel dank hiervoor. Verder herinner ik je als prettige 
begeleider tijdens beklimmingen (met Australische hoed!) weekenden en 
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congressen.  Ik hoor graag nog eens van je hoe je sportiviteit, wetenschap, 
kliniek en een gezinsleven in 24 uur past en er zo relaxed bij blijft. 
Beste prof. dr. M.T.E. Hopman, prof. dr. J.B.L. Hoekstra en prof. dr. J.G. van der 
Hoeven, dank dat jullie wilden plaatsnemen in de promotiecommissie en 
dank voor jullie kritische beschouwing en goedkeuring van dit manuscript.
Suzanna de Vries, als cardioloog, maar vooral als onderzoeksmaatjes stonden 
we zij aan zij tijdens beklimmingen, trainings- en testweekenden, congressen 
en vele andere activiteiten. We delen samen de liefde en interesse voor 
(berg)sport en hoogte. Jouw Friese duidelijkheid, onvermoeibare door zettings-
vermogen, humor (“KN weer!”) en sportiviteit hebben me vaak geholpen en 
werkten soms heerlijk relativerend. Heel veel dank voor dit alles! Het zou 
leuk zijn nog eens een berg te doen samen, maar laten we beginnen met 
een biertje en het ophalen van alle avonturen na afloop van deze promotie. 
Dan kunnen we nadien kijken of die 5 Watt/kg nog kunnen trappen. 
Beste collega’s van het Zwolse Isala laboratorium: Als ik om 7 uur ’s ochtends 
op het lab aankwam voor overleg was het altijd een warm welkom (met 
nodige koffie). Hans Krabbe, veel dank voor onze soepele samenwerking 
in de “tank studie”. Bert Dikkeschei en Marion Fokkert, buisjes afnemen, 
koelkasten op muildieren, proBNP meters opwarmen bij Rijk; dank voor het 
brengen van jullie “lab” en klinisch chemische kennis -maar ook humor- 
naar onze beklimmingen. Bert, ik genoot van onze gesprekken tijdens 
afdalingen; ik weet nu hoe ik een KC moet benaderen om voor mij een lab 
bepaling te verrichten. Marion, jouw onvermoeibare energie werkt aanstekend. 
Dit en het vrezen voor een corrigerende tik van een judoka motiveerden mij 
om scherp en fit te blijven tijdens onze expedities.  
Veel dank ben ik verschuldigd aan de Bas van de Goor Foundation welke 
(bijna) alles heeft mogelijk gemaakt! 
 Beste Bas, als ex-olympier is jouw enthousiasme om mensen aan te 
zetten tot bewegen en het aangaan van “challenges” je van nature eigen. 
Het is ook de rede dat je samen met Petra, Jeroen en Sjoukje nu een 
fantastische stichting hebt weten op te zetten. Wij delen enige vorm van 
chaotisme en weten dit te combineren met Brabantse gezelligheid. Dit 
maakte dat ik me meteen thuis voelde in “jouw familie”. Dank dat ik met je 
mee mocht tijdens deze beklimmingen, de New York marathon en andere 
C




challenges. Ik ben er trots op dat je mijn paranimf wil zijn en ik hoop dat ik 
in de toekomst als één van je vele ambassadeurs nog kan bijdragen aan 
het succes van de foundation. Mensen motiveren tot leefstijlverandering en 
sport, dat is nog geen enkel tabletje tot op heden gelukt. Als je bedenkt dat 
dit voor mensen met (en zonder) diabetes essentieel is, dan is de BvdGF 
van levensbelang. 
 Petra (en ook Jeroen en Sjoukje) als rechterhand (en hersenhelft ?) van 
Bas geldt bovenstaande natuurlijk ook voor jullie. Dank!
Ronald Hoogendoorn, fotograaf met zes oo’s, dank voor jouw enorme 
enthousiasme, natuurlijke positieve effect op de groep, maar vooral prachtige 
plaatjes!
Camera team, Abisae en Goodluck (Kilimanjaro Film Institute Tanzania) en 
Peter en Robbert (United Broadcast Facilities) en natuurlijk Femke van der 
Horst (Visionalize), dank voor het vastleggen van de beklimmingen op film 
en voor jullie gezelligheid. Dankzij jullie kan ik (en iedereen) op elke gewenst 
moment weer even genieten van de mooie beelden van onze avonturen. 
Rene de Bos en Snowleopard travel, dank voor jouw hoogte expertise en 
begeleiding tijdens onze expedities. Als “eerste hoogste Nederlander” zou 
ik graag nog eens je ervaringen van de Himalaya zien en horen, maar liever 
nog; een mooie reis uitstippelen. 
Gidsen, dragers, koks dank voor het verzorgen van ons huis, keuken, eten en 
“onderzoekslab” tijdens onze beklimmingen; geen top zou behaald zijn zonder 
jullie! Asante sana. Shokran. 
Andere belangrijke mensen tijdens ons onderzoek: Helga Snaak: dank voor al 
je cardiale echo’s, Yvonne Jongenburg als diabetesverpleegkundige altijd 
goed voor praktische tips en inzicht, Lex Goudswaard: huisarts (en trauma 
chirurg voor de camera ploeg!) en mijn tentmaatje, Eglantine Barents 
(diëtiste DVN) en Hannie Piels (dieetinzicht.nl); dank voor jullie (calorische-) 
steun op afstand. Karin Bilo; als proefpersoon, privéchauffeuse en optimist 
(meer grappen paraat dan papa) gewoon fijn om erbij te hebben. 
Afdeling radiologie van het Leids Universitair Medisch Centrum, onder - 
zoekers en medewerkers, Hildo Lamb en Jacqueline Jonker in het bijzonder: 
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dank voor de fijne samenwerking en analyseren van alle MRI beelden. 
Jacqueline, veel succes met het afronden van je opleiding en wie weet tot 
ziens op de werk- (of dans-?)vloer. 
Theo van de Kerkhof (toen APC Cardiovasculair), dank voor je werk rondom 
de Sensewear armbanden en het voortzetten van de positieve effecten van 
de Atlas op zeeniveau. 
Centrum voor Mens en Luchtvaart Soesterberg en alle medewerkers, dank 
voor het beschikbaar stellen van de hypobare tank en onze eerste kennis - 
making met het (te) snel bereiken van 5000m hoogte. Ik zal nooit vergeten 
hoe men stond te grijnzen om mijn trage handelingen en bleke gezicht. En 
ik maar beweren dat alles prima ging.
Medtronic Nederland, Inge, Kasper, Joyce en anderen, dank voor het leveren 
van sensoren en bijbehorende service. Dankzij jullie steun konden we dag en 
nacht beschikken over (meestal) nauwkeurige glucose curves en zodoende 
onder de vele moeilijke omstandigheden op hoogte ons voordeel doen als 
proefpersoon en wetenschapper. 
Lieve collega’s van de Buitenhoek; Pleun, Edwin, Rinke, Janna, Tim, Suzanne, 
Henri, Heleen. Heel veel dank voor bakjes koffie, effe sparren over lastige 
editors, statistiek hulp, het hoe-zit-dit-ook-alweer-in-GraphPad/Excel/SPSS/ 
Word?, lachen om filmpjes, lunchen op het bankje in de zon, samen plezier 
en spanning delen op congres, een luisterend oor als de promotie niet wil 
vlotten, en nog veel meer. 
 Dank aan jullie allemaal, succes met jullie carrières als postdoc, internist, 
onderzoeker en voor sommigen succes met het afronden van de promotie!
Beste dr. A.S.M. Dofferhoff en dr. M.J.T.M. Mol, beste Ton en Mark, met jullie 
als opleiders en de andere internisten begon mijn carrière als internist i.o. in 
het CWZ te Nijmegen. Hier werd de basis gelegd voor hard, nauwkeurig en 
steeds meer zelfstandig werken. Dit draag ik nog dagelijks mee om een zo 
goed mogelijke arts te zijn voor mijn patiënten. Door jullie werd (tussen de 
poli’s door) mij de mogelijkheid geboden om mijn onderzoek op te starten. 
Ook werd hier mijn interesse voor de oncologie (dank Dick Johan en 
Caroline) gewekt. Bedankt voor deze 3 mooie jaren!
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Beste oud collega’s CWZ: (te veel namen om op te noemen maar als 
je dit leest, dikke kans dat je erbij hoort!) dank voor alle gezelligheid, 
gesprekken over opleiding, poli’s, het altijd weer drukke rooster, lastige 
cases of dokters en koffie na de overdracht! 
 Het zou leuk zijn straks weer samen te werken of gewoon een bakkie te 
doen op de NIV dagen.
Beste opleiders interne geneeskunde van het Radboud UMC. De voort - 
zetting van mijn opleiding in de academie was even wennen, maar mede 
dankzij jullie kon ik snel het spoor weer oppikken. Prof. de Graaf, Jacqueline, 
opleidster als geen ander, jou wil ik in het bijzonder bedanken voor je 
luisterende oor, kritisch meedenken, begrip en coaching; hoe fijn is het om 
na een kort gesprek met “de baas” je gesteund te voelen en met nieuwe 
energie aan de slag te kunnen om je doelen te bereiken. 
 Beste collega’s van het Radboud UMC en met name de afdelingen 
interne geneeskunde en medische oncologie; dank voor de leerzame tijd, 
samenwerking, vele overlegmomenten, gezelligheid (m.n. op de onco 
fellow kamer/villa), congresbezoeken, koffie en lunchpauzes (te weinig) en 
gedeelde humor. Door al deze momenten wordt het leven van een AIOS/
promovendus een stuk leuker en makkelijker. 
Beste vrienden. “Draaiende dokters”: kletsen en kilometers trappen door 
“het Limburgs Hooggebergte” met nadien de luxe van huize Saris: elk jaar 
zie ik uit naar dit gezellig samenzijn met grote verhalen. Mannen van “ de 
Mannenavond”: zullen we dit, inclusief afzakkertje, gewoon doorzetten 
totdat we grijs zijn en krom lopen? Toon, al 36 jaar vrienden, daarvan heb ik 
er maar één. Deze en andere vrienden: dank allen voor de ontspannende 
momenten, adviezen en soms heerlijk relativerende woorden. 
Lieve familie, papa en mama, jullie hebben me de basis meegegeven waardoor 
ik nu hier kan staan. Op jullie kan ik altijd rekenen voor praktische steun 
(oppassen, een manuscript nakijken) een luisterend oor, een goed gesprek 
met een wijntje, gezelligheid met de kinderen; kortom echt even “thuiskomen”. 
Jullie lieten me mijn eigen keuzes maken en ik denk dat de combinatie 
van jullie beiden (de interesse voor regelmechanismen (pap) en voor de 
menselijke psyche en taal (mam)) mij hebben gevormd als mens en dokter. 
Dank voor jullie liefde en vertrouwen. 
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 Lieve Bram, met jou als paranimf is succes verzekerd. Ik vind het zo 
leuk dat wij dit als broers samen kunnen doen. Lieve zus, Sas, met jou kan 
ik altijd fijn “intercollegiaal” overleggen over het dokter zijn, maar vooral ook 
alles daar omheen. Meerdere malen wist je me daarbij de juiste spiegel 
voor te houden. Dank!
 
Mijn stoere meiden, lieve Sam en Nina. Papa verheugt zich altijd op zijn 
thuiskomst: de deur vliegt open met “Pappie!” en mijn dag kan niet meer 
stuk. Samen boekjes lezen, terugfietsen van school, zondagochtend in 
bed, genieten als trotse papa van twee mooie, vrolijke prinsessen. Ook al 
zullen jullie (nog) niets begrijpen van het boek dat papa heeft geschreven 
en van de hele promotie, papa had jullie zo graag in de zaal er al bij gehad. 
Het geluk dat jullie en mama mij dagelijks geven maakt deze promotie klein. 
Lieve Franca, mijn superwoman, zonder jou was ik zeker niet gepromoveerd. 
Ik kan over jou een heel artikel schrijven en dan nog doe ik je tekort. Vaak 
was jij (minstens) de helft van mijn brein als mijn hoofd “vol zat”. Naast dat 
je daarmee eigenlijk ook 5 auteursposities verdient kon ik altijd rekenen 
op jouw steun en vertrouwen ook al ging dit soms ten koste van je eigen 
ambities en agenda. Twee maal liet ik je zwanger achter en vertrok ik voor 
onderzoek naar een berg. Op deze bergen stonden we helaas niet samen, 
maar met jou en onze meiden aan mijn zijde is elk vergezicht super. 
Voorlopig even geen onderzoek meer maar droomreizen samen, heel graag! 
Jouw P houdt van jou (met P< 0.00000001). 
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